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Abstract 
 
Development of subunit vaccine formulation requires a careful selection of potent antigen, efficient 
adjuvant and route of delivery. The desirable physicochemical characteristics of the mesoporous 
silica nanoparticles (MSNs) such as ease of synthesis, excellent in vivo biocompatibility and good 
thermal and chemical stability, make them optimal nanocarriers for various biomolecules (Mody et 
al. Nanoscale, 2013). Freeze-drying process can be used to further improve both th 
e short and long-term stability of protein-loaded nanovaccine components (Mody et al. Drug Deliv. 
Lett., 2012). Bovine Viral Diarrhoea Virus-1 (BVDV-1) is one of the most serious pathogens, 
which causes tremendous economic loss to the cattle industry worldwide, meriting the development 
of improved subunit vaccines. E2 is the structural envelope glycoprotein of BVDV-1 and is a major 
immunogenic determinant, making it an ideal candidate for the development of subunit vaccines. 
The current research project investigated range of silica nanoparticles with different physico-
chemical characteristics for the development of ‘non freeze-dried’ (wet or non-FD) and ‘freeze-
dried’ (FD) vaccine delivery systems using model protein Ovalbumin (OVA) and BVDV-1 
Escherichia coli-expressed optimised E2 (oE2) protein. The nanoparticles repertoire included 
amino functionalised mesoporous silica nanoparticles (AM-41), amino functionalised hollow 
mesoporous silica nanoparticles (HMSAs) and novel silica vesicles (SV).  
 
The capacity of AM-41 sized 90 nm to act as self-adjuvants and nanocarriers was first investigated 
for model protein OVA as non-FD as well as FD [after freeze-drying with trehalose (5%) and 
PEG8000 (1%)] nanovaccine formulations. Administration of the non-FD and reconstituted FD 
OVA-41 (after storage for 2 months at ambient temperature) nanovaccine induced both humoral as 
well as cell-mediated immune responses after four immunisations of 10 !g OVA/150 !g AM-41 
(Mody et al. Int. J Pharm, 2014). Low protein adsorption capacity of AM-41 (72 µg OVA/mg AM-
41) was a major limitation of this study. Therefore, HMSAs, (particle size 120 nm, pores on the 
wall of entrance sized 2 nm) were investigated for developing recombinant BVDV-1 E2 
nanovaccine (60-80 µg oE2 /mg HMSA). The immunogenicity of the oE2/HMSA nanovaccine 
before and after a freeze-drying with trehalose (5%) and glycine (1%) was evaluated in a sheep 
trial. The non-FD and FD oE2/HMSA generated oE2 specific antibody and cell-mediated immune 
responses after three subcutaneous injections with 500 !g oE2 adsorbed to 6.2 mg HMSA. 
Importantly, it was found that the long-term cell-mediated immune responses were detectable up to 
five months after immunisation (Manuscript submitted to PLoS ONE).  
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In order to further improve the oE2 adsorption and immunogenicity of the nanovaccine as compared 
to conventional adjuvant Quil-A, novel silica vesicles termed SV-140 (diameter 50 nm, wall 
thickness 6 nm, perforated by pores of entrance size 16 nm and total pore volume of 0.934 cm3g-1) 
were evaluated. The SV-140 significantly improved the loading capacity (~250 µg/mg) and 
controlled release of oE2 protein. The in vivo functionality of the developed vaccine delivery 
system was validated in mice immunisation trials comparing oE2 plus Quil-A (50 µg of oE2 plus 10 
µg of Quil-A) to the oE2/SV-140 (50 µg of oE2 adsorbed to 250 µg of SV-140). Compared to the 
oE2 plus Quil-A, which generated BVDV-1 specific antibody responses at a titre of 104, the 
oE2/SV-140 group induced a 10 times higher oE2 specific antibody response. In addition, the cell-
mediated response, which is essential to recognise and eliminate the invading pathogens, was also 
found to be higher [1954-2628 spot forming units (SFU)/million cells] in mice immunised with 
oE2/SV-140 compared to oE2 plus Quil-A (512-1369 SFU/million cells) (Mody et al. Biomaterials, 
2014).  
 
The ability of oE2/SV-140 and a FD oE2/SV-140 formulation (excipients trehalose (5%) and 
glycine (0.1%) used to freeze-dry), to generate long-term immune response was investigated after 
only two subcutaneous injections in mice. The oE2 (100 !g)/SV-140 (500 !g) and FD oE2 (100 
!g)/SV-140 (500 !g) nanovaccines generated oE2-specific antibody responses for up to six months 
post the final second immunisation in mice. Significantly, the cell-mediated responses were 
consistently high in all the four mice immunised with oE2/SV-140 (1500 SFU/million cells) at the 
six month time point. The FD oE2/SV-140 also generated strong cell-mediated responses (340-1500 
SFU/million cells) at the six month time point. Histopathology studies on the site of injection and 
different organs of mice immunised with 500 !g SV-140 nanovaccine showed no morphological 
changes. This showed that the oE2/SV-140 can elicit long-term balanced immune responses for at 
least six months both as non-FD and FD nanoformulation with SVs acting as excellent self 
adjuvants and nanocarriers (Manuscript submitted to PLoS ONE). The advancement made in this 
project addresses key features of: reduction in vaccine dosage, adjuvants, long-term balanced 
immune response and elimination of cold chain storage towards vaccine delivery. 
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1. 
Introduction                                                                          
 
 
 
 
 
 
 
 
 
 
1.1 Aim 
 
The aim of this research was to develop efficient vaccine delivery systems using a variety of novel 
silica nanoparticles as adjuvants and nanocarriers for the delivery of model protein Ovalbumin 
(OVA) and real virus protein Bovine Viral Diarrhoea Virus-1 (BVDV-1) E2. The following types 
of silica materials, amino functionalised MCM-41 (Mobil Composition of Matter No. 41) termed as 
AM-41, amino functionalised hollow mesoporous silica nanoparticles (HMSA) and the novel silica 
vesicles (SV) were investigated to develop nanovaccine formulations. Development of successful  
 
 2 
nanoparticle based vaccine delivery systems requires a thorough understanding of adjuvants and 
their use in vaccine formulations, to produce a safe, stable and immunogenic product. 
  
Silica nanoparticles have desirable characteristics such as high surface area, large entrance size, 
tunable pore size, and large pore volume, which make them ideal candidates for adsorption of 
proteins/antigens. Protein was first adsorbed onto silica nanoparticles to develop nanovaccine and 
subsequently the release kinetics of protein was investigated. Following the cellular uptake and 
cytotoxicity analyses the efficacy of the developed nanovaccine formulation was verified in animal 
models. The specific objectives of the project were to: 
 
1. Test a variety of silica nanoparticles for developing vaccine delivery systems. 
2. Optimise the adsorption of protein and the desorption kinetics of protein loaded silica 
nanoparticles.  
3. Investigate the cellular uptake and cytotoxicity of the silica nanoparticles/protein loaded silica 
nanoparticles. 
4. Optimise the freeze-drying process for the nanovaccine formulations. 
5. Analyse the physico-chemical characteristics of the ‘wet’ (non-freeze-dried) and ‘freeze-dried’ 
(FD) nanovaccine formulations. 
6. Test the biological functionality of the developed ‘non-FD’ and ‘FD’ vaccine delivery systems 
in animal trials 
 
1.2 Background 
 
Bovine Viral Diarrhoea Virus-1 (BVDV-1), a bovine pestivirus, is a viral infection of cattle well 
recognised as a significant disease in both beef and dairy herds in Australia and many countries 
around the world. Genetically classified in the virus family Flaviviridae which includes diseases 
such as hepatitis C, yellow fever and dengue in the genus Pestivirus [1] BVDV species have been 
classified into type-1 and type-2 viruses and recently a new group has been classified as BVDV-3. 
[2, 3] BVDV-1 infection in cattle has been highly investigated in several countries due to its clinical 
and economical importance. A major concern regarding pestiviruses is not only limited to the 
substantial economic losses incurred but also to the fact that these viruses are not host specific 
signifying that they can easily spread amongst livestock such as sheep and pigs. It has been well 
established that sheep and goats can carry and be infected with BVDV-1 and then be able to pass 
the virus back to cattle. [4] BVDV-1 has also been found in bison and water buffaloes. [5] 
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BVDV-1 is a major contributor to the bovine respiratory disease (BRD) complex, which also causes 
tremendous economic loss to the cattle industry. An economic analysis in 2009 has shown that 
yearly losses due to BVDV could reach approximately US$88 per animal. [6] BVDV-1 is of high 
economic importance to the Australian cattle industry as over 80% of all feedlots having some 
exposure to the virus. It has been reported that in Queensland the cattle/beef industry is estimated at 
$3.5 billion each year, [7] economic losses from BVDV-1 through loss of cattle and productivity is 
estimated at $60 million each year. [8]  
 
Infections of BVDV-1 can occur either via persistent infected (PI) or acutely infected animals. 
Transmission of BVDV-1 occurs when uninfected animals come in contact with the body fluid 
discharges from infected cattle. The virus is mainly transmitted through PI animals as they 
continuously shed large amounts of virus in the environment and are an important source of virus 
transmission within and between herds. [9, 10] A persistent infection can develop if the foetus is 
infected with the virus in the first trimester or up to the first 125 days of gestation an abortion or 
stillbirth may occur resulting in reduced productivity. [11] If a developing foetus survives to the end 
of pregnancy, the calf may be PI infected and may be born with severe birth defects, be 
developmentally delayed or appear normal. PI calves spread BVDV-1 to the other cattle as they 
constantly shed the virus throughout their life. In acute infection, even though the virus is excreted 
in lower amounts the virus is shed for two to three weeks by animals. The virus generally is 
incubated for 3-4 days and then circulated in the blood for a further 7-10 days, any secretion of 
body fluids may result in easy transmission of virus. [12] BVDV-1 infected cattle have a reduced 
immune response thus making them more susceptible to other diseases like pneumonia, mastitis, 
BRD and diarrhoea. Immunosupression caused by BVDV-1 infection can lead to a secondary 
infection, which mainly is the major cause of death in BVDV-1 infected cattle. [13, 14]  
 
Killed Virus (KV) and modified-live vaccines (MLV) can be used to protect cattle from BVDV-1 
infection. However, both of these types of vaccines can have certain drawbacks, MLV vaccines 
may be deactivated beyond certain temperatures or by some chemicals and revert to virulence while 
KV vaccines require more antigen per dose compared to the MLV and are more expensive.[15]  
Current Vaccines: To date, only one BVDV vaccine has been approved for use in Australia known 
as Pestigard® produced by Zoetis. The vaccine needs to be administered as two doses, 6-8 weeks 
apart with annual booster injections required thereafter, it has a shelf-life of one month when 
refrigerated. Vaccination can reduce BVDV diseases; therefore, many countries in the European 
Union (EU) have developed an eradication program to assist in the fight and control of the disease  
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with the use of vaccines. [16] BVDV vaccine Bovilis BVD by Merck available in the UK too 
requires an annual booster dose and has a shelf-life of 18 months and needs to be stored at +2°C to 
+8°C, however, once the vaccine bottle is opened the shelf-life is reduced to 10 h. [17] 
The economic impact BVDV-1 pathogen underpins the merits of the development of improved 
subunit vaccines. The BVDV-1 genome is a 12.3 kb single stranded RNA molecule containing a 
single open reading frame that is translated into a single polyprotein, which is processed into 
individual viral proteins by viral and cellular proteases. [18] E2 is the major structural glycoprotein 
of BVDV-1 and is the most immunogenic determinant of BVDV-1 virion. [13, 19-22] E2 when 
used in immunisation studies induces neutralizing antibodies, which are required to fight BVDV-1 
infection. [2, 23-25] This makes E2 protein an excellent candidate for the development of subunit 
vaccines.  
 
Fig 1.1. BVDV genome with the individual protein labelled. [26] 
 
The major role of veterinary vaccines is to improve the health and welfare of the animals and 
increase production of livestock in cost-effective manner. Veterinary vaccines comprise of 
either whole pathogens, protein subunit vaccines, genetically engineered organisms or chimeras, 
vectored antigen formulations or naked DNA injections. [27] Vaccines are designed to mimic 
the immune responses associated with an active infection whilst avoiding the undesirable 
effects of disease. [28] Administration of a priming dose of the subunit vaccine followed by two 
or three booster doses facilitates immunogenicity, which occurs with repeated or sustained 
exposure to the same antigen. [29] Protein antigens can get degraded by proteases limiting their 
bioavailability and reducing their immunogenicity. Hence, vaccines utilise adjuvants to improve 
the immunogenicity by providing pro-inflammatory signals and prolonging the persistence of 
vaccine antigens. [30]  
 
Adjuvants are often added to the subunit vaccine formulations in order to generate strong 
antigen specific immune responses. Unfortunately, the currently available adjuvants may induce 
undesirable side effects and may not generate long-term balanced humoral and cell-mediated 
immune responses, which limits their use in clinical studies. [31-33] To find an optimal antigen 
carrier and an optimal adjuvant are the most challenging aspects in the development of subunit 
 
 
 5 
vaccines. As premature release and degradation of an antigen before uptake and activation of 
DC, in addition to generation of both humoral and cell-mediated responses have acted as a 
limiting factor in development of subunit vaccines comprising of protein antigens.  
 
Veterinary vaccines comprise of approximately 23% of the global market and this sector has 
been growing consistently due to the new technological innovations. [27] Recent, advancements 
include development of nanoparticle based veterinary vaccine delivery systems, as continuous 
presentation of antigens by nanoparticles could be the crucial factor in inducing long-term 
immune responses. The sustained release of the antigen from the nanoparticles creates a ‘depot 
effect’ and enhances the immunogenicity of the adjuvants by producing prolonged 
immunological response. [34] Nanoparticles such as the polymeric [35], nucleoprotein [36] 
have been investigated to develop bovine veterinary vaccines and hydroxyapatite nanoparticles 
have been researched for development of diagnostic tests for cattle infected with 
Mycobacterium bovis [37]. 
 
Silica nanoparticles can be the new generation of adjuvants and delivery vehicles for protein 
antigens. Currently, they are used in diverse number of applications including enzyme 
adsorption and immobilisation [38], cell imaging and labelling. [39] Structurally, silica 
nanoparticles can exist as three dimensional solid spheres or can be porous with pore diameters 
in the microporous (< 2 nm), mesoporous (2-50 nm) and macroporous range (> 50nm). They 
can be structurally modified to be in different shapes such as rods and have chirality. [40] Since 
the discovery of the M41S family of mesoporous materials in 1992, a number of different 
mesoporous silica nanoparticles have been invented, which include MCM-n [41], SBA-n (Santa 
Barbara Amorphous) [42], IBN-n (Institute for Bioengineering and Nanotechnology) [43] and 
FDU-n (Fudan University). [44] Different organic functional groups such as amino (-NH2), 
thiol (-SH), vinyl (-CH=CH2) and phenyl (-C6H5) can be incorporated into or onto the walls of 
the silica particles. [45] The advantage of functionalisation of silica depends on the type of 
application. For example, amino functionalised have been explored in areas such as adsorption 
[46], catalysis [47] and enzyme immobilisation [48] with very promising results.  
 
Protein antigens can either bind on the surface or internal pores of the silica nanoparticles. The 
sites at which the proteins bind to the nanoparticles greatly depend on the type and properties of 
the target proteins and pore structure, as well as available pore surface area of the nanoparticles. 
[49, 50] The forces that bind the proteins to the nanoparticles are the electrostatic protein- 
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surface interactions, hydrogen bonding and weak van der Waals interactions. [51] It is 
interpreted that if the protein is larger than the pore size of the nanoparticle, the protein will 
only adsorb onto the surface of the material and not utilise the high surface area provided by the 
pores. [52] In addition, other factors like functionalisation of the nanoparticles and pH of the 
protein can also affect the adsorption capacity. The pH at which the protein has an overall 
neutral charge is known as the relative isoelectric point (pI). Above the pI, the protein has a 
negative charge and below the pI it has a positive charge. [52] The highest amount of 
adsorption is observed when adsorption is carried out at the pI point of the protein. [53] 
However, the pH at which maximum loading can be achieved does not necessarily indicate that 
the activity of the protein is at its highest. Therefore, during adsorption it is important to select 
the pH as well as the buffer solution, which helps preserve the biological activity of the protein.  
 
Mesoporous silica nanoparticles (MSNs) are considered highly advantageous for adsorption of 
proteins due to their large pore size, which allows adsorption of proteins into the particles and 
protects the protein molecules from degradation. [54] MSNs can act as both the nanocarriers as well 
as adjuvanting components to enhance vaccine efficacy. [55-59] A comprehensive review study on 
MSNs and adsorption of different proteins on MSNs to develop vaccine delivery systems has been 
included in Chapter 2.  
 
Freeze-drying is a technique which can be used to further enhance the stability of nanovaccine 
formulations. [60] By freeze-drying unstable biomolecules such as proteins and peptides their 
chemical properties can be preserved for longer periods of time. [61-63] Freeze-drying of proteins 
offers the advantages such as prolonged shelf-life, improved storage and ease of shipping to the end 
user. [60, 64] These are all important issues in developing countries where maintenance of cold 
chain storage can be problematic. [65] Moreover, freeze-drying strategies are extensively used to 
facilitate the stability of nanoparticle-based vaccine formulations and enhance the antigen 
immunogenicity. [56, 60] While nanoparticle technologies can improve overall stability of some 
vaccines the degree of improvement can be dependent on the specific formulation under evaluation. 
A detailed review about freeze-drying process and advantages associated to freeze-drying 
nanovaccine formulations are included in Chapter 3. 
 
Recently, there have been increasing reports focusing on development of nanoparticle based 
vaccine delivery systems using silica nanoparticles with a particular focus on BVDV-1. [31, 55-57,  
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66] In our laboratory, generation of soluble and endotoxin-free BVDV-1 E2 protein using an E. coli 
expression system has been well established. [66, 67] Reports from Mitter laboratory has 
demonstrated that model protein OVA delivered by AM-41 [68] and oE2 delivered by amino 
functionalised hollow mesoporous silica nanoparticles (HMSAs) [55] generated immune responses 
in animal studies. Though, OVA adsorbed AM-41 and oE2 adsorbed HMSAs induced detectable 
antibody and cell mediated responses, a major limitation was the low protein adsorption efficiency 
of 60-80 µg protein/mg particles. Therefore, in order to improve the antigen adsorption and 
facilitate sustained release of the antigen, ‘novel’ SV were evaluated as the ‘new-generation’ 
vaccine adjuvants and delivery systems. These 50 nm SV were designed specifically with thin shell 
wall and large entrance size for improving the BVDV-1 E2 adsorption.  
 
1.3 Significance of project 
 
The advancement made in this vaccine delivery system project is highly significant, as this research 
work identifies the use of protein loaded silica nanoparticles towards the development of a new 
platform technology for safer and more effective subunit vaccines. To demonstrate that silica 
nanoparticles can efficiently deliver a virus antigen and act as strong adjuvants we chose the BVDV 
E2 protein due to the global economic significance associated with the disease throughout the 
world. The silica nanoparticles used in the current study included AM-41, HMSAs and SV for the 
delivery of model protein OVA and with a viral antigen E2.  
 
The ability of the developed nanovaccine formulations to generate humoral and cell-mediated 
responses in animal trials was compared to immunisation of antigen together with the traditional 
adjuvant Quillaja saponira Molina tree saponins (Quil-A). The OVA protein adsorbed on amino 
functionalised MCM-41 (AM-41) (72 µg OVA/mg AM-41) was freeze-dried with 5% trehalose and 
1% PEG8000 as excipients, the ability of the developed freeze-dried vaccine formulation was tested 
in an animal trial. The non-FD and the FD 10 µg OVA adsorbed to 150 µg AM-41 nanovaccine 
generated OVA-specific antibody and cell-mediated immune responses lower than the traditional 
adjuvant Quil-A (50 µg OVA plus 10 µg Quil-A) after four immunisations. [56] However, the work 
on the freeze-dried OVA adsorbed AM-41 provided the proof-of-concept in small animal (mice) 
trials that freeze-dried nanovaccine formulations were able to elicit both humoral and cell-mediated 
immune responses.  
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Moving forward, the amino functionalised hollow mesoporous silica nanoparticles (HMSAs) with 
small pore entrance size 2 to 3.5 nm were investigated for BVDV E2 adsorption [55], only 60-80 µg 
oE2 adsorbed to per mg of HMSA. The efficacy of the non-FD and FD oE2/HMSA nanovaccine 
was tested in sheep after three immunisations. The level of the antibody responses to both the non-
FD and FD 500 µg oE2 adsorbed to 6.2 mg HMSA nanoformulations were similar to those obtained 
for oE2 plus Quil-A, which provided a proof-of-concept that the E2 nanoformulations were 
immunogenic in a large animal and freeze-drying did not affect the immunogenicity of the 
nanoformulation. Importantly, it was found that the long-term cell-mediated immune responses 
were detectable up to five months after immunisation. The cell-mediated immune responses were 
consistently high in all sheep immunised with the freeze-dried oE2/HMSA nanovaccine formulation 
(>2200 spot forming units (SFU)/million cells) compared to the non-FD nanovaccine formulation 
(213-500 SFU/million cells) (Manuscript submitted to PLoS ONE). However, to further improve 
the BVDV E2 adsorption efficiency and immunogenicity of the nanovaccine, different types of 
novel SV were investigated.  
 
Silica vesicles were rationally designed using a two-step synthesis process and have a uniform size 
of 50 nm. In the first step the vesicular structure was formed and in the second step the entrance size 
(5.7 nm to 16 nm) of the vesicle was controlled by tuning the temperature. The hydrophobic 
modified SV have shown to be exceptional nanocarriers for cellular delivery applications of 
therapeutical biomolecules like Ribonuclease A. [69] The four SV (SV-140, SV-140-A, SV-100 
and SV-100-A) investigated in this study have controllable entrance size in the range of 5.7-16 nm 
and total pore volume in the range of (0.49-1.24 cm3/g). They also have a thin porous shell wall 
with a thickness of ~6 nm, the large entrance size of all the four SV resulted in higher oE2 protein 
adsorption (~250 µg/mg SV) and slow release of the antigen. Based on the results from the in vitro 
studies the SV-140 was selected for in vivo investigation. [57] Mice were immunised with oE2 plus 
Quil-A (50 µg of oE2 plus 10 µg of Quil-A) or oE2/SV-140 (50 µg of oE2 adsorbed to 250 µg of 
SV-140) or oE2/SV-140 together with 10 µg of Quil-A. The animals in the oE2/SV-140 group 
generated oE2 specific antibody response at a titre of 105 compared to oE2 plus Quil-A group that 
generated antibody response at a titre of 104. In addition, the oE2/SV-140 group also induced higher 
cell-mediated response (1954-2628 SFU/million cells) compared to oE2 plus Quil-A (512-1369 
SFU/million cells).  
 
The ability of SV-140 as nanocarrier and adjuvant was further investigated in a long-term 
immunisation study and it was also used to develop a freeze-dried vaccine. Mice were immunised  
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with two subcutaneous injections of the non-FD and FD oE2 (100 µg)/SV-140 (500 µg) 
nanovaccine formulations. The non-FD as well as the FD oE2/SV-140 nanovaccines elicited total 
anti-oE2 IgG responses for at least six months post vaccination. The cell-mediated responses were 
found to be consistently higher with the oE2/SV-140 compared to all the treatment groups at the 
six-month time point. The FD oE2/SV-140 induced cell-mediated responses comparable to oE2 
plus Quil-A at the six-month time point. This work for the first time demonstrated that vaccination 
with non-FD and FD oE2 /SV-140 elicited balanced T-helper type-1 (Th1) and T-helper type-2 
(Th2) responses for up to 6 months post the final second immunisation (Manuscript submitted to 
PLoS ONE). The most promising results for efficient adsorption, sustained release and in vivo 
delivery of BVDV E2 antigen were obtained with SV-140. The capacity of SV to induce robust 
balanced humoral and cell-mediated immune responses is a huge advantage over traditional 
adjuvant such as Quil-A, which often induces only one arm of the immune response. This extensive 
research work will provide a platform to develop advanced veterinary vaccines using silica 
nanoparticles.  
 
1.4 Structure of the thesis 
 
The thesis consists of eight chapters. Chapters 2-7 are collection of journal papers that have been 
published or submitted as manuscripts for journal publications.  
 
Chapter 1: Introduces the background along with the scope of this research work. 
 
Chapter 2: Mesoporous Silica Nanoparticles as Antigen Carriers and Adjuvants for Vaccine 
Delivery (Published in Nanoscale 2013, 10, 5167-5179). 
 
Chapter 3: Freeze-drying of Protein loaded Nanoparticles for Vaccine Delivery (Published in Drug 
Delivery Letters 2012, 2, 83-91). 
 
Chapter 4: Freeze-drying of Ovalbumin loaded Mesoporous Silica Nanoparticle Vaccine 
Formulation Increases Antigen Stability under Ambient Conditions (Published in International 
Journal of Pharmaceutics 2014, 465, 325-332). 
 
Chapter 5: Immunisation of sheep with Bovine Viral Diarrhoea Virus, E2 protein using a Freeze-
dried Hollow Silica Mesoporous Nanoparticle Formulation (Manuscript submitted to PLoS ONE, 
K Mody as co-author). 
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Chapter 6: Silica Vesicles as Nanocarriers and Adjuvants for generating both Antibody and T-cell 
mediated Immune Responses to Bovine Viral Diarrhoea Virus E2 protein (Published in 
Biomaterials 2014, 35, 9972-9983). 
 
Chapter 7: Silica Vesicle Nanovaccine Formulations Stimulate Long-term Immune Responses to 
the Bovine Viral Diarrhoea Virus E2 protein (Manuscript submitted to PLoS ONE). 
 
Chapter 8: Conclusions and Recommendations. 
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2. 
  Literature Review 
Mesoporous Silica Nanoparticles as Antigen Carriers and 
Adjuvants for Vaccine Delivery 
 
 
 
 
 
 
 
 
 
 
The aim of Chapter 2 is to understand the fundamentals of silica nanoparticle based vaccine 
delivery systems. In this literature review, different aspects of mesoporous silica nanoparticles 
(MSNs) based nanovaccine delivery systems like MSNs as antigen carriers, MSNs as adjuvants in 
vaccine formulation and biocompatibility and biodistribution of MSNs were discussed in depth.  
 
 19 
 
Fig 2.1. Schematic representation showing the development of silica nanoparticles based vaccine 
delivery systems. Chapter 2 is as published in Nanoscale 2013, 10, 5167-5179 
 
2.1 Introduction 
 
Development of efficient and potent vaccines still remains as one of the most effective 
strategies for preventing diseases. [1] Traditional vaccines comprise of attenuated pathogens 
(live vaccines) or inactivated pathogens, which can elicit a strong immune response. But, 
traditional vaccines are generally difficult to deploy, may have side effects like inflammation at 
the site of vaccination, require multiple doses for effective immunisation [2, 3] and are often 
expensive. On the other hand, subunit vaccines comprise of highly purified recombinant 
antigens such as proteins and peptides, these vaccines are more stable and have better safety 
profiles compared to the conventional vaccines. [4] However, subunit vaccines can have poor 
immunogenicity and are often unable to cross intestinal mucosal tissues due to degradation by 
metabolic enzymes. [5-9] To improve the immunogenicity of subunit vaccines, adjuvants are 
often added to the formulation.  
 
Adjuvants can be defined as compounds that are added to the vaccine formulations in order to 
enhance the activation of the dendritic cells (DC) and generate robust immune responses. [10] 
Adjuvants can be classified in two categories, depending on whether they have an 
immunostimulatory effect on the antigen presenting cells (APCs) or function as delivery 
systems initiating antigen uptake. [11] However, very few adjuvants have been approved for 
animal as well as human use as they can be highly toxic and induce undesirable severe side 
effects, limiting their use in clinical studies. [12] Adjuvants approved for use in human vaccines 
include, aluminium-based mineral salts (Alum), MF59® (oil-in-water emulsion), virus like 
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particles (VLPs), MPL® (a glycolipid), immunopotentiating reconstituted influenza virosomes 
(IRIV) and cholera toxin. [13] Two of the most challenging aspects in the development of novel 
vaccines are finding the optimal antigen carrier and optimal adjuvant combination. 
 
In the past few years application of nanotechnology has undergone a rapid development holding 
promise to provide a new generation of improved vaccines. Nanoparticles are molecular 
materials that range between 1–1000 nm to which drugs or biologically active material can be 
entrapped or encapsulated, adsorbed or attached. [14] When an antigen is associated with 
nanoparticles, a stronger immune response is generated compared to the soluble antigen 
alone.[15] Nanoparticles due to their unique chemical, physical and biological properties are 
considered efficient delivery vectors to deliver drugs, proteins, peptides and nucleic acids. 
Several particle-based vaccine delivery systems such as polymeric [14, 16-21], lipid-based [22, 
23] and chitosan [24] nanoparticles have been investigated. Though, polymeric and liposomal 
nanoparticles have been designed to achieve controlled drug release, release of antigenic 
proteins and induce immune responses very effectively, [21, 23] these nanoparticles are 
structurally unstable and are prone to hydrolysis in the harsh gastric environment. In most cases 
the entrapped molecules in the matrices of polymer or inorganic particles would leak out within 
a few hours due to diffusion or degradation of the polymer matrix. This premature release and 
degradation of the drug or antigens during intestinal transit presents a major challenge in 
vaccine development. Mesoporous silica nanoparticles (MSNs)[25-28] are being investigated as 
the likely candidates to overcome instability and leakage issues associated with other 
nanoparticles. 
 
Since the discovery of MCM-41 type MSNs in 1992 by Mobil scientists, [29] significant efforts 
have been devoted to establish a clinical potential of these particles in the biomedical field. [30] 
In addition many research studies have focussed on synthesis, biocompatibility and 
biodistribution of MSNs. [15, 31-45] Various studies have shown that MSNs are excellent 
vehicles for gene and drug delivery because of their ease of synthesis, surface functionalisation, 
excellent in vivo biocompatibility as well as good thermal and chemical stability. [40, 46, 47] 
Additionally, MSNs are capable of controlling the release of drugs or proteins depending on 
their size, shape and surface modification. [15, 35] These properties of MSNs make them very 
attractive vehicles for targeted delivery and release of biomolecules such as nucleic acids, 
enzymes, proteins and peptides. [20, 25, 32, 33, 48-51] In vitro studies using HeLa cells 
demonstrated that MSN could successfully deliver the membrane-impermeable protein 
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cytochrome c. [49, 52, 53] Advancements on different types of drugs and enzymes immobilised 
on to MSNs have already been exhaustively reviewed by Popat et al.[25]. Despite rapid 
developments made on biomedical applications of MSNs, there is very limited literature citing 
the use of MSNs as vaccine adjuvants or as antigen delivery carriers. [28, 51, 54] Hence, it is 
important to provide a concise and critical review of the latest advances in the field of vaccine 
delivery using MSNs. This review will give us an overview on different types of 
proteins/antigens that have been delivered using MSNs and also discuss key factors affecting 
the loading and release of antigens to/from MSNs. Additionally, the cytotoxicity of MSNs, an 
important aspect in clinical applications will be addressed. Lastly, we will focus on some of the 
challenges faced by researchers in this field; provide some outlook and concluding remarks.  
 
2.2 MSNs as antigen carriers 
 
Examples of different proteins loaded on to MSNs for a variety of applications are summarised 
in Table 2.1. Surface modified MSNs have been investigated as efficient protein delivery 
systems. [45, 55-57] Aminosilane functionalised ordered silica materials (SBA-15) have been 
used to study the adsorption and release kinetics of different proteins including bovine serum 
albumin (BSA), lysozyme and myoglobin. [42, 58] Recently, studies have been focusing on the 
use of hollow mesoporous silica nanoparticles (HMSNs) for the delivery of proteins due to their 
desirable characteristics such as the high loading capacity. Functionalised and unmodified cell 
membrane-permeable hollow mesoporous silica capsules (HMSCs) have been used for 
intracellular delivery of BSA and goat IgG. [43] 
 
In our laboratory, we have developed nanoparticle-based vaccine delivery systems using model 
protein ovalbumin (OVA) and the viral antigen E2 from Bovine Viral Diarrhoea Virus (BVDV) 
and amino functionalised MSNs and HMSNs type materials. We observed that the optimal 
protein and nanoparticle combination needs to be developed empirically as the adsorption and 
desorption kinetics is dependant on various factors such as functionalisation of nanoparticles 
and zeta potential of proteins and nanoparticles. HMSNs can significantly improve the protein 
loading capacity. Different parameters including synthesis, functionalisation, adsorption and 
release studies of the mesoporous silica used for protein delivery and vaccine development are 
discussed below. 
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In the literature various techniques for the synthesis of MSNs have been discussed. The first 
reports on the synthesis of MSNs with uniform pore size and ordered pore structure using 
surfactant and structure-directing agents were published in 1992. [59, 60] The deep 
understanding of the sol-gel chemistry and availability of the different types of surfactants have 
made possible to produce MSNs with varied structures. Until now most of the research has 
focused on using MCM-41, MCM-48 and SBA-15 type MSNs for delivery applications. One of 
the major drawbacks of these conventional MSNs is their limited pore size (2-10 nm), which 
restricts their use in adsorption of large molecules such as proteins and DNA. Recently, several 
reviewers have discussed in depth the synthesis of various types of MSNs, [30, 61, 62] thus in 
this review we will only focus on recent advances in synthesis of MSNs especially in the area of 
vaccine delivery. 
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Table 2.1. Summary of different types of proteins loaded onto the mesoporous silica 
nanoparticles 
 
 
Material Modification Protein Ref. 
Hollow 
Mesoporous 
silica 
nanoparticles 
Unmodified PC2 GST-ORF2-E2 [26] 
Hollow 
Mesoporous 
silica capsules 
Carboxy, Amino, 5- 
aminofluorescein (AFL) 
BSA (bovine serum 
albumin), 
Goat IgG 
[43] 
MSN 
2-(methoxy 
[polyethyleneoxy]propyl) 
BSA [45] 
MSN CD4 HIV-gp120 [55] 
MSN Citraconic amide Cytochrome C [56] 
MSN Aminopropyl Insulin [57] 
SBA-15 Unmodified BSA [51] 
SBA-15 Unmodified BSA [28] 
SBA-15 Aminosilane Lysozyme [42] 
SBA-15 Aminosilane Myoglobin [42] 
SBA-15 Aminosilane Myoglobin [58] 
SBA-15 Aminosilane BSA [58] 
SBA-15 Aminosilane Lysozyme [58] 
SBA-15 Amine BSA [71] 
SBA-15 Unmodified 
Bacterial recombinant 
protein Int1! 
[54] 
SBA-15 Unmodified 
Snake venom proteins 
(20 proteins from 84-7 
kDa) 
[54] 
MCM-41 Unmodified Cytochrome C [49] 
MCM-41 PEGylated BSA [86] 
FDU-12 Unmodified BSA [87] 
FDU-12 Amine BSA [88] 
FDU-12 
Amine, Mercapto, 
Vinyl, Phenyl 
BSA [89] 
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Typically, a base-catalysed sol-gel process has been used to produce silica nanoparticles with 
suitable particle properties. [63] The Stöber method has been applied to produce monodispersed 
solid silica nanoparticles ranging between 20-2000 nm in size, by using the ammonia-catalysed 
hydrolysis of tetraethylorthosilicate (TEOS) in a water-alcohol solution. [64] Later, Cai et 
al.[65],[66] reported factors affecting morphology control and particle size of MCM-41. They 
synthesised particles with a variety of shapes and sizes using alkaline conditions. Subsequently, 
Zhao et al.[67] reported the synthesis of SBA-15 particles with highly ordered, 2-D hexagonal 
(space group p6mm) silica-block copolymer mesophases in acidic media with a particle size of 
approximately 1 !m. Although, MCM-41 and SBA-15 are amongst the most widely discussed 
family of MSNs in the biomedical field, their use in some specific applications such as protein 
adsorption and separation is limited due to its pore size and structure. 
 
Current studies have focused on the synthesis of new types of MSNs with specific structures 
(large pores, small particle size) and controlled release properties like hollow and rattle-type 
nanomaterials, the methods to fabricate hollow and rattle-type particles has been recently 
reviewed. [68] The synthesis of hollow structures can be classified into four groups, 
conventional hard templating, sacrificial templating, soft templating and template-free 
techniques. Extension of hard templating method to the sacrificial templating is known to be the 
most promising as it does not require additional surface functionalisation and readily forms a 
shell by chemical reaction. [68] These hollow/rattle type MSNs consist of an interstitial hollow 
space and a mesoporous shell with low density and high specific area. The high loading 
capacity of these particles makes them ideal as the next-generation of nanomaterials for vaccine 
delivery. [68]  
 
HMSNs have been synthesised using a sol-gel/emulsion method with modifications to adsorb 
antigens; [69] in addition, HMSCs with novel capsular morphology have been synthesised using 
the cetyltrimethyl ammonium bromide (CTAB) micellar assembly in cholesterol emulsion. [43] 
Synthesising materials with large pore (~30 nm to 50 nm), small particle size (50 nm to 200 
nm) and tunable surface properties will allow sufficient space for proteins and peptides to 
adsorb and release the payload at the desired site, and hence remains the area of intense focus. 
 
One of the most useful features of MSNs is its flexible physical and chemical properties 
through which adsorption and release of biomolecules can be tuned. [70] Functionalisation is 
one of the most widely used strategies to alter release of biomolecules from MSNs. To achieve  
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higher endocytosis MSNs that have been functionalised with positively charged functional 
groups (e.g. amino, triethanolamine, polyethylenimine, etc) have been investigated. Varieties of 
functional groups have been used to achieve adjustable stimuli responsive delivery systems 
such as pH,[71-78] time,[79] enzyme,[80-82] thermal and light. [73, 83] The pH responsive 
functionalisation is most widely used in cancer targeting utilising the distinct pH difference 
between intra and extracellular environment. Functionalisation is also vital for gene therapy as 
silica nanoparticles from a negative to a positive charge allowing the binding nucleic acids, 
which are also negatively charged. Additionally, functionalisation can also protect peptides and 
siRNA from degradation, ensuring their effectiveness as therapeutic delivery agents. Hence, 
efforts has been devoted to prepare positively charged MSNs to adsorb and protect DNA, 
siRNA and proteins for gene therapy. [47] 
 
In the pioneer work, Kneuer et al.[83] employed solid silica spheres (SSS) and modified them 
with primary amino groups to form complexes with negatively charged DNA. The concept of 
co-delivery of drug/gene therapy became feasible by delivering the specific siRNA to inactivate 
the gene responsible for a particular disease, followed by the release of an active moiety to 
achieve high efficiency. MSNs have emerged as one of the most promising components for co-
delivery of drugs and genes in the last decade. Traditionally, MSNs loaded with drugs have 
been functionalised with positively charged polymer to form complexes with proteins and 
peptides. [84, 85]  
 
Functionalisation of porous silica with a positive charge is also used to adsorb and separate a 
variety of protein-based antigens (Table 2.1). Song et al.[71] showed amino functionalised 
SBA-15 particles adsorb more BSA than bare silica due to strong interaction between 
negatively charged protein and amine. Post-synthesis grafting method was used to functionalise 
inner and outer surfaces of MSNs, which resulted in higher protein adsorption (~ 23%), 
compared to bare silica. The release of BSA from functionalised particles was low compared to 
the unfunctionalised counterparts, which is consistent with other studies. [45, 58] Interestingly, 
this phenomenon is protein dependent as Kim et al.[42] demonstrated a faster release of 
lysozyme and myoglobin from the amino functionalised material compared to the unmodified 
particles. Although, BSA successfully adsorbed onto amine modified SBA-15, spherical MSNs 
showed about ~50% of BSA adsorption due to high surface area and small particle size. [28] 
The protein adsorption efficiency could be further increased if these MSNs are functionalised 
with amino groups. Release of proteins from functionalised MSNs is a challenge and materials  
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with better adsorption and release kinetics are required in order to utilise MSNs as functional 
nanovaccine carrier. Many studies have been conducted on adsorption and release of DNA and 
siRNA using positively charged molecules. This strategy is less utilised when it comes to 
adsorption and release of proteins and peptides especially to induce immune response.  
 
The encapsulation of antigenic proteins onto a silica nanoparticle carrier system mainly takes 
place through adsorption and/or encapsulation (Fig 2.2). To determine the level of protein 
adsorption, protein-adsorbed samples are centrifuged and the unbound protein remaining in the 
supernatant is measured and compared to the pre-adsorption concentration using a colorimetric 
protein assay or by measuring the absorbance of the Soret band of the protein. The potential of 
ordered mesoporous silica as a vaccine adjuvant was first observed by Mercuri et al.[54], using 
SBA-15 as a carrier and adjuvant for bacterial recombinant protein Int1!. They demonstrated an 
increased immune response in mice. However, there was no evidence of in vitro release of the 
protein from the silica carriers.  
 
Fig 2.2. Schematic representation of preparation of antigen loaded nanoparticles by adsorption 
method.
Many researchers have studied the adsorption and release of proteins such as BSA, cytochrome 
c, lysozymes, and other antigens onto MSNs (listed in Table 2.1). Hartono et al.[89] 
demonstrated that the adsorption of BSA was significantly dependent on the type of functional 
group when using the large pore FDU-12. Amino functionalised and vinyl functionalised FDU-
12 particles showed the highest adsorption capacities of 132.6 and 50 mg/g respectively. 
Although protein adsorption was dependent on the pore entrance and cavity size, amino 
functionalised FDU-12 particles adsorbed BSA due to electrostatic interaction, while vinyl  
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functionalised particles relied on hydrophobic interaction for protein adsorption. However, in 
most cases the protein was used as a model drug but not as an antigen for gene therapy or 
immunotherapy. The adsorption and release kinetics of Type 2 ORF2 protein from porcine 
circovirus adsorbing to HMSN particles, suggests adsorption takes place in a two-step process 
with the capacity of 150 !g protein/mg HMSN. In vitro release behaviour of this protein was 
very fast in first 12 hr followed by a slow release for about a week confirming a weak 
interaction between protein and HMSNs. [26] Additionally, lymphocytes proliferation and IFN-
" responses showed encouraging results.  
 
Silica architecture also affects adsorption and release of large antigens such as proteins and 
peptides. BSA was shown to bind highest to the 430 nm S1 particle with an eye combed pore 
structure, compared to S2 (130nm) and SBA-15 (1-2µm). [28] S1 bound BSA also resulted in 
the highest antibody titres in vivo, which is in line with earlier studies. [88, 90] While these 
results are encouraging, more work needs to be done in designing nanocarriers for vaccine 
delivery. For instance, higher protein loading capacity will reduce the systemic concentration of 
silica nanoparticles whilst maintaining a high antigen dose. Elicitation of an immune response 
is heavily dependent on how the antigen is presented or released. It is also dependant on its 
uptake by M-cells (microfold cells) and APCs. M-cells are involved in transport of particles 
from gut lumen to immune cells across epithelial barrier in order to generate mucosal immunity. 
Thus, precise control over release of the antigen is necessary in order to achieve target 
specificity. Novel nanomaterials with high protein loading and immune cell specific release are 
sought after in order to achieve clinically acceptable formulation based on MSNs.  
 
2.3 MSNs as Adjuvants in vaccine formulation 
 
Adjuvants are often added to vaccine formulations to obtain a desired level of immunogenicity 
against the antigens and they can be classified based on their component sources, mechanisms 
and physicochemical properties. Adjuvants act as immunostimulants by directly acting on the 
immune system or as delivery vehicles carrying antigens to the immune system. [13] Adjuvants 
must be suitably formulated for stability and maximum effect. The advantages of adjuvants 
include: 1) they increase the total antibody titre, 2) decrease the number of doses required to 
achieve complete immunisation, 3) enhance immune response, and 4) potentiate cell-mediated 
immunity, mucosal immunity and provide cross-protection. [91] 
 
 
 28 
In general terms, immunity is divided into two major categories: innate and acquired immunity. 
Innate immunity is the first line of defence; however when a foreign organism is not removed 
by innate immunity acquired immunity produces antigen specific B-cells and T-cells to prevent 
reinfection with the same organism. Furthermore, acquired immunity is divided into two 
separate arms of defence, B-cell mediated or humoral immunity and T-cell mediated or cellular 
immunity. [92] There are two subsets of T-lymphocyte cells. CD4+ T helper cells and CD8+ 
cytotoxic T cells. The T-cell receptors on the surface of T-cells regulate the cells and eliminate 
antigen to mount an effective immune response. [93] CD4+ T cells differentiate into T-helper 
type 1 (Th1) cells and T-helper type 2 (Th2) cells. Th1 cells drive the immune response towards 
a cell-mediated immune response and Th2 cells promote a humoral or allergic response (Fig 
2.3). [94] Adjuvants on their own have limited or no efficacy, nonetheless strong adjuvant 
activity in a formulation is often correlated with increased toxicity and adverse side effects. 
Therefore, both adjuvant components and formulation specifications e.g. resuspension medium, 
particle size, and charge are crucial for enhancing vaccine potency. [13] 
Fig 2.3. Schematic representation of induction of T-cell mediated immune response.  
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Quil-A, an extract from the bark of Quillaja saponaria and its purified saponin QS-21 is the 
most common adjuvant used in mice trials. The saponin-based adjuvants stimulate Th1 immune 
response and production of cytotoxic T-lymphocytes against antigens, making them ideal for 
use in subunit vaccines for infectious diseases and cancer immunotherapy. [95-97] However, 
disadvantages like pain at the site of injection, severe local reactions and toxicity profile of 
these adjuvants make them unsuitable for human use. [13, 98] Freund’s complete adjuvant 
(FCA) and immune-stimulating complexes induce both humoral and cellular immune responses, 
making FCA as one of the most effective adjuvant. Nevertheless, FCA is known to induce high 
toxicity and severe reactions, limiting its use in humans. [99] 
 
Alum-type adjuvants are widely used in human and veterinary vaccines. The Food and Drug 
Administration (FDA) of the United States have only approved aluminium salts as adjuvant for 
human use. [100] Alum based adjuvants induce strong antibody responses and directly activate 
DCs. Adsorption of antigens to aluminium compounds can help retain the antigen at the 
injection site at a higher concentration, therefore providing a sufficient uptake time for DCs. 
However, drawbacks associated with these adjuvants is that they are not effective for all 
antigens and often induce local reactions at the site of injection and generally fail to induce 
CD8+ T-cell immunity. [101] Reed et al.[13] have comprehensively covered different types of 
immune responses triggered by a variety of delivery systems and have given an overview on 
different types of adjuvants that are being used in the development of human vaccine 
formulations in pre-clinical and clinical trials. [13]  
 
Most of the conventional vaccines produce either a Th1 or Th2 mediated response (Table 2.2), 
hence there is a need for a robust, non-toxic and effective adjuvant that can induce the co-
production of immune responses with minimal or no side effects. [102, 103] Silica 
nanoparticles may provide us with a solution as they have the potential to act as adjuvants in 
vaccine delivery (Table 2.3).  
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Table 2.2. Different types of immune responses elicited by nanocarriers or delivery systems. 
 
As an alternative to currently available adjuvants, new approaches in vaccine development have 
been antigen encapsulation, surface-immobilisation or protein adsorption onto nanoparticles. 
The potential of any biomaterial to act as an adjuvant is determined by the degree of DC 
maturation induced (Fig 2.4). 
Carriers or delivery systems 
Th1 
response 
Th2 
response 
Cross 
priming 
B-cell 
response 
Aluminium salts (Alum)  ✓ - ✓ 
Saponins (Quil-A) ✓  - ✓ 
Incomplete Freund’s adjuvant and 
Complete Freund’s adjuvant 
- ✓ - ✓ 
ISCOMs ✓ ✓ ✓ ✓ 
Liposomes ✓  ✓ ✓ 
Emulsions (MF59®) ✓ - - ✓ 
Silica nanoparticles (SBA-15, 
HMSNs [hollow mesoporous 
silica nanoparticles]) 
✓ ✓  ✓ 
Polymeric microparticles, PLA 
(polylactic acid), PLG 
(poly[lactide-co-glycolide]) 
✓ ✓  ✓ 
Chitosan nanoparticles ✓ ✓  ✓ 
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Fig 2.4. Schematic representation of initiation of immune responses by silica nanoparticle-based 
vaccine. 
Table 2.3. Summary of different sized silica particles showing the systemic adjuvant effect. 
 
Particle 
type  
Size Antigen Route Result Ref. 
HMSN 200 nm PC2 GST-ORF2-
E2 
i.m. Protein loaded nanoparticles induced 
a higher humoral and cellular immune 
response compared to protein alone 
[26] 
S1 
S2 
SBA-15 
430 nm 
130 nm 
1-2 !m 
BSA i.m. / 
oral 
IgG and IgA titers obtained with 
protein loaded silica nanoparticles 
were in the order of S1 > S2 > SBA-
15. 
[28] 
SBA-15 10–12 
nm 
BSA i.m. / 
oral 
Induced coproduction of both IgG2 
and IgG1 isotypes. 
[51] 
SBA-15    Recombinant 
protein 
  Int1! and snake 
  venom proteins 
s.c. SBA-15 showed better adjuvant 
property than alum 
[54] 
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The maturation of DC is associated with increased expression of several cell surface markers, 
including the co-stimulatory molecules: CD40, CD80, CD83, CD86, MHC class I and II. DC 
maturation can be induced by inflammatory cytokines like tumour necrosis factor-alpha (TNF-
!) or inflammatory factors like lipopolysaccharide and bacterial DNA. The DC maturation 
process is highly important for the initiation of immune response. [104, 105]  
 
Moghimi et al.[106] have demonstrated that by attaching a polyethylene glycol (PEG) or any 
other type of polymer to nanoparticles a hydrophilic environment can be created which protects 
the nanoparticles from non-specific recognition. Antigen loaded nanocarriers have shown 
promising potential in cancer therapy due to their capacity of being actively taken up by the 
APCs and eliciting antigen-specific immune responses. [107] Few studies have focused on the 
use of biodegradable nanoparticles as adjuvants for vaccine delivery. [95, 108]  
 
Gennari et al.[109] conducted an in vivo study to compare the effect of silica injection on 
antibody responsiveness to selection antigens in H and L mice of four selections. They reported 
that administration of amorphous silica particles had a weakening effect on macrophage (M") 
cell activity and its treatment constantly improved antibody response. They administered silica 
intravenously or locally in one hind footpad at 6 h or 24 h before immunisation by the same 
route. M" have a weak APCs capacity but are known to initiate innate or acquired immune 
response as they compete with B-lymphocytes and DCs, which have a powerful APC function, 
necessary to initiate an efficient immune response. [54]  
 
Silica nanoparticles might provide a solution to tackle the issues associated with conventional 
adjuvants and improve the overall safety profile of the vaccine formulations. However, whether 
or not MSNs act as adjuvants and induce an immune response greatly depends on the factors 
including architecture of the particle and protein, binding capacity of the particles, protein 
conformation, concentration and surface charge of the nanoparticles and proteins, and uptake of 
protein loaded nanoparticles by M-cells and APCs as well as their release profile.  
 
The first report on the use of porous silica nanoparticles as an adjuvant was described in 2006 
using ordered mesoporous silica SBA-15 particles. [51, 54] To explore the efficiency of SBA-
15 as antigen carrier Mercuri et al.[54] used bacterial recombinant protein Int1! (16.5 kDa) and 
20 snake (Micrurus ibiboboca) venom proteins. Mice were immunised by a 200 #L 
subcutaneous injection (s.c.) dose containing Int1! (10 µg) encapsulated in 100 #g SBA-15 or  
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100 !g aluminium hydroxide [Al(OH)3], the booster dose for Int1! consisted of the same 
concentration. The Micrurus venom (2 µg) was administered with SBA-15 (20 µg) or with 
incomplete Freund adjuvant (IFA). The authors compared the efficacy of the protein loaded 
SBA-15 particles to that of protein plus traditional adjuvant using antibody responder mouse 
lines high (H) and low (L). The antibody titres of IgG1 and IgG2a were determined using the 
sera samples and the SBA-15 was found to have a better adjuvant property than Al(OH)3 and 
was found to be as effective as IFA in maintaining the antibody levels for 30 days during the 
primary response. After the second immunisation with Int1! protein the animals were 
challenged with Int1! (10 µg) in Al(OH)3. Mice primed with SBA-15 containing Int1! gave 
better antibody titres of 8.5 log2 compared to the mice immunised with protein plus traditional 
adjuvant Al(OH)3 which only gave an antibody titre of 5.2 log2. This study established the 
potential of SBA-15 nanoparticles to induce a memory response.  
 
The ability of SBA-15, as an adjuvant, to carry, protect and deliver entrapped antigens and to 
elicit an immune response was further analysed by Carvalho et al.[51] using BSA. They 
compared the adjuvant effect of BSA adsorbed to SBA-15 or Al(OH)3 or emulsified in IFA. H 
and L antibody responsive (Selection III and IVA) mice were vaccinated with a 50 µL dose via 
intramuscular (i.m.) injection or a 200 µL dose was given orally comprising of 10 µg of BSA 
adsorbed to SBA-15 or Al(OH)3 or BSA emulsified in IFA via i.m. In the Selection IVA mice, 
the antibody response difference in the responder H and L lines is mainly due to antigen 
catabolism of M" and other APC, and in the Selection III mice, the difference is due to the 
basic genetic modifications of B-lymphocytes. [110-112] Both H and L lines for Selection IVA 
and III elicited comparable serum specific IgG antibody titres when immunised through i.m. 
and oral route with BSA in SBA-15. However, the levels of anti-BSA IgG in the LIVA mice 
immunised with BSA in Al(OH)3 were 16 fold lower than the HIVA after the initial 
immunisation and 4 fold lower after the second immunisation. In comparison the Selection III 
mice had 4 fold lower anti-BSA IgG titres after the initial immunisation and the difference 
increase to 256 fold after the booster dose. Both SBA-15 and IFA elicited comparable antibody 
titres. Administration of BSA in SBA-15 or emulsified on the IFA, corrected the antibody 
responsiveness of the low responder mice and eliminated the phenotypic differences between 
the H-L responders in both Selections III and IVA. The protein encapsulated/adsorbed SBA-15 
nanoparticles induced an antibody response comparable to that of the traditional adjuvant IFA 
in mice. Furthermore, the administration of SBA-15 did not induce any local tissue damage or 
granulomas formation. [51]  
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An earlier report has shown that the administration of colloidal silica greatly increased antibody 
responsiveness in LIVA but not in LIII, additionally the effect of silica was found to be absent in 
HIII and HIVA.[109] Wang et al.[28] investigated three kinds of silica nanoparticles (S1, S2 and 
SBA-15) with different sizes (430 nm, 130 nm and 1–2 µm) and pore characteristics for 
adsorption of BSA and to develop vaccine delivery systems. They compared the immune 
responses obtained by BSA loaded onto silica with BSA emulsified in FCA. Mice were 
administered a 200 µL dose by intragastric gavage and 100 µL dose via i.m. injection with the 
doses consisting of 10 µg of BSA. The oral immunisation with BSA alone did not produce any 
IgG antibodies, but the mice vaccinated with BSA loaded on silica nanoparticles produced 
significant amount of BSA-specific IgG antibody response (S1 > S2 > SBA-15) in the plasma. 
However the IgG titre of BSA plus S1 nanoparticles was lower than the BSA antigen emulsified 
in FCA. The mucosal immune response was assessed using the intestinal and oral secretions and 
negligible amount IgA response was obtained following (i.m.) vaccination with BSA plus FCA 
and oral BSA, whilst oral immunisation with protein loaded silica nanoparticles resulted in a 
higher IgA immune response, with S1 showing the highest titre, followed by S2 and SBA-15. It 
was found that the immune response elicited was significantly dependant on the uptake and 
release profile of the antigen and the structure of silica. Slowing down the release rate of 
proteins from 47% (SBA-15) to less than 8% (S1) enhanced the antibody titre. All the three 
nanoparticles had different release rates, the justification by the authors is that it might be due 
to the different pore sizes; large pores improve the interaction of antigen with the nanoparticles 
and lead to their slow release. Increase in the particle size can reduce the release of BSA, which 
in turn would allow a longer interaction between antigen and the immune system. [28]  
 
The hollow structured MSNs (HMSNs) have been used as an antigen delivery vehicle for 
Porcine circovirus type-2 (PCV2) ORF2 protein. The mice were immunised intramuscularly 
with a 100 µg dose (0.7 mg HMSNs loaded with 100 µg of protein) or GST-ORF2-E protein 
alone or empty HMSNs. The humoral antibody titres of mice injected with GST-ORF2-E 
protein alone increased in the 2nd week and reduced dramatically in the 3rd week post-
immunisation. However, the antibody titres of the mice administered HMSNs loaded with GST-
ORF2-E protein increased continuously for three weeks post-immunisation. Similarly, HMSNs 
loaded GST-ORF2-E protein gave a higher T-lymphocyte mediated immune response compared 
to the mice immunised with GST-ORF2-E protein alone. The percentage of CD4+ and CD8+ 
cells in mice immunised with HMSN/GST-ORF2-E was found to be higher than the mice 
immunised with HMSNs particles only and GST-ORF2-E protein at the 4th and the 6th week.  
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The authors have highlighted that HMSNs as vaccine carriers can improve both humoral and 
cell mediated immune responses and induce persistent immune response. [26]  
 
Slowing et al.[52] explained that the slow release of antigens from silica nanoparticles can be 
due to the highly stable and rigid framework of the porous silica, which might form a barrier to 
prevent the degradation of the antigen in the stomach and digestive tract. In our laboratory, we 
successfully loaded model antigen OVA and the viral antigen E2 from Bovine Viral Diarrhoea 
Virus onto mesoporous silica nanoparticles and conducted in vivo mice studies. Immunisation 
with OVA loaded onto amino fuctionalised MSNs induced both Th1 and Th2 immune responses 
(Mahony et al., in press). Immunisation with E2 viral protein loaded onto amino functionalised 
HMSN induced both antibody and cell mediated immune responses (personal communication). 
 
The research reviewed above, highlights the exciting progress that has been achieved in the area 
of vaccine delivery using silica nanoparticles in the last decade. In addition, the FDA recently 
approved the use of ultrasmall multimodal silica nanoparticles termed Cornell dots (C dots) in 
the first-in-human clinical trial for diagnostics of advanced melanoma. [113, 114]  
 
Indeed, MSNs have a bright future as adjuvants for vaccine delivery. Nonetheless, in vivo 
biodistribution and biocompatibility of these novel nanocarriers is still a topic of intense 
research and demands long-term in vitro and in vivo trials in future as discussed in the 
following section.   
 
2.4 Biocompatibility and Biodistribution of MSNs 
 
For in vivo biomedical applications it is highly important that nanoparticles perform their 
desired function and do not cause any histopathological lesions or abnormalities. Even though, 
silica is considered non-toxic in low doses, having been used in the pharmaceutical industry as 
an excipient for decades, the long-term effect of MSNs in vivo needs to be assessed. The 
biocompatibility of MSNs depends on the particle size, morphology, structure, surface 
properties and the dosage. At lower concentrations MSNs are found to be non-toxic in a variety 
of cell lines but at higher concentrations they can have inhibiting effect on cells. [36, 115, 116] 
In vitro interactions of MSNs with various cell lines like HeLa cells,[57, 117] 3T3 endothelial 
cells,[118] human mesenchymal stem cells,[119] and human colon carcinoma[120] have been 
investigated. The compatibility of nanoparticles is directly related to their biotranslocation. [30]  
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In this section we discuss the cytotoxicity and in vivo toxicity effect of MSNs, their distribution 
when injected in small animals like mice and their route of excretion from the immune system.  
The surface area of the particles is positively correlated with the toxicity of nanoparticles. Small 
sized nanoparticles with large surface areas and abundant silanol groups have the ability to 
generate reactive oxygen species (ROS), which play a role in the ability of nanoparticles to 
cause injury. [121]  
 
Eom et al.[122] studied the relationship between physico-chemical properties and toxicity of 
silica nanoparticles and their ability to activate transcription factors and the signal transduction 
pathway. They further demonstrated that MSNs (MCM-41 and SBA-15) can inhibit cellular and 
mitochondrial respiration causing oxidative stress. [122, 123] Recently, it was found that the 
pore architecture of silica nanoparticles too greatly influences their biocompatibility. In vitro 
and in vivo studies on spherical 100 nm MSNs exhibited less cytotoxicity (time and dose 
dependant), reduced inflammatory response, and contact hypersensitivity than the colloidal 
solid counterparts. [124]  
 
Toxic effects of silica nanoparticles on the immune system are mainly due to the interference 
with signalling pathways involved in immune response activation. MSNs elicit lower 
expression of pro-inflammatory cytokines, such as TNF-!, interleukin (IL)-1" and IL-6 in M#. 
The lower activation of mitogen-activated protein kinases, nuclear factor-$B, and caspase 3 by 
MSNs are responsible for reduced inflammatory response and apoptosis. Similarly, porous 
MSNs induce less cytotoxicity compared to the non-porous counterparts,[124, 125] 35 nm and 
70 nm non-porous silica nanoparticles when administered intravenously to mice can cause 
pregnancy complications. [126] Lin et al.[127] demonstrated that MSNs have low haemolytic 
activity compared to the non-porous counterparts and the pore stability of MSNs determined the 
hemolytic activity. Modifying the silanol surface with PEG coating can eliminate haemolytic 
activity. Porous silica was found to be less toxic than the non-porous silica due to the larger 
surface area while the ‘cell-contactable surface area’, the area available for proteins and other 
biomolecules to interact with the porous silica is lower. [125] In addition, the porosity of silica 
nanoparticles determines the cellular uptake of MSNs by cells.  
 
Using human monocyte derived dendritic cells, Vallhov et al.[128] reported that the particle 
size and concentration of MSNs affected the viability, uptake and immune regulatory markers 
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of the cells. Smaller particles (270 nm) with lower concentrations had a lesser affect on the cells  
 
compared to large sized particles (2.5 µm) at higher concentrations; encouraging the use of 
small sized MSNs for vaccine delivery. [128] Lu et al.[129] demonstrated 50 nm MSN particles 
showed the maximum cellular uptake by HeLa cells, which was about two times greater than 
the uptake of 30 nm particles. Cellular uptake of 110 nm, 280 nm and 170 nm MSNs was 
observed to be proportionally lower. In addition, the authors established that the excretion 
properties of MSNs was also size dependent. Different sized (80, 120, 200 & 360 nm) spherical 
and PEGylated MSNs were administered intravenously into mice to study biodistribution and 
excretion of the particles. [31] The results indicated that after immunisation, MSNs were mainly 
distributed in liver and spleen, with a minority in the lungs and a small amount in the kidney 
and heart. Significantly, neither MSNs nor PEG MSNs caused in vivo tissue toxicity. The 
biodistributed percentage of both MSNs and the PEG-MSNs in the liver and spleen increased 
with the increase in the particle size for 30 min after injection, however, the PEG-MSNs with 
360 nm diameter were found to be an exception as they were not captured by spleen within 30 
min of injection. This indicates that mostly the organs can easily capture both MSNs and PEG-
MSNs with larger particle size. In addition, the excretion from urine significantly increased 
with the increase in particle size, importantly smaller sized particles had longer blood 
circulation lifetime. [31]  
 
Polymers like PEG are known to improve the circulation time of particles by delaying 
opsonisation and reducing the excretion rate.[130] The in vivo biodegradation and excretion rate 
of the degraded products is highly dependant on particle size. Research studies using 45 nm 
MSNs found that the particles largely accumulated in liver, kidney and urinary bladder a few 
hours after intravenous injection and were excreted through the renal route. [131] In another 
study it was found that approximately 95% of MSNs (100-130 nm) were excreted in urine and 
faeces. [36] Burns et al.[132] found smaller sized silica nanoparticles (3.3 nm and 6.0 nm) had 
a longer blood circulation time and the particles were excreted via renal filtration.  
 
It is clear from the above-mentioned studies that majority of the particles are excreted from the 
immune system via the renal route. Sergent et al.[133] studied the toxic effect of core-dye 
doped silica nanoparticles (25 nm and 100 nm) to track nanoparticles using confocal and video 
microscopy in human epithelial intestinal HT-29 cells. They used the sulforhodamine B (SRB) 
test, which measures the global metabolism activity based on Skehan protocol [134] as well as 
conventional approaches like flow cytometry and !-H2Ax foci. In addition they performed real-
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time monitoring of cell proliferation to measure the physico-chemical characteristics of the  
 
nanoparticles. Both SiO2-25 nm and SiO2-100 nm induced limited cytotoxic effect on the cells 
after 24 h exposure (at concentrations ranging from 10 to 150 µg mL-1) However, an inverse 
dose-dependant relationship was observed with the 100 nm nanoparticles, increasing the dose of 
SiO2-100 nm particles lower the cytotoxic effect on the cells compared to the SiO2-25 nm 
particles.  
 
Similarly, Passagne et al.[135] demonstrated toxicity of silica nanoparticles on human HK-2 
and porcine LLC-PK1 renal proximal tubular cells to be time (24 h, 48 h, 72 h) and size (20 nm 
and 100 nm) dependant. The 100 nm particles were found to be less toxic than the 20 nm 
particles, and when observed using an transmission electron microscope (TEM) the 20 nm 
particles were localised in vesicles. [135] Hudson et al.[34] reported a detailed study on the 
cytotoxicity and biocompatibility of mesoporous silicates (MCM-41, SBA-15 and mesocellular 
foam) with different sizes and pore diameters on in vitro mammalian cells and in vivo mouse 
models. They found that administration of 30 mg mesoporous silicates was found to be toxic 
when administered intraperitoneally or intravenously, but not subcutaneously.  
 
SBA-15 particles have a smaller surface area and poor porosity compared to MCM-41. Tao et 
al.[123] found that positively charged amino functionalised SBA-15 and MCM-41 particles did 
not cause significant cell death in human T-cell lymphoma (Jurkat) cells, as the positively 
charged quaternary amines prevent cellular injury from mesoporous nanoparticles. They 
confirmed this by conducting an endocytosis study using bright field microscopy and cell 
imaging with TEM, and observed that the unmodified MSNs got internalised but not the amino 
functionalised MSNs. However, the SK-N-SH cells were found to be more resistant to both 
unmodified and functionalised nanoparticles. Only at a high dose of 200 µg/mL amino 
functionalised MSNs induced a noticeable cell death. Unmodified MSNs have a negative zeta 
potential and rapidly associate with serum opsonin after entering the blood stream and are 
cleared by M! in the reticuloendothelial system (RES). The authors concluded that structures, 
dose-dependency as well as surface functionalisation of silica nanoparticles (MCM-41, SBA-15 
and solid-cored spheres) can have cytotoxic effects on Jurkat and human neuroblastoma cells. 
[123]  
 
Surface modification plays an important role in changing the surface properties of MSNs, hence 
improving the biocompatibility and in vivo circulation time of the particles. Although, 
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PEGylation can decrease the endocytosis of mesoporous silica nanoparticles,[123, 136] a recent  
study has suggested that the PEGylated nanoparticles can induce production of specific anti-
PEG IgM, which is responsible for accelerated blood clearance of nanoparticles after repeated 
injection. [137] At higher concentrations the mesoporous silicates induce toxicity, although 
toxicity can be reduced by addition of a functional group. [123] Even though, our understanding 
on biocompatibility and biodistribution of MSNs and their interaction with the immune system 
has improved significantly, the adjuvant effect of MSNs still requires deeper investigation and 
understanding before its use in a clinical setting. 
2.5 Conclusion and Future Outlook 
 
In conclusion, we have reviewed the potential of MSNs as antigen carriers and their ability to 
act as adjuvants in vaccine delivery. MSNs can be easily synthesised with controlled size, shape 
and structure, making them highly attractive as delivery vehicles. Nonetheless, the application 
of MSNs in vaccine delivery is a relatively new area and has not been studied in great details. 
There exist unsolved questions and challenges that need to be addressed before their practical 
use in clinical applications.  
 
Designed synthesis of new MSNs with optimised structures and functions is of ultimate 
importance for generating highly efficient adjuvants. Ideally, MSNs as adjuvants should be 
prepared using simple, reproducible, economical and scalable methods. It will be of great 
advantage to synthesise MSNs with low toxicity, large loading capacity, and controlled antigen 
release profiles. A comprehensive understanding on the impact of structural parameters of 
MSNs, such as morphology, size, and surface functional groups, on the antigen adsorption and 
release performance, may provide useful guide for the rational choice of suitable MSNs. 
Apart from the interaction between antigen and MSNs, the cellular interaction of MSNs as well 
as antigen loaded MSNs should be studied in more details. Although the influence of a few 
parameters (e.g. the particle size) on cellular uptake has been studied, the interplay of various 
structural parameters of MSNs, interactions of antigen-MSNs and MSNs-cells has received 
little attention, which may significantly impact on the in vivo release profiles of antigen and the 
effective dosage, hence the eventual generation of immune response. Moreover, the in vivo 
immune response is an outcome of a sequence of complicated biological events, including the 
interaction of antigens and MSNs as the adjuvants with various types of immune cells (e.g., 
macrophage or phagocytic cells). Variation in one parameter such as the antigen or MSNs may 
change the overall response. It is suggested that future studies should focus on the entire  
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immune system, which includes antigen-MSNs-various immune cells as an integrated system. 
Systematic studies in the regard may provide genuine and comprehensive information towards a 
highly efficient vaccine formulation. 
 
The factors like nanoparticles architecture, antigen type, antigen loading/encapsulation, dose 
administered, and immunisation route can influence the adjuvant properties of silica 
nanoparticles. To test the immune response of a formulation, a pre-clinical model is crucial 
which provides more information compared to cell studies. It is important to select a reliable 
and reproducible biological model and conduct biocompatibility and immune response studies 
at the cell biology, molecular biological and immunochemistry levels. In this regard, material 
scientists, biologists and immunologists are expected to work closely and bring in 
complementary expertise from various fields in order to have a deep understanding on the 
fundamental interaction mechanisms in a complex bionano system. Multidisciplinary and 
collaborative research will provide a concrete platform to bring MSNs as promising adjuvants 
for vaccine delivery in practical applications. The capacity of MSNs to induce both humoral 
and cell-mediated immune responses is advantageous over traditional adjuvants, which often 
induces only one arm of the immune response, taking us one step closer towards developing 
effective and safe vaccines.  
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3. 
Literature Review 
Freeze-drying of Protein loaded Nanoparticles for 
Vaccine Delivery 
 
 
 
 
 
 
 
 
 
 
In Chapter 3, the basics of the freeze-drying process and its impact on development of nanoparticle 
based vaccine delivery systems was investigated. This literature review discusses different steps of 
freeze-drying process, role of excipients, freeze-drying of protein loaded nanoparticles and 
assessment of the physico-chemical characteristics of the formulation after freeze-drying. Chapter 
3 is published in Drug Delivery Letters 2012, 2, 83-91. 
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3.1 Introduction 
 
Vaccination is considered as one of the greatest achievements in the field of science. [1] Most of the 
vaccines currently available in the market comprise of biomolecules, protein, antigens and nucleic 
acids and they have drawbacks such as instability and limited efficacy associated to them. 
Biomolecules like proteins and peptides when delivered as oral vaccines can fail to cross biological 
barriers due to metabolic enzymes and impermeable mucosal tissues in the intestine and hence fail 
to reach the target sites. [2-4] In addition, some conventional vaccines have issues such as 
manufacturing difficulties and storage instability and this encourages development of safe, stable 
and effective vaccines.  
 
Nanoparticles can be used as delivery vehicles to deliver drugs, proteins, peptides and nucleic acids 
as they have desirable chemical, physical and biological properties. The nanoparticles can act as 
both the delivery vehicles and adjuvants, [2, 5] in addition strong immune responses can be induced 
when an antigen is associated to nanoparticles. [6-8] Development of novel delivery systems for 
peptide and protein vaccines has the potential to be useful in clinical medicine and research; by 
providing antigen protection and thereby improving the pharmacokinetics of easily degradable 
peptides and proteins, which often have short half-life in vivo. [4, 9, 10] Adsorbing proteins 
(antigens) to nanoparticles can enhance the shelf-life of the vaccine. [11] While nanoparticle 
technologies can improve overall stability of some vaccines the degree of improvement can be 
dependent on the specific formulation under evaluation. To further enhance stability of 
nanovaccines formulations freeze-drying techniques can be used.  
 
The freeze-drying process also known as lyophilisation; removes water from a frozen sample and 
has been used to preserve unstable molecules for long periods of time by maintaining the chemical 
properties of substances like proteins, peptides and other complex synthetic organic molecules. [12-
14] Freeze-drying proteins offer the advantages of prolonged shelf-life, improved storage and ease 
of shipping to the end user all of which are important issues in developing countries where 
maintenance of cold chain storage can be problematic. [15] In addition, freeze-drying strategies are 
extensively used to facilitate the stability of nanoparticle-based vaccine formulations and thereby 
the long-term antigen immunogenicity as well as ensuring formulation sterility. [16] Abdelwahed et 
al. [16] have reviewed freeze-dried nanoparticle formulations with different encapsulated drugs. 
Zillies et al. [17] have briefly discussed examples of different nanoparticle formulations that have 
been successfully freeze-dried and reported in the literature. However, very limited information is  
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available about successful freeze-drying of protein-loaded nanoparticles for vaccine delivery 
applications.  
 
The focus of this paper is to provide an overview on different parameters of the freeze-drying 
process that may have an impact on the potency of nanoparticle-protein formulations. Description 
of the freeze-drying process, importance of using cryoprotectants and lyoprotectants towards the 
development of new protein-based nanovaccines and assessment of physico-chemical 
characteristics on the freeze-dried samples has been reviewed. 
 
3.2 Freeze-drying Process 
 
During the freeze-drying procedure the solvent is removed from the frozen solution by sublimation 
and desorption under reduced pressure. [18] The freeze-drying process is divided into three steps, 
freezing (solidification), primary drying (ice sublimation), and secondary drying (desorption of 
unfrozen water). [16] 
 
3.2.1 Freezing 
The initial freezing step of the nanoparticle suspension can be performed rapidly in liquid nitrogen 
or by slowly freezing of the samples (-20°C or -80°C). Slow freezing can increase the protein 
damage in systems prone to phase separation [19] and liquid nitrogen freezing is more suitable for 
freezing smaller volumes. [12]  
 
3.2.2 Primary drying 
Primary drying is the longest step of the freeze-drying cycle and it has a significant impact on the 
final product outcome. [20] Determining the optimal drying parameters for the primary drying step 
can require extensive experimental studies. During the primary drying step the shelf temperature is 
increased, and the heat in the chamber is removed by ice sublimation. Properties of the proteins and 
excipients are used determine the collapse temperature of the formulation (Tc). This is the 
temperature at which the freeze-dried product collapses during the freeze-drying process and loses 
its structural integrity. [12, 21] The primary drying step is used to optimise the product temperature 
(Tp) [12] and the Tp depends on various factors such as type of freeze-dryer, shelf temperature, 
chamber pressure, the container system, heat transfer, type of vials, the volume of sample to be 
freeze-dried and product resistance. [22] Since the primary drying step depends on the various 
factors mentioned above it is difficult to optimise the freeze-drying process for the nanoparticle  
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formulation even when the Tc of the formulation and the glass transition temperature (Tg’) are 
known. [12] The target product temperature, collapse temperature of the formulation, chamber 
pressure, shelf temperature, and target product temperature of the protein formulation, need to be 
considered to design an optimised primary drying step and have been reviewed by Roy et al.[15], 
Tang et al. [12] and Abdelwahed et al.[16]. 
 
3.2.3 Secondary drying 
This is the last stage of freeze-drying process during which water that did not freeze is removed, 
and this stage usually lasts only a few hours. For the desorption of the water to occur the secondary 
drying is always performed at higher temperature relative to the temperature used for the primary 
drying. [12] The preferred amount of residual moisture content in the final product controls the 
length of the secondary drying cycle. The main objective of the secondary drying stage is to get a 
stable product with residual moisture content of less than 1% [16]; freeze-drying process can only 
be developed empirically and is assessed by testing the physico-chemical characteristics of the 
resulting freeze-dried products. 
  
3.3 Role of Excipients  
 
Freeze-drying process involves two denaturing conditions: freezing and drying. The addition of 
excipients can protect protein-loaded nanoparticles from freezing and drying stresses. [14, 15, 23-
25] The excipients used to protect from the freezing stress are known as cryoprotectants while the 
lyoprotectants are known to minimise the effects caused by the drying stress. [26] Various studies 
have revealed that during the freeze-drying process, protein solutes start to freeze; pure water is 
separated as ice and may cause proteins to undergo physical stress leading to protein denaturation, 
unfolding and aggregation. [27] By using cryo/lyo protectants during the drying process water that 
is normally hydrogen-bonded to the surface of proteins is replaced by the cryo/lyo protectants to 
protect the protein conformation and structural integrity. [28]  
 
Many sugars like glucose, sucrose, mannitol, and trehalose have been used as protein stabilisers. 
The widely used cryoprotectants include sugars/polyols, polymers, amino acids, proteins itself and 
surfactants; these cryoprotectants can also be used as lyoprotectants except for non-aqueous 
solvents like PEG and glycerol, as they reduce the loss of protein activity during freezing. [26] 
Moreover, the commonly used excipients are classified as bulking agents, buffering agents, or 
solubilising agents. Examples of the bulking agents are mannitol, lactose, sucrose, and trehalose,  
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amino acids like arginine, glycine, and histidine and polymers like dextran and polyethylene glycol 
(PEG). Bulking agents are added to aid the formation of bulk and provide adequate structure to the 
freeze-dried cake. Buffering agents like hydrochloric acid and sodium hydroxide control the pH of 
the freeze-dried product thereby avoiding degradation of the vaccine during processing, storage and 
reconstitution. Examples of solubilising agents include surfactants, co-solvents and complexing 
agents like ethylenediamine tetra acetic acid (EDTA). If the freeze-dried cake demonstrates poor 
wetting characteristics the solubilising agents can be added at low concentrations to assist 
reconstitution. [29]  
 
Sugars in combination with non-aqueous solvents can be used to preserve the characteristics and 
maintain stability of both the protein as well as nanoparticles during lyophilisation. [13, 14, 30] For 
example, Carpenter et al. [31] and Prestrelski et al. [32]  described a two-component excipient 
system in which PEG acted as the cryoprotectant and glucose at low concentration acted the 
lyoprotectant. They determined that until the native form of protein was protected during freeze-
drying with the help of excipients complete recovery of active protein on reconstitution could be 
difficult. Different excipients may stabilise the proteins in different ways depending on the target 
proteins. [31, 32] Amphiphilic excipients like PEG when dispersed into sugar-matrices act as good 
stabilisers for freeze-drying proteins. [33] PEG has a high molecular weight [34] and increases the 
collapse temperature of the product resulting in higher drying temperature and enhances product 
stabilisation probably by creating steric interference. [16, 24] For example, high-molecular weight 
PEG like 8000 and 10000 have negative preferential interactions with the human serum albumin 
protein stabilising the native form of the protein. [35] 
 
Surfactants are usually present in the original nanoparticle formulation post-synthesis so very few 
studies have focused on the use of surfactants as excipients to preserve the nanoparticle integrity 
during freeze-drying. [34] Poly(lactide-co-glycolide) (PLG) nanoparticles lyophilised with 100% 
and 131% (w/w) polyvinyl alcohol (PVA) as an excipient, once resuspended retained their initial 
size, however, lowering the PVA concentration between 10% to 66% (w/w) led to particle 
aggregation. As the Food and Drug administration (FDA) rarely allows surfactants in injectable 
drugs, the 100% (w/w) amount of PVA required for complete particle resuspension might not be 
feasible for vaccine formulations. [36] According to the research carried out by Quintanar-Guerrero 
et al. [37] the best cryoprotectants were sugars for freeze-drying poly(D,L-lactic acid) (PLA) 
nanoparticles. This study suggested that the size of PLA nanoparticles increased significantly post- 
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lyophilisation, however when glucose units were added to the formulation the nanoparticle size did 
not change significantly. [37] 
 
Freeze-drying nanoparticle-based delivery systems with excipients protect the nanoparticles from 
freeze-drying stress resulting in a stable end product. The level of product stabilisation can also be 
dependant upon the concentration and type of excipients used; when bovine serum albumin (BSA)-
loaded chitosan nanoparticles were freeze-dried with different concentrations of PEG 2000, 6000, 
8000 and 10,000, it resulted in inconsistent sized nanoparticles which were difficult to resuspend. 
However, the particle size was maintained when sucrose was used as lyoprotectant in the BSA-
chitosan nanoformulation. [14] The hepatitis B surface antigen (rHBsAg)-loaded chitosan-based 
nanoparticles containing 2.5% glucose as an excipient readily resuspended in water and also 
preserved the structural entity of the antigen and the physico-chemical characteristics of the 
chitosan nanoparticles for at least 3 months storage at 4oC. [38]  
 
Sameti et al. [39] investigated the freeze-drying process for silica nanoparticles and DNA 
formulations. They reported that the physical properties of the freeze-dried nanoparticles were 
preserved post lyophilisation depending on whether the lyoprotectants interacted with the 
nanoparticle surface prior to lyophilisation. The addition of sugars helped inhibit permanent particle 
aggregation and preserve the DNA-binding activity of the particles. Addition of either 5% (w/v) 
trehalose or 10% (w/v) glycerol helped preserve the DNA binding activity of the cationic silica 
nanoparticles. Freeze-drying of the silica nanoformulation resulted in a stable final product suitable 
for nanoscaled drug delivery system. [39] 
 
Addition of excipients can also influence the zeta-potential of the nanoformulations. Zeta potential 
studies on the polyethylenimine (PEI)-dextran sulfate (DS) nanoparticles showed that modification 
in the ratio of polymers or difference in the pH of PEI solution did not change the zeta-potential 
(+26 mV) of the nanoparticles significantly, however, the zeta potential of the nanoparticles 
increased when the amount of zinc sulfate was decreased. [40] The zeta-potential of cationically 
modified silica nanoparticles before and after lyophilisation showed that at pH 3.0 the nanoparticles 
had a surface charge of +46 mV but at pH 10 it decreased to -37 mV. At pH 4.0, the zeta-potential 
of the nanoparticles did not change significantly upon addition of lyoprotectants (5%) - trehalose, 
glucose, mannitol, sorbitol, acetic or glycerol. However when these lyoprotectant were added to 
nanoparticle formulation at higher concentrations (up to 20%) the positive zeta-potential decreased 
significantly with the exception of acetic acid. [39] de Chasteigner et al. [41] discovered that the  
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addition of 10% sucrose as an excipient to itraconazole loaded poly(!-capro-lactone) nanospheres 
during the freeze-drying process significantly decreased the negative surface charge of the 
nanosphere formulation from -40.9 to -20.4 mV. The interaction between the OH groups of the 
cryoprotectants and the wall of the nanospheres might have resulted in surface modification of the 
nanospheres. [41] 
 
Presence of excipient in the nanoformulation during lyophilisation can also affect the nanoparticle 
size. The size of ovalbumin (OVA) encapsulated poly(gamma-glutamic acid) ("-PGA) 
nanoparticles before and after freeze-drying was measured in PBS by dynamic light scattering 
(DLS). [42] The samples freeze-dried with 1% glucose formed aggregations above 1 µm compared 
to the samples freeze-dried with 2.5% glucose, which did not form any large aggregations and 
nanoparticle size was also preserved. DLS was also used to study insulin-loaded PEI-DS 
nanoparticles with and without zinc sulphate as a stabiliser. [40] Freeze-dried nanoformulation 
without zinc sulfate showed two fold increase in the mean particle size compared to the samples 
before lyophilisation. Zinc sulfate maintained the particle size before and after lyophilisation, 
presumably through electrostatic interactions that increase the stability of the nanoparticles. 
Work in our laboratory is in progress on optimising the freeze-drying process for mesoporous silica 
nanoparticles (MSN) using OVA as a model protein. The OVA-loaded MCM-41 silica 
nanoparticles were freeze-dried in the presence of the excipients trehalose and PEG 8000. Addition 
of these excipients prevented particle aggregation as assessed by TEM analyses (manuscript in 
preparation). 
 
3.4 Adsorption of protein on nanoparticles  
 
Development of successful protein-based vaccines depends on a close understanding of their 
biological characteristics, chemical, physical stability and their safety profile. [43] The use of 
nanoparticles as delivery systems can improve protein and peptide stability, enhance protection and 
facilitate presentation of antigen to the immune system. [40, 44] Protein/antigens on adsorption onto 
the nanoparticles, can either adsorb on the surface or internal pores of the nanoparticles; site at 
which the proteins bind to the nanoparticles greatly depend on the type and properties of the target 
proteins and nanoparticles (Fig 3.1). The electrostatic protein-surface interactions, hydrogen 
bonding and weak van der Waals forces adsorb protein to nanoparticles. The pore surface area 
determines the protein binding capacity. The surface area of the nanoparticles can be easily adjusted 
by modifying the concentration of the nanoparticles in the aqueous phase. [45]  
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Fig 3.1. Protein-based nanovaccine: (A) Protein (B) Nanoparticle (C) Internalised protein (D) 
Protein on the surface of the nanoparticles. 
 
Nguyen et al. [46] reported adsorption kinetics of BSA protein to SBA-15 silica nanoparticles. On 
adsorption the BSA protein could not penetrate into the conventional SBA-15 because the pore size 
of the nanoparticles is very small compared to the size of protein. Therefore, most of the protein 
was adsorbed on the external surface of the nanoparticles or at the mouth of the pore; however, 
adsorption of protein on the inside of the particles can be obtained by increasing the pore size of the 
SBA-15 particles. This shows that the pore size also plays an important role in determining the 
protein binding capacity. Park et al. [47] described the use of MSN for protein delivery. They 
designed MSN functionalized with citraconic amide with terminal carboxyl group to deliver model 
protein horse heart Cyt C. They demonstrated that modifying the functionalisation of nanoparticles 
from positive to negative facilitated the release of proteins. Their in vitro studies showed that MSN 
could act as an efficient intracellular delivery vehicle for many membrane-impermeable therapeutic 
proteins. Chesko et al. adsorbed different proteins like BSA, OVA, carbonic anhydrase (CAN), 
lysozyme (LYZ), lactic acid dehydrogenase, and an HIV envelope glycoprotein to PLG 
microparticles. They found similar results that protein adsorption and release from the PLG 
microparticles occurs through a combination of electrostatic and van der Waals interactions taking 
place at the polymer-solution interface. [45]  
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Skwarczynski and Toth have reviewed that nanoparticle-based vaccine delivery systems can 
improve synthetic peptides immunogenicity as vaccines. [11] Biodegradable and biocompatible 
polyesters such as derivatives of chitosan and chitosan nanoparticles have promising future as 
protein carriers, since the polymers are non-toxic and are biodegradable. [48] Biodegradable 
polymeric PLGA nanoparticles have been extensively studied and used for delivery of proteins and 
peptides as they are stable in biological fluids and can protect the encapsulated antigen. Polymeric 
nanoparticles when administered intravenously can be easily recognised by the body’s immune 
systems. [49, 50] Moon et al. [51] demonstrated that when malaria antigen VMP001 was combined 
with PLGA nanoparticles along with monophosphoryl lipid A (MPLA) as adjuvant a better antigen-
specific response was elicited with significantly higher antibody titers in vivo, while the vaccines 
composed of soluble protein mixed with adjuvant MPLA showed less response. [51] The use of 
adjuvants is usually necessary with PLGA based vaccine delivery systems to produce enhanced 
immune response.  
 
Biodegradable !-PGA nanoparticles have also been excellent delivery vehicles for different proteins 
and peptides. [52, 53] Matsuo et al. reported that OVA entrapped !-PGA nanoparticles when 
injected subcutaneously into mice produced strong immune responses by inhibiting the growth of 
OVA-transfected tumors, compared to mice vaccinated with OVA and Freund’s complete adjuvant. 
[54] They further investigated the antitumor efficacy and immune responses in mice vaccinated 
with OVA/!-PGA nanoparticles via the nasal cavity. They found that immune responses to 
cytotoxic T lymphocytes (CTLs) and interferon-!-secreting cells specific for OVA in the spleen and 
lymph nodes were produced whether the vaccination was administered via subcutaneously or 
intranasal route. These nanoparticles have a promising future in development of non-invasive 
vaccines. [55] Nanoparticles are used to create and develop mucosal vaccines because of their 
adjuvanting properties. Mucosal vaccines offer great potential as they can be administered via oral 
and intranasal delivery routes. Administration of mucosal vaccines does not require trained 
personnel, in addition it avoids the use of needles and helps with overall pateint acceptability. [56] 
Nanovaccines can be delivered through oral or nasal route, allowing development of pain-free 
vaccine delivery technology. [57] 
 
Nanotechnology has paved way for development of novel diagnostic and therapeutic applications. 
The advantages associated with polymeric nanoparticles and nanobeads has been found to be useful 
in developing protein and peptide based nanovaccines as reviewed by Nandedkar. [58] 
Conventional subunit vaccine formulations need multiple immunisations to elicit immune response.  
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[59] However, encapsulating antigen on to the nanoparticles can protect the proteins from 
degradation and enhance target delivery of the proteins. Protein loaded nanoparticle-based vaccine 
delivery system improve the presentation of proteins immunogens when incorporated into 
nanoparticles as they are protected against enzymatic degradation and are presented to the immune 
system more effectively inducing a good immune response without the need of a traditional 
adjuvant. [11]  
 
 3.5 Freeze-dried nanoformulations  
 
As with most traditional subunit vaccines, nanovaccines also have stability issues that need to be 
addressed to facilitate their use in vaccine formulations. The increasing development of therapeutic 
protein based nanovaccines has highlighted issues such as proteins stability, elimination of cold-
chain storage and efficacious vaccine delivery to avoid adverse immunogenic side effects. Freeze-
drying process (Fig 3.2) can lead to shelf stable vaccines. Freeze-drying of nanoparticle 
formulations can enhance the physical and chemical stability of the nanoparticles, by removing 
water from these systems [20], and also improve the optimal efficacy and thermostability range of 
the final vaccine. [38]  
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Fig 3.2. Schematic representation of the overall freeze-drying process. 
 
Immunization studies on freeze-dried Gantrez® AN nanoparticles encapsulated with OVA showed 
that the nanoparticles acted as an excellent adjuvants when orally administrated in mice as they 
helped enhance the Th1 and Th2 immune responses. [60] Manosroi et al. [61] conducted studies 
using human insulin loaded onto liposomal formulations like DPPC (dipalmitoyl phosphatidyl 
choline) mixed with cholesterol and CTA [cholest-5-en-3-ol (3 beta)(trimethylammonio) acetate] or 
DDAB (dioctadecyl dimethyl ammonium bromide). Insulin bound to freeze-dried liposomes 
showed enhanced stability when stored at different temperatures for 4 months compared to the 
samples stored in aqueous solution. [61]  
 
Long-term stability studies conducted on freeze-dried human serum albumin (HSA) nanoparticles 
showed that 3% trehalose protected the particles from aggregation. Furthermore, freeze-dried HSA 
samples stored for 13 weeks between 2-8°C showed no increase in the residual water content. [13] 
Genetically engineered hydrophobin fusion protein when coupled with two cellulose domains 
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facilitated drug (itraconazole) nanoparticle binding to nanofibrillar cellulose. These drug 
nanoparticles were freeze-dried with D±trehalose (1:1.25 protein:D±trehalose ratio) as an excipient, 
and were immobilised in nanofibrillar cellulose matrix. The matrix provided protection to the 
nanoparticle morphology during processing and storage. Differential scanning calorimetry (DSC) 
studies revealed that trehalose formed an amorphous matrix which prevented dehydration of 
proteins and protected the formulation from aggregation and induced controlled release of the drug. 
[62] Storage temperature and length impacts the long-term stability of the nanoparticles. These 
factors may cause reduction in particle size and eventually lead to degradation of particles. For 
example, no major changes were observed in tripolyphosphate (TPP) chitosan nanoparticles stored 
between 4 and 25°C for 12 months, but at 40°C the chitosan nanoparticles degraded within 6 
months of storage. [63] It is likely that hydrolysis during storage affected the polymer chains 
resulting in decrease in particle size and subsequent degradation. Stability of these nanoparticles 
could be improved with the freeze-drying technique in the presence of different excipients.  
 
Vandana and Sahoo [14] found sucrose was the most effective excipient in maintaining the size and 
surface charge of the chitosan nanoparticles after freeze-drying using the model protein BSA. 
Optimisation of different parameters like particle size, encapsulation efficiency and in vitro release 
led to improved encapsulation and controlled release of the BSA protein. [14] Freeze-drying 
rHBsAg loaded chitosan-based nanoparticles preserved the characteristics of the antigen for up to 3 
months of storage at 4°C. Addition of 2.5% glucose to the nanoformulation helped preserve the 
physico-chemical properties of the nanoparticle. The ability of these lyophilised nanoparticles to 
induce an immune response was confirmed by an animal immunisation trial indicating that 
chitosan-based nanoparticles are a promising adjuvant candidate with the capacity to enhance and 
prolong the immune response of the rHBsAg after in vivo administration. [38] 
 
Freeze-drying oligonucleotide-loaded gelatin nanoparticles in the presence of the excipients 
trehalose, sucrose and mannitol produced a highly concentrated formulation that retained its 
biological in vivo activity after 4 weeks of storage at 40°C. [17] Akagi et al. [42] developed a 
biodegradable !-PGA nanoparticle with a hydrophilic segment, an inner hydrophobic core and 
carboxyl functional groups at the side chains, allowing hydrophobic drugs to be easily entrapped 
within the core via hydrophobic interactions. The model protein OVA was immobilised onto the !-
PGA nanoparticles by an amide bond between the carboxyl group on the surface of the 
nanoparticles and the amide group of OVA. Both untreated and freeze-dried OVA encapsulated 
nanoparticles released less than 5% of the loaded OVA. This proved that the OVA-encapsulated  
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!-PGA nanoparticles were highly suitable for the freeze-drying process. The freeze-dried OVA 
encapsulated !-PGA nanoparticles with 1, 2.5, and 5% glucose showed less particle aggregation 
compared to particles without cryoprotectants. [42] 
 
Tiyaboonchai et al. [40] developed a freeze-dried nanoparticle delivery system for insulin using the 
polymers PEI and DS. The system achieved a high level of insulin entrapment and preserved its 
secondary structure and biological activity with no degradation of insulin in the reported potency 
studies. The presence of zinc sulfate in the formulation stabilised the nanoparticles and prolonged 
the release of protein over a 4 h period. In addition, the results proved that when the freeze-dried 
nanoparticle formulation was stored for 6 months in a desiccator at 2-8°C, the insulin 
nanoformulation revealed similar potency and purity as the initial freeze-dried preparation. [40] 
 
Protein encapsulated/adsorbed to silica nanoparticles have been used for the successful delivery of 
proteins due to their great capability for the entrapment of antigenic proteins. [36, 64] Carvalho et 
al. [64] reported that the mesoporous SBA-15 silica acted as an adjuvant in in vivo studies. [64] 
Uptake studies using HeLa cells demonstrated that MSN could successfully deliver the membrane-
impermeable protein cytochrome C in vitro. [65-67] Collectively these studies demonstrated that 
silica nanoparticles have an encouraging future in delivery of proteins, peptides and other antigens, 
this has been reviewed in more detail in [68].  
 
In our laboratory, we have been investigating the usefulness of MCM-41 mesoporous silica 
nanoparticles for the in vivo delivery of OVA antigen. OVA showed significant degradation when 
stored at room temperature, however, freeze-dried MCM-41 bound OVA showed no degradation 
for up to two months when stored under similar conditions, as analysed by polyacrylamide gel 
electrophoresis. Our research showed that freeze-dried OVA encapsulated MCM-41 nanoparticles 
released less than 5% OVA, this was comparable to the results obtained for freeze-dried OVA 
encapsulated !-PGA nanoparticles. [42] The freeze-dried OVA nanoformulation showed complete 
reconstitution within 30 seconds upon the addition of injectable saline. The ability to completely 
resuspend a vaccine is important to obtain a stable vaccine that can be safely administered. Mice 
immunised with the freeze-dried OVA nanoparticles vaccine resulted in enhanced antibody and 
cell-mediated responses compared to the equivalent dose of unprocessed OVA bound nanoparticles 
(manuscript in preparation). There is very limited information available on stability of freeze-dried 
protein-based or protein-loaded nanoparticle systems. Few examples of freeze-dried 
protein/nanoparticle delivery systems have been summarised in Table 3.1.  
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Table 3.1. Comparison of freeze-dried protein/nanoparticles systems using different excipients and 
freeze-drying conditions 
 
* The pressure units have been converted from mTorr to mbar for ease of comparison. 
 
Nanoparticles Protein Excipients Freeze-drying 
process 
References 
Poly (gamma-
glutamic acid)(!-
PGA) 
 
Ovalbumin 1, 2.5, 5% Glucose Freezing- 
Liquid nitrogen 
10min 
Freeze-dried for 24 
h 
[42] 
Polyethylenimine 
(PEI) and Dextran 
Sulfate (DS) 
Insulin 5%(w/v) Mannitol 
Zinc sulfate 
Freezing (-46°C) 
Primary drying 1.695 
mbar* for 24 h 
[40] 
Itraconazole 
nanoparticles 
Hydrophobin 
fusion protein 
Cryo/lyoprotectants 
with D±Trehalose 
1:1.25 (drug: 
excipient) ratio 
Primary drying 
0.133mbar* 
- 40°C 3 h 
-30°C 17 h 
Secondary drying 
0.133 mbar* 
-25°C to 40°C, 5°C 
step each for 1h 
[62] 
Chitosan 
nanoparticles 
Bovine serum 
albumin 
2000-10,000 PEG, 
sucrose, mannitol, 
mannose, glucose in 
concentration of 
20 mg/ml 
Freezing (-80°C) 
Lyophilisation at  
0.05 mbar 
-48°C, 48 h 
 
[14] 
Chitosan 
nanoparticles 
Hepatitis B 
surface 
antigen 
(rHBsAg) 
0,1,2.5, and 5% 
glucose 
Freezing (-80°C)  
Primary drying   
35°C 40 h under 
high vacuum 
Secondary drying 
8h gradually 
increasing the 
temperature to 
+20°C 
 
 
[38] 
Human serum 
albumin (HSA) 
With and 
without 
1, 2 and 3% (w/v) 
trehalose, sucrose 
Freezing 
0.08mbar, shelf 
[13] 
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3.6 Assessment of physico-chemical characteristics of the nanoformulation after freeze-drying  
 
After lyophilisation, high-resolution microscopic techniques like transmission electron microscopy 
(TEM), scanning electron microscopy (SEM), and atomic force microscopy (AFM) can be used to 
observe the architecture of the nanoparticles. The final freeze-dried cake should appear voluminous 
and snow-like; TEM images can provide information about the preservation status of the 
nanoparticles. For example, after negative staining of freeze-dried rHBsAg loaded chitosan-based 
nanoparticles TEM images showed that the nanoparticles maintained their spherical shape and were 
homogenously scattered. [38] A similar finding was found for freeze-dried cationically modified 
silica nanoparticle formulation. [39] The samples freeze-dried with 5% trehalose showed a matrix 
separating individual nanoparticles; additionally the trehalose formed a coat that over the 
nanoparticle surface.  
 
For the freeze-dried nanoformulation to be injectable and efficient it is important that on 
reconstitution the protein is stable and the nanoparticles do not form aggregation as well as have 
uniform structure and size. Reconstitution of freeze-dried nanoparticles is achieved by the addition 
of water at a volume equal to the assimilated volume during the freeze-drying process. 
Reconstitution usually occurs rapidly but may require mechanical agitation (shaking, gentle 
vortexing) or sonication. [16] The type and concentration of excipients used during lyophilisation 
can also potentially impact upon reconstitution of the freeze-dried samples. Cationically modified 
silica nanoparticles rehydrated readily by inverting the tube 10 times when freeze-dried using 
trehalose, but required vortexing when freeze-dried using higher concentrations of trehalose and 15 
min sonication was required when freeze-dried with lyoprotectants like glucose, acetic acid and 
mannitol. [39]  
 
Naproxen (an anti-inflammatory drug) nanoparticles when freeze-dried with 10 wt% sucrose 
resulted in aggregation, however, freeze-drying of the samples with 25 or 40 wt% PEG as a 
cryoprotectant maintained the particle size and the final freeze-dried product resuspended easily. 
[23] The ciprofloxacin HCl-loaded PLGA nanoparticles were freeze-dried in the presence of 
different cryoprotectants such as 5.0% (w/v) mannitol, trehalose or glucose, and 5.0% (w/v) or 
15.0% (w/v) dextran. Samples containing glucose did not reconstitute easily presumably because 
after freezing the nanoparticle formulation formed a sticky freeze-dried cake. In addition, the 
samples freeze-dried with dextran aggregated on reconstitution. [69]  
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Surfactant-free PLGA nanoparticles when lyophilised with 2.0% (w/v) sucrose, trehalose and 
lactose, reconstituted completely into aqueous solution without significantly affecting the particle 
size, whereas with 1.0% (w/v) mannitol the particles precipitated. Furthermore, the authors showed 
that testosterone-encapsulated PLGA nanoparticles reconstituted with 2.0% (w/v) sucrose, trehalose 
and lactose. [70] SEM was used to observe the freeze-dried PCL nanospheres containing silicon 
dioxide (SiO2) and it was observed the nanospheres readily dispersed and formed lower sized 
nanostructures of about 80 nm onto the microparticle surface. The samples freeze-dried without 
SiO2, formed an agglomerate of nanoparticles with diameters between 150 nm and 200 nm, which 
were similar to those characterised in the original suspension. [71] These results demonstrate that 
reconstitution of freeze-dried nanoformulation greatly depend on the type of excipients used during 
lyophilisation.  
 
The Karl Fischer titration technique can be used to analyse the residual moisture content of the 
freeze-dried samples. This method has been used to determine the residual moisture content of 
freeze-dried doxorubicin-loaded human serum albumin (HSA) nanoparticles. All the freeze-dried 
samples irrespective of the excipients used had a residual water content of about 3% (w/v). 
Furthermore, no increase in the residual water content was observed when the samples were stored 
for 13 weeks at 2-8°C, however samples stored at 25°C/60% relative humidity and 40°C/75% 
relative humidity showed a 5% increase in water content, which may be due to the moisture coming 
from the stoppers. [13] As discussed before residual moisture content is important in the final 
vaccine as it influences the structural and thermal properties of freeze-dried proteins and 
nanoparticles. [16]  
 
3.7 Conclusion 
 
This review shows that development of freeze-dried nanovaccine delivery systems is an emerging 
area with the capacity to facilitate important advancements in this field. We have highlighted that it 
is critically important to characterise and establish the optimal freeze-drying conditions for each 
nanovaccine formulation during the development phase, as each vaccine formulation may behave 
differently. Freeze-drying of protein-loaded nanoparticles can not only help preserve the chemical 
and physical integrity of nanoparticle structures but it can also facilitate the maintenance of the 
immunogenicity of the biological vaccine components. The application of freeze-drying process to 
nanoparticle based vaccine platforms can be easily applied to vaccine manufacturing in cost 
effective manner if considered early in the vaccine development pipeline. Moreover the successful  
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development of a freeze-drying procedure is critical, as it facilitates the elimination of cold storage 
chains and enhancement of shelf-life under environmental conditions which are key considerations 
in long-term stability and wide spread nanovaccine adoption. This area of work is highly significant 
with the potential to pave way for the next generation of vaccine delivery technologies. 
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4.  
Freeze-drying of Ovalbumin loaded Mesoporous Silica 
Nanoparticle Vaccine Formulation Increases Antigen 
Stability under Ambient Conditions  
 
 
 
 
 
 
 
 
 
 
In this chapter the in vitro and in vivo capacity of freeze-dried Ovalbumin (OVA) loaded amino 
functionalised mesoporous silica nanoparticles (AM-41) was determined. The ability of OVA 
loaded AM-41 (OVA/AM-41) vaccine formulation was first investigated by Mahony et al. [1] in a 
small animal study. The results obtained from that study provided the proof-of-concept that silica 
nanoparticles could act as excellent adjuvants and nanocarriers. However, OVA has a short shelf-
life at room temperature, hence, to improve the shelf-life of the nanovaccine formulation by 
eliminating cold chain storage, I developed the freeze-drying process for OVA/AM-41  
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(termed as OVA-41). The optimal excipient formulation for freeze-drying of OVA bound AM-41 
was determined to be 5% trehalose and 1% PEG8000. This formulation preserved both the OVA 
protein integrity and AM-41 particle structure. To investigate the efficacy of the freeze-dried 
formulation Dr. Donna Mahony and I successfully ran a mice trial and found that the developed 
freeze-dried OVA/AM-41 nanovaccine generated both Th1 and Th2 immune responses (Fig 4.1). 
 
 
 
Fig 4.1. Schematic diagram showing the development of OVA/AM-41 vaccine delivery system. 
Chapter 6 is published in International Journal of Pharmaceutics 2014, 465, 325-332 
 
4.1 Introduction 
 
The role of vaccines is to elicit protective immunity against infectious agents, while improvements 
have been made with the development of protein and peptide based subunit vaccine formulations, 
many challenges still remain. Key challenges include the complexities associated with physical and 
chemical stability of the vaccine antigen components. [2-6] Freeze-drying and novel delivery 
systems can address the issue of instability of conventional and subunit vaccines.  
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Mesoporous silica nanoparticles (MSNs) have emerged as excellent carriers for delivery of 
biologically active molecules such as drugs, genes, therapeutic proteins and enzymes. The ease of 
MSMs synthesis and characteristics such as porous structure, large surface area, flexible surface 
chemistry and in vivo biocompatibility all contribute the utility of this carrier system. [7-10] The 
efficiency of ordered silica nanoparticles (SBA-15) and MSNs as adjuvants and protein carriers 
have already been explored in mice immunisation studies. [9, 11-13] Silica nanoparticles have 
emerged as a new approach to address the limitations of current technologies such as high toxicity, 
severe side effects, and inflammation at the site of injection associated with conventional adjuvants 
and improves the overall safety profile of the vaccine formulations. [14]  
 
The current investigation focused on the development of a freeze-dried MSN based vaccine 
delivery system. The freeze-drying process can preserve unstable molecules such as proteins and 
nanoparticles [15, 16] by removing water from the frozen sample by sublimation and desorption 
under specific vacuum pressure and temperature conditions. However, the freeze-drying process 
can damage biological molecules leading to loss of activity, therefore, excipients such as sugars, 
surfactants, amino acids and polymers are added to the formulation to protect and enhance the 
overall stability of proteins. [5, 17] The excipients used to protect from the freezing stress are 
known as cryoprotectants, whereas the ones protecting from drying stress are known as 
lyoprotectants. [18]  
 
The physico-chemical property of freeze-dried human serum albumin nanoparticles was retained by 
addition of 3% trehalose. [19] It has been established that physical characteristics of freeze-dried 
polymeric nanoparticles such as poly(lactide-co-glycolide), poly(gamma-glutamic acid) and 
poly(D,L-lactic acid) have been preserved by the addition of excipients. [20-22] However, since the 
discovery of Mobile Crystalline Materials No. 41 (MCM-41) type MSNs in 1992 by Mobil 
scientists [23], no information has been reported on the freeze-drying of protein loaded MCM-41 
type MSNs or the capacity of these formulations to elicit immunogenicity following reconstitution.  
 
Here we report the successful freeze-drying of amino functionalised MCM-41 nanoparticles (AM-
41) following the loading of the model antigen Ovalbumin (OVA). The OVA loaded AM-41 
nanoparticles are termed as OVA-41. The OVA antigen was chosen for this study as we have 
observed degradation of OVA when stored at ambient temperature for periods as short as 16 h. We 
investigated the impact of the freeze-drying process and the effect of excipients trehalose and 
PEG8000 on the stability of OVA. The freeze-dried samples were stored at ambient temperature for  
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two months, following which the immunogenicity of the formulation was tested in mice. We have 
demonstrated the capacity of the freeze-dried OVA-41 nanoformulation to induce humoral and cell-
mediated immune responses. 
 
4.2 Materials and Methods 
 
4.2.1 Materials 
OVA Grade III, D-(+)-trehalose dihydrate, PEG8000, Bovine Serum Albumin (BSA) and PBS-T 
[PBS (1x), Tween-20 (0.1%)] were all obtained from Sigma-Aldrich (St. Louis, USA). PBS (137 
mM NaCl 2.7mM KCl 10mM Phosphate buffer pH 7.2) was obtained from Amresco (Solon, USA). 
Dulbecco’s Modified Eagle Medium (DMEM), antibiotic/antimycotic (containing penicillin G 
sodium, streptomycin sulphate, Fungizone) and Foetal Bovine Serum (FBS) were obtained from 
Life Technologies (Carlsbad, USA). ELISPOTPLUS kit for the detection of the mouse Interferon 
(IFN)-! by splenocytes was obtained from MabTech (Sweden).  
 
4.2.2 Preparation of mesoporous silicate nanoparticles  
The nanoparticles used in this investigation were unfunctionalised and amino functionalised MCM-
41. The nanoparticles were prepared by co-condensation method as described previously. [11] To 
ensure maximum availability of the external surface area of the nanoparticles, the nanoparticle 
suspension was prepared in PBS. Nanoparticles (100 mg) and PBS (10 mL) were combined and 
ultrasonicated in a glass vial for 1 min at room temperature (RT) using probe (Hielscher UP100H, 
Teltow, Germany) set at 80% amplitude.  
 
4.2.3 Trypan blue staining for in vitro cytotoxicity assay 
Madin-Darby bovine kidney (MDBK) cells (ATCC) were seeded at 80-90% confluency onto glass 
coverslips in a 24 well plate and allowed to adhere overnight at 37°C, 5% CO2. To investigate the 
effect of nanoparticle concentration on the cells a dilution range (0.5 mg/mL, 0.1 mg/mL and 0.01 
mg/mL) of MCM-41 and AM-41 particles in Earle’s Minimum Essential Media (containing 5% 
FBS) were prepared and gently added drop wise to the adherent cells. The cells and nanoparticles 
were incubated at 37°C, 5% CO2 for 20 h. Media was carefully removed and the wells were gently 
washed three times with PBS to remove the nanoparticles. To determine the cell viability 0.2% 
trypan blue stain (Life Technologies) was added for 2 minutes. Trypan blue stain was carefully 
removed and the wells were washed once with PBS. Cells were fixed in 4% paraformaldehyde 
(PFA) pH 7.4 for 15 minutes, and then washed three times with PBS.  
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Coverslips were mounted with 5 µl of MOWIOL (Sigma). Cell viability was determined by 
imaging on a Zeiss HAL100 microscope under bright field. 
 
4.2.4 OVA loaded AM-41 nanoparticles 
Loading reaction consisted of 20 mg of AM-41 particles and OVA at 0.8 mg/mL in a 5 mL final 
volume of PBS at pH 7.0 as previously described (Mahony et al. 2013). This particle-protein slurry 
was placed in a shaker at 25°C for 240 min. A 200 µl sample of the particle-protein slurry was 
removed and centrifuged 16.2 g for 5 min. The amount of unbound OVA protein remaining in the 
supernatant was assessed by Biorad DC kit protein assay and visualised on SDS-PAGE gels.  
 
4.2.5 Freeze-drying process 
Following OVA loading, the sample was centrifuged at 16.2 g for 1 min and the supernatant was 
removed. The protein-nanoparticle (OVA-41) (4 mg OVA: 20 mg AM-41) pellet was freeze dried 
with different combinations of excipients: 1) OVA-41 alone, 2) OVA-41 + 20% trehalose, 3) OVA-
41 + 1% PEG8000, 4) OVA-41 + 5% trehalose + 1% PEG8000. The final formulation was obtained 
by mixing the excipients to the nanoparticle-protein pellet at fixed concentration to make up the 
final volume to 1 mL. Samples were frozen in liquid nitrogen then placed in a Christ freeze-dryer 
(Model LPC-32, Martin Christ, Osterode AM Harz, Germany) at 24°C, 0.1 mbar for 17 h. Freeze-
dried samples were stored in a vacuum desiccator at ambient temperature (23-27°C). 
 
4.2.6 Desorption studies on the freeze-dried samples 
Following 3 days of storage at ambient temperature, the freeze-dried samples were resuspended in 
200 µL of PBS and centrifuged for 5 min at 16.2 g to remove the supernatant. Vaccinations were 
prepared by suspending the freeze-dried samples in 500 µL of saline. Hence, the nanoparticle pellet 
obtained was resuspended in 500 µL of pre-warmed PBS and incubated at 37°C for 120 min on a 
shaker at 200 rpm. The samples were centrifuged as above and the supernatant was assessed for 
desorbed protein by electrophoresis on SDS-PAGE gels. 
 
4.2.7 Polyacryalamide gel electrophoresis (PAGE) 
To prepare the particulate and the supernatant samples, particle slurry (20 µL) was taken and 
centrifuged at 16.2 g for 5 min. The supernatant and nanoparticle samples were resuspended in SRB 
(SDS Reducing Buffer consisting of 62.5 mM Tris-HCl (pH 6.8), 117 mM DTT, 10 % Glycerol, 2 
% SDS, 0.02 % Bromophenol blue), incubated at 85 °C for 2 min then subjected to electrophoresis 
on 10 % Tris-Glycine gels (Invitrogen). The gels were visualised by staining in 50% methanol, 10%  
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acetic acid, 0.25% Coomassie Blue R250 for 30 minutes, followed by destaining in 30% methanol, 
10% acetic acid with three 30 min washes. 
 
4.2.8 Reconstitution, zeta-potential and transmission electron microscope (TEM) of lyophilised 
samples 
Samples were reconstituted in 1 mL sterile PBS. The zeta-potential was measured on a Nanosizer 
Nano ZS analyser (Malvern Instruments, Worcestershire, UK) in PBS. The physical characteristics 
of the freeze-dried nanoparticles were observed using transmission electron microscopy (TEM) 
before and after freeze-drying. 
 
4.2.9 Mouse immunisation studies 
Animals – C57BL/6J mice were purchased from and housed in the Biological Resource Facility, 
The University of Queensland, Brisbane, Australia under specific pathogen-free conditions. Eight 
week old female mice were housed in HEPA-filtered cages with 4 animals per group in an 
environmentally controlled area with a cycle of 12 h of light and 12 h of darkness. Food and water 
were given ad libitum. All the animals were closely monitored throughout the study. All procedures 
involving animals were approved by the The University of Queensland Animal Ethics Committee. 
Immunisation – Blood samples were collected by retro-orbital bleeds using heparin coated 
hematocrit tubes (Hirschmann Laborgeräte, Heilbronn, Germany).  
 
Pre-immunisation blood samples collected prior to the first immunisation were referred to as the 
preimmune (PI) samples. OVA-41 reactions were prepared aseptically as described in the methods 
section ‘OVA loaded AM-41 nanoparticles’. Quil-A (Superfos Biosector, Vedback, Denmark) was 
resuspended at 2 mg/ml in sterile injectable water (Pfizer, Brooklyn, USA). The ‘wet test group’ 
comprised of freshly prepared OVA-41 nanoformulation. The five groups used in the trial were: a 
positive control group (50 !g OVA+10 !g Quil-A), ‘wet’ and freeze-dried test groups (10 !g OVA, 
150 !g AM-41), negative control groups comprising of (freeze-dried AM-41, 150 !g) and 
unimmunised group. The freeze-dried groups were stored at ambient temperature for 2 months prior 
to injection. The doses were prepared in 0.9% saline (Pfizer) and 100 !L was administered into the 
tail base by four subcutaneous injections using a sterile 27 gauge needle (Terumo, Tokyo, Japan). 
Four injections were administered at 2 week intervals and mice were sacrificed 14 days after the 
final immunisation. 
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4.2.10 Enzyme-Linked ImmunoSorbent Assay (ELISA)  
ELISA was used to detect the OVA-specific antibody. Microtitre plates (96 well, Nunc, Maxisorb, 
Roskilde, Denmark) were coated overnight with OVA antigen (2 ng/!L, 50 !L) in PBS at 4 °C. To 
remove the coating solution, the plates were once washed with PBS-T. The plate was then blocked 
with 5% BSA and skim milk (5%, Fonterra, Auckland, New Zealand) in PBS (200 !L) for 1 h with 
gentle shaking at RT. To remove the block the plates were washed with PBS-T three times. The 
mouse sera samples were diluted in PBS (50 !L) from 1:100 to 1:6400, each dilution was added to 
the wells and the plate was incubated for 2 h at RT. To detect the mouse antibodies HRP conjugated 
polyclonal sheep anti-mouse IgG antibody (Chemicon Australia, Melbourne, VIC, Australia) 
diluted to 1:1000 in PBS was added to each well and incubated for 1 h at RT with gentle shaking. 
Plates were washed with PBS-T three times. To each well 100 !L of TMB substrate (Sigma-
Aldrich) was added and the plate was incubated for 15 min at RT. To stop the chromogenic reaction 
100 !L of 1N HCl was added to all the wells. At the end of the experiment the plates were read at 
450nm on a Labsystems Multiskan RC plate scanner. 
 
4.2.11 IFN-! ELISPOT assays 
After the final immunisation spleens from the mouse were aseptically removed following 
euthanasia and placed into ice cold DMEM media (5 mL) supplemented with 10% FBS, Hepes (20 
mM, pH 7.3), sodium pyruvate (1 M), Glutamax (1 M), penicillin G (100 units/mL), streptomycin 
(100 !g/mL), Fungizone (0.25 !g/mL). The spleen samples were then gently disrupted and using a 
syringe plunger passed through a nylon mesh (100 !m, Becton Dickinson, Franklin Lakes, NJ). The 
splenocytes were washed with 5 ml of DMEM and centrifuged at 800 g for 5 min at 4 °C and then 
resuspended in lysis buffer (NH4Cl (0.15 M), KHCO3 (10 mM), Na2-EDTA (0.1 mM), 1 mL) for 5 
min at RT. The wash steps were repeated twice with DMEM (9 mL and 5 mL) each time. Cell 
pellets obtained at the end were resuspended in DMEM (2 mL) and the cell numbers were 
calculated by staining with trypan blue (0.2%). Cells from each mouse were seeded in triplicate at 
1.0 – 1.5 x 105 cells/well into Polyvinylidene fluoride (PVDF) ELISPOT plates. In the presence or 
absence of synthetic OVA peptide (1 mg/mL, SIINFEKL, Auspep, Parkville, VIC, Australia) or the 
polyclonal activator concavalin A (Con A, 1 mg/mL, Sigma Aldrich) as a positive control the cells 
were were incubated in complete DMEM medium at 37 °C and 5% CO2 for 40 h. IFN-" ELISPOT 
(Mabtech) assay was performed following manufacturer’s guide. The ELISPOT plates were read on 
an ELISPOT reader (Autoimmun Diagnostika, Strassburg, Germany). 
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4.2.12 Statistical Analysis 
The unpaired two-tailed Student’s t-test (Microsoft excel) was used for statistical comparisons of 
the number of spot forming units (SFU)/million cells for all the individual animals by as determined 
by the ELISPOT assay.  
 
4.3 Results 
 
4.3.1 Characteristics of MSN 
The physical properties and atomic percentages of the MCM-41 and AM-41 nanoparticles were 
determined using TEM analysis, low angle powder X-ray diffraction (XRD), nitrogen adsorption 
isotherm and X-ray photoelectron spectra (XPS) analysis as described by Mahony et al. (2013).  
The pore size and diameter of the particles were calculated by Barrett-Emmett-Teller (BET) and 
Barrett-Joyner-Halenda (BJH) methodologies respectively. The measured and calculated properties 
of the particles are summarised in Table 4.1. 
 
Table 4.1. Physical characteristics of MCM-41 and AM-41 
 
4.3.2 In vitro cytotoxicity of MSN  
The cytotoxicity of the MCM-41 and AM-41 nanoparticles was determined by trypan blue dye 
exclusion staining of MDBK cells treated with varying concentrations of nanoparticles. Dead cells 
exhibited a blue colour due to the uptake of the dye via permeabilised cell membranes whereas 
viable cells remain intact and do not take up the stain. Both MCM-41 and AM-41 nanoparticles had 
toxic effects at 0.5 mg/mL on the MDBK cells (Fig 4.2 c and f) after 20 h incubation. However, at  
 
Material MCM-41 AM-41 
Particle size (nm) 90 90 
BET surface area (m2 g-1) 956.2 854.4 
BJH Pore Diameter (nm) 3.6 3.7 
Pore volume (cm3 g-1) 1.01 0.79 
Atomic% as determined by XPS                                    
Si 
O 
C 
N 
24.79 
65.58 
9.63 
0 
 
22.12 
60.15 
14.55 
3.17 
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0.1 mg/mL concentration only the MCM-41 were slightly toxic (Fig 4.2 b). Cells exposed to MCM-
41 at a lower concentration of 0.01 mg/mL (Fig 4.2 a) did not exhibit any overt signs of toxicity and 
appeared similar the control cells (Fig 4.2 g). The AM-41 particles on the other hand did not show 
any toxic effect on cell viability at either 0.01 mg/mL or 0.1 mg/mL (Fig 4.2 d and e). Based on 
these semi-quantitative cytotoxicity results all further experimental investigations were carried out 
using OVA-41.  
 
Fig 4.2. Cytotoxicity studies of nanoparticles using trypan blue Staining (0.2%) of MDBK cells;  
(a) 0.5 mg/mL MCM-41; (b) 0.1 mg/mL MCM-41; (c) 0.01 mg/mL MCM-41; (d) 0.5 mg/mL AM-
41; (e) 0.1 mg/mL AM-41; (f) 0.01 mg/mL AM-41; (g) MDBK cells alone without nanoparticles.  
 
4.3.3 Effect of excipients on in vitro stability of OVA -41 nanoparticles 
The OVA protein was loaded onto the AM-41 nanoparticles at a concentration of 72 µg per mg of 
AM-41 particles as determined by protein assay. The loading isotherm reaction of protein to 
nanoparticle ratio was determined as 1:5; at this ratio complete binding of the OVA protein to the 
AM-41 nanoparticles was obtained as determined by SDS-PAGE analysis (Mahony et al., 2013).  
Excipients were added to OVA-41 nanoformulation and subjected to rapid freezing in liquid 
nitrogen and subsequently freeze-dried.  
 
The physical appearance of the freeze-dried samples was assessed and recorded at the end of the 
process. The sample freeze-dried with 20% trehalose formed a flaky crystal-like structure on top of 
the freeze-dried cake (Fig 4.3 a, i). The formulation freeze-dried with 1% PEG8000 alone resulted 
in a dry white powder with an estimated shrinkage of 50% (Fig 4.3 a, ii). Lyophilisation with 5% 
trehalose and 1% PEG8000 resulted in a freeze-dried cake that did not collapse, maintained its 
structural integrity and appeared voluminous and snow-like without any shrinkage (Fig 4.3 a, iii).  
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The freeze-dried samples were reconstituted in PBS; the samples containing 5% trehalose and 1% 
PEG8000 and 1% PEG8000 alone dissolved readily within 30 seconds, but the sample containing 
20% trehalose required additional measures such as gentle vortexing to facilitate solubilisation.  
 
The stability of OVA contained in the freeze-dried OVA-41 was determined using SDS-PAGE 
analysis. The molecular weight of OVA is 45 kDa, seen as a doublet on PAGE (Fig 4.3 b. lane 1). 
Complete degradation of OVA protein was observed, when it was in the solution at the 
concentration of 0.8 mg/mL after 16 h of incubation at ambient temperature (Fig 4.3 b lane 2). OVA 
in the OVA-41 formulation remained stable when freeze-dried in the presence of the excipients (Fig 
4.3 c lanes 3, 4 and 5), however, degradation of OVA occurred when it was freeze-dried without 
excipients (Fig 4.3 c lane 2). Distortion in the electrophoretic profile of OVA protein was observed 
in the samples containing PEG8000 as an excipient (Fig 4.3 c, lane 4 and 5).  
 
To determine if the integrity of the OVA protein and its association with the AM-41 particles after 
the freeze-drying process, desorption studies were performed on reconstituted freeze-dried OVA-41 
samples after storage for 3 days. Gel analysis on the supernatant showed no release of OVA (Fig 
4.3 d lanes 1, 2 and 3). The protein remained associated to the nanoparticles post freeze-drying, 
storage and reconstitution (Fig 4.3 d lanes 4, 5 and 6). Furthermore, after desorption, the migration 
rate of the freeze-dried samples containing 1% PEG8000 was restored (Fig 4.3 c compare lanes 4, 5 
to Fig 4.3 d lanes 5 and 6). 
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Fig 4.3. (a) Appearance of the freeze-dried OVA-41 formulation in the presence of different 
excipients, i: Freeze-dried OVA-41 with 20% Trehalose; ii: Freeze-dried OVA-41 with 1% 
PEG8000; and iii: Freeze-dried OVA-41 with 5% trehalose and 1% PEG8000. (b) Evaluation of 
OVA protein after 16 h storage by SDS-PAGE, lane 1: OVA protein at 4°C; lane 2: Degraded OVA 
protein at ambient temperature. (c) Evaluation of Freeze-dried OVA-41 nanoformulations, lane 1: 
‘wet’ OVA-41; lane 2: Freeze-dried OVA-41 without excipients; lane 3: Freeze-dried OVA-41 with 
20% trehalose; lane 4: Freeze-dried OVA-41 with 1% PEG8000; lane 5: Freeze-dried OVA-41 with 
5% trehalose and 1% PEG8000. (d) Desorption studies of the freeze-dried OVA-41. Lanes 1-3: 
Supernatants; lane 1: Freeze-dried OVA-41 with 20% trehalose; lane 2: Freeze-dried OVA-41 with 
1% PEG8000; lane 3: Freeze-dried OVA-41 with 5% trehalose and 1% PEG8000. Lanes 4-6: 
Nanoparticles; lane 4: Freeze-dried OVA-41 with 20% trehalose; lane 5: Freeze-dried OVA-41 with 
1% PEG8000; lane 6: Freeze-dried OVA-41 with 5% trehalose and 1% PEG8000.  
 
Zeta potential measurement for OVA-41 before and after the addition of 5% trehalose and 1% 
PEG8000 was also determined. The ‘wet’ OVA-41 formulation had a charge of +13.9 mV whereas 
the addition of excipients changed the zeta potential to -1 mV. The final zeta potential of the freeze-
dried particles after 2 months of storage was found to be -3.34 mV at pH 7.0.  
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As observed by TEM, nanoparticles were found to be homogenously distributed and maintained 
their spherical shape and size following freeze-drying (Fig 4.4). The net-like structure formed over 
the surface of the nanoparticles might have been due to the presence of trehalose in the formulation. 
 
Fig 4.4. Morphology of AM-41 nanoparticles visualized by transmission electron microscope 
(TEM), (a) AM-41 particles before lyophilisation (b) OVA-41 particles after lyophilisation matrix 
formation in the presence of 5% trehalose and 1% PEG8000.  
 
4.3.4 In vivo responses to ‘wet’ and freeze-dried OVA-41  
The IgG responses of the immunised mice were analysed by anti-OVA-specific ELISA assays after 
four subcutaneous injections. The antibody responses to immunisation of mice with the ‘wet’ and 
the freeze-dried OVA-41 formulation were compared. The ELISA results (Fig 4.5) from the 
terminal bleeds suggest that the positive control group (50 !g OVA+10 !g Quil-A) showed an 
excellent antibody titre up to a dilution of 1:6400 with an average OD450nm of 0.8 (Fig 4.5 a). 
Though the mice injected with freeze-dried OVA-41 and ‘wet’ OVA-41 (10 µg OVA/150 µg 
nanoparticles) showed a lower response compared to the positive control, both groups were similar 
in their antibody response up to the 1:6400 dilution (Fig 4.5 b and c). Even though, the positive 
control group induced excellent antibody response, variation in the response between the four 
animals was observed. However, the four mice receiving freeze-dried OVA-41 showed less mouse 
to mouse variation (Fig 4.5 b). The negative control group receiving freeze-dried AM-41 
nanoparticles with excipients showed no specific antibody response to OVA protein (Fig 4.5 d), 
which was similar to the unimmunised mice group. In addition, administration of freeze-dried  
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OVA-41 had no visible toxic effects on the mice, as the mice remained in the normal weight range 
throughout the trial period (data not shown). 
 
Fig 4.5. ELISA data of terminal sera bleeds of all 4 individual mice in each group. M1 to M4 are 
the individual mice in each group. All the mice were administered 100 µL dose at 2 week intervals 
to the tail base with a) OVA (50 µg)  plus Quil-A (10 µg), b) ‘wet’ OVA (10 µg) loaded AM-41 
(150 µg) nanoparticles, c) Freeze-dried OVA (10 µg) loaded AM-41 (150 µg) nanoparticles d) 
Freeze-dried AM-41 (150 µg). Sera of individual animals were diluted from 1:100 to 1:6400. 
 
The cell-mediated response of mice immunised with the OVA-41 formulation was investigated 
using ELISPOT assay. To determine the Th1 cell-mediated immune response, two weeks after the 
final immunisation spleens from sacrificed mice were collected and harvested to obtain splenocyte 
cell populations. Splenocytes were used to determine T-cell IFN-! response to OVA peptide. The 
mice from the positive control group, OVA plus Quil-A, showed high cell-mediated immune 
responses to OVA epitope. The ‘wet’ and the freeze-dried OVA-41 groups showed similar IFN-! 
response. The result from the ELISPOT assay indicates that the freeze-dried OVA-41 did not have 
an adverse effect on the IFN-! detected responses. Even though, the mice in the freeze-dried AM-41 
and the unimmunised negative control groups produced some background IFN-! response, the  
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response was not specific to the OVA antigen, as the response elicited with no antigen and OVA 
antigen looked similar (Fig 4.6). 
 
Fig 4.6. Detection of antigen specific IFN-! secretion by ELISPOT assay of murine splenocytes 
from immunised mice. M1 to M4 are the individual mice in each group. The black bars in the figure 
indicate the spot forming units (SFU) producing IFN-! in response to the OVA peptide, SIINFEKL 
(1 µg/mL). 
 
4.4 Discussion 
 
In this proof-of-concept study, we have developed a freeze-dried nanoparticle-based delivery 
system, to demonstrate the ability of MSNs as adjuvants and the improved stability of the vaccine 
formulation. This study confirms a previous study which demonstrated the nanoparticles can act as 
immune-potentiators in the absence of conventional adjuvants, such as Quil-A, in vaccine 
formulations (Mahony et al., 2013).  The results of the study presented in this report extend these 
findings by demonstrating the combination of nanoparticle delivery and freeze-drying provides the 
basis for a highly effective vaccine delivery strategy. Freeze-drying process has proved an effective 
strategy for enhancing the stability of the vaccines. [24] Freeze-dried vaccines offers several 
advantages such as prolonged shelf-life, improved storage and ease of shipping to the end user.[25]  
 
Nanoparticle based delivery systems can increase the delivery of the proteins to antigen presenting 
cells and act as nanocarriers as well as adjuvants in nanoparticle based vaccine formulations. [2, 26] 
Availability of different liquid crystal mesophases and surfactant assemblies makes the synthesis of  
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MSNs with controlled size, shape and structure easy [27], these characteristics of MSNs makes 
them highly attractive as delivery vehicles for proteins.  
 
Guo et al. (2012) highlighted the capacity of hollow mesoporous silica nanoparticles (HMSNs) as 
antigen delivery vehicles for porcine circovirus type-2 ORF2 protein, as the HMSN/protein 
complex was able to elicit immune response in mice. The slow release of antigens from silica 
nanoparticles could be due to the highly stable and rigid framework of the porous silica forming a 
barrier to prevent the degradation of the antigen in the stomach and digestive tract as demonstrated 
by Slowing et al., (2008). The present study not only confirmed the promising nature of these 
materials for use in vaccines but also extended it by utilizing OVA loaded AM-41 nanoparticles in 
the freeze-dried formulations to elicit in vivo immune response after storage at ambient temperature.   
 
The first step in the current investigation was to select the MSN with minimal cytotoxicity. 
Previous in vitro studies on cytotoxicity of the amorphous silica nanoparticles have shown that 
although they are believed to be non-toxic and are used in several biomedical applications, 
cytotoxicity is dependent on the concentration and size of the particles. [28, 29] Di Pasqua et al. 
(2008) using human neuroblastoma cells demonstrated that amino functionalised MCM-41 and 
solid sphere silica nanoparticles were less toxic compared to the pure MCM-41. The results of the 
current study also support the functionalisation of nanomaterials as a way of reducing in vitro 
cytotoxicity of nanomaterials (Fig 4.2). Future elucidation of the mechanisms of this phenomenon 
could be useful in understanding and documenting the in vivo safety of these novel nanomaterial 
based vaccination studies. In addition, previous research has shown that some cellular damage in 
vivo can be beneficial for generating strong immune responses. [30] However, a balance needs to be 
attained to ensure that over stimulation of the immune system does not negate the positive effects of 
vaccination. 
 
It is critical to characterise and establish the optimal freeze-drying process for each nanovaccine 
formulation. The biological activity of DNA loaded on to cationic silica nanoparticles was restored 
when freeze-dried with either 5% trehalose or 10% glycerol as excipient. [31] While freeze-drying 
of the hepatitis B surface antigen adsorbed to chitosan-based nanoparticles with 2.5% glucose 
helped preserve the characteristics of the antigen for up to 3 months of storage at 4°C. [32]  
 
In the current study, the combination of 5% trehalose and 1% PEG8000 as excipient was found to 
be the most suitable for freeze-drying OVA-41 formulations. The PEG8000 it is postulated to have  
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acted as the cryoprotectant and trehalose as the lyoprotectant. In this two-component excipient 
system the PEG protects from freezing stress while sugar protects from drying stress. [33, 34] The 
OVA-41 freeze-dried with 5% trehalose and 1% PEG8000 in combination, resulted in rapid 
reconstitution of the freeze-dried sample within 30 seconds. In vitro desorption studies on the 
freeze-dried OVA-41 stored at ambient temperature for three days showed that protein once bound 
did not easily dissociate from the particles (Fig 4.3 d).  
 
Previously in our lab desorption studies have been conducted at different time points ranging from 5 
min to overnight on OVA-41. However, protein only desorbed during the first 5 to 30 min, and no 
desorption was observed at later time points (Mahony et al., 2013). Even though, the OVA protein 
did not desorb in vitro in PBS at pH 7.0, when the reconstituted freeze-dried formulation was 
injected in the mice it elicited both humoral and cell-mediated immune responses, indicating that 
the protein may desorb from the nanoparticles in vivo. An alternative hypothesis would be that 
degradation of the nanoparticles in vivo results in additional and/or sustained release of OVA 
leading to immune stimulation. Further experimentation is required to fully elucidate the mode of 
action of these findings. 
 
The aberrant migration rate of OVA-41 in Fig 4.3 c lanes 4 and 5 may have been caused by 
PEG8000 in the freeze-dried samples distorting the electrical flow within the gel. [35] Addition of 
excipients often changes the zeta-potential of the nanoformulations, the positive zeta potential 
measurements of cationic silica decreased significantly when lyoprotectants like trehalose, glucose, 
mannitol sorbitol and glycerol were added at a higher concentration (up to 20%) at pH 4.0. [31] 
Difference in the zeta potential measurements of the OVA-41 particles was observed before and 
after the addition of excipients at pH 7.0.  
 
The potential of nanoformulations to induce antigen specific immune responses depends on various 
factors such as the architecture of the particle and protein, particle binding capacity, the uptake of 
the particle protein complex by antigen presenting cells and the release profile of the protein from 
the particle. [14] In the current study the OVA-41 formulation was stored for two months prior to 
reconstitution and immunisation of mice. We administered the vaccine subcutaneously as our 
hypothesis was that the nanovaccine would get adsorbed more slowly from the site of injection 
creating a depot effect and potentiating immune response. Following immunisation no local adverse 
reactions at the injection site were evident. In addition, administration of the stored freeze-dried  
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OVA-41 had no detectable toxic effects on the mice, as the mice remained in the normal weight 
range throughout the trial period.  
 
Mahony et al., (2013) conducted histopathology studies of heart, lung, liver, spleen, kidney, lymph 
nodes (local and peripheral) and the injection site area (including skin and under- lying tissue) of 
mice injected with OVA loaded AM-41, no morphological changes could be detected between all 
organs derived from animals in the unimmunized control group compared to the treatment groups 
receiving the nanovaccine for the duration of the study. While these observations are qualitative in 
nature they do support the in vivo safety of MSN materials, as previously reported by Mahony et al. 
(2013).  
 
For comparative purposes a treatment group was immunised with OVA plus Quil-A, a conventional 
immunopotentiating adjuvant with the capacity to induce both cell mediated and humoral immunity 
in vivo. [36, 37] We used Quil-A in our study, as it is one of the most widely used adjuvant in mice 
immunisation studies. [38, 39] The positive control group were immunised with 50 µg OVA plus 10 
µg Quil-A to ensure that the mice had a robust and measurable immune responses to OVA. As 
expected strong immune responses were detected in this treatment group (Fig 4.5a). A possible 
limitation of the AM-41 particles was the amount of OVA that could be loaded to the material, as it 
was limited to 72 µg of protein per mg of nanoparticles. To reduce the likelihood of adverse effects 
in mice receiving OVA-41 formulations, a maximum of 150 !g of nanoparticles per injection was 
used, which limited the OVA to 10 !g per dose. As a result of this limitation, mice immunised with 
the ‘wet’ and freeze-dried nanoformulations received almost five times less of OVA protein 
compared to the positive control group (50 !g of OVA per dose). Despite this dramatic reduction in 
dose, strong antibody and cell-mediated response were detected in the mice immunised with OVA-
41 formulations. These results indicated that the AM-41 nanoparticles have the capacity to stimulate 
strong immune responses with reduced levels of antigen. Further experimentation needs to be 
conducted to test higher concentration of antigen by improving the loading capacity of the 
nanoparticles. 
 
4.5 Conclusion 
 
We have presented a successful strategy for the freeze-drying of OVA loaded AM-41 nanoparticles 
utilising 5% trehalose and 1% PEG8000 as excipients. The freeze-dried formulation increased the 
ambient stability of this model antigen for at least two months. Once reconstituted and injected  
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subcutaneously into mice the freeze-dried OVA-41 elicited humoral and cell mediated responses. 
These findings demonstrate the potential effectiveness of freeze-dried AM-41 nanoparticles as 
carriers for improving the stability of vaccines.  
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5. 
Immunisation of sheep with Bovine Viral Diarrhoea 
Virus, E2 protein using a Freeze-dried Hollow Silica 
Mesoporous Nanoparticle Formulation 
 
 
 
 
 
 
 
 
 
 
The capacity of amino functionalised hollow type mesoporous silica nanoparticles (HMSA) loaded 
with BVDV-1 Escherichia coli-expressed optimised E2 (oE2) protein to induce immunogenicity 
before and after freeze-drying was investigated in this chapter. oE2/HMSA nanovaccine, which was 
freeze-dried using trehalose and 1% glycine as excipients, was tested in vivo by Dr. Donna Mahony  
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and myself to determine the vaccines capacity to induced both antibody and cell-mediated immune 
responses in sheep. In addition, the integrity of E2 protein was preserved in the FD nanovaccine 
even after 14 months of storage at ambient temperature. This study was the first to demonstrate that 
silica nanoparticles can act as an efficient antigen carriers and adjuvants in a production animal. The 
following manuscript is submitted to PLoS ONE.  
 
5.1 Introduction 
 
BVDV-1 infection occurs in the target species of cattle and sheep herds worldwide and therefore 
remains of economic importance. BVDVs are a group of positive sense, single-stranded RNA 
viruses classified in the Pestivirus genus within the Flaviviradae family. [1] The BVDV-1 genome 
is transcribed as a single, large (~12.3 kb) open reading frame which is translated into a single 
polyprotein, and processed into individual viral proteins by viral and cellular proteases. [2] 
Currently there is no commercially available recombinant subunit vaccine for BVDV-1, only 
modified live or inactivated vaccines. The E2 membrane glycoprotein has been shown to be the 
major immunogenic protein of BVDV-1 [2] and is the viral antigen that is efficiently recognised by 
the immune system. [3] Therefore E2 has been the focus as a potential candidate for the 
development of a subunit BVDV-1 vaccine in a number of studies. [4-8] 
 
Subunit vaccines often require the addition of an adjuvant which potentiates the immune response 
to the protein antigen in the vaccinated host. The role of mesoporous silica nanoparticles (MSNs) as 
an antigen carrier and adjuvant has been recently been reviewed. [9,10] MSNs are proving to be a 
valuable alternative to conventional adjuvants such as aluminium hydroxide (or alum) which can 
have adverse effects at the injection site when administered subcutaneously or intradermally. [11] 
Various types of silica nanoparticles have been used to deliver antigens in immunisation studies that 
have induced both humoral and cell-mediated immune responses. [12-16]. Injection of MSNs 
showed no local reactions at the injection site both at a gross and histopathological level and they 
are well tolerated in the mammalian system. [16-18] 
 
Recently we have demonstrated that E2 delivered by amino functionalised hollow mesoporous 
silica nanoparticles generated balanced immune responses in mice with both antibody and cell-
mediated immunity.[17] Here, we expand on our previous work by developing a freeze-dried 
process for E2 adsorbed hollow type MSN with surface amino functionalisation (HMSA) and 
compare the immunogenicity of the non-freeze dried and freeze-dried nanoformulations in sheep.  
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To the best of our knowledge this is the first time that silica based nanoparticles have been used in a 
large animal model. Immunisation of sheep with the E2 nanovaccine did not show any adverse 
effects on animal health and produced both humoral and cell-mediated immune responses. 
Importantly, the long-term cell-mediated immune responses were detectable up to five months after 
immunisation and were higher in the sheep immunised with the freeze-dried E2 nanovaccine 
formulation. 
 
5.2 Material and Methods 
 
5.2.1 Preparation of amino functionalised hollow mesoporous silica nanoparticles (HMSA) 
The nanoparticles used in this study were hollow mesoporous silica nanoparticles with amino 
groups added to the particle surface. The synthesis method of the HMSA nanoparticles used in this 
study has been described previously. [17] To obtain a monodisperse suspension, nanoparticles (100 
mg) were dispersed in PBS (10 mL) and ultrasonicated in a glass vial for 1 min at ambient 
temperature (25°C) using a 5mm probe sonicator (Hielscher UP100H, Teltow, Germany) at 60% 
amplitude. 
 
5.2.2 Adsorption of oE2 to HMSA for freeze-drying 
An Escherchia coli codon-optimised, truncated version of E2 (which lacks the membrane binding 
domain of native BVDV E2) was expressed, purified, endotoxin-treated and then solubilised as 
described previously for oE2 protein. [19]  
Suspensions of HMSA (10 mg/mL in 50 mM Tris (pH7.0), 0.2% Igepal CA630, (Sigma Aldrich, St. 
Louis, USA) were prepared as described above. Adsorption of oE2 protein on HMSA were 
performed at 25°C using 200 !g of oE2 and 2 mg HMSA (10 mg/ mL) in 50 mM Tris, 0.2% Igepal 
CA630 buffer (pH7.0) at 200 rpm for 22 h. A 200 !L sample of the particle-protein slurry was 
removed and centrifuged (16.2 g, 1 min). The amount of oE2 protein remaining in the adsorption 
supernatants were visualised by gel electrophoresis and quantified using a microtitre plate format 
protein assay kit (Biorad DC kit, Hercules, USA) following the manufacturer’s instructions. 
 
5.2.3 Freeze-drying process 
Following oE2 adsorption to the HMSA particles, the samples were centrifuged at 4500 g for 5 min 
and the supernatants were removed. Different combinations and concentrations of excipients were 
added to the oE2/HMSA pellets prior to freeze-drying and the final volume adjusted to 1 mL. 
Samples were frozen in liquid nitrogen then placed in a freeze-dryer (Martin Christ Model LPC-32,  
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Osterode AM Harz, Germany) at 24°C, 0.11 mbar for 20 hr for the primary drying step. The 
secondary drying step was at 24°C, 0.01 mbar for 2 hr. Freeze-dried samples were stored in a 
vacuum desiccator at ambient temperature. 
 
5.2.4 Reconstitution and transmission electron microscope (TEM) of lyophilised samples  
Samples were reconstituted in 1 mL sterile PBS. The physical characteristics of the freeze-dried 
nanoparticles were observed using transmission electron microscopy (TEM) before and after freeze-
drying. 
 
5.2.5 SDS-PAGE Electrophoresis 
SDS-PAGE analysis was performed using XCell SureLock® Mini-Cell precast system (Invitrogen, 
Carlsbad, USA) with NuPAGE 10% BIS-Tris gels according to manufacturer instructions. Size 
estimations were determined against SeeBlue® Plus2 (Invitrogen) pre-stained molecular weight 
standards. The resolved proteins were visualised by staining in 50% methanol, 10% acetic acid, 
0.25% Coomassie Blue R250 for 30 min, followed by destaining in 30% methanol, 10% acetic acid 
for 10 min three times. 
 
5.2.6 Screening of sheep to determine BVDV status 
Forty sheep were purchased from Mungindi on the border between Queensland and New South 
Wales, Australia. All the procedures involving the animals were approved by The Department of 
Agriculture, Fisheries and Forestry Animal Ethics Committee. Ethics approval number SA 
2011/05/358. The sheep were housed in 3 x 3 m pens with 4 animals per pen (in accordance with 
the Animal Ethics guidelines) for the first 3 months of the study and then the sheep were put out to 
pasture for the remaining 4 months of the study. 
 
Since BVDV-1 is endemic in many sheep herds it was essential to screen the animals to determine 
whether they were currently infected or had been previously infected with BVDV-1 to determine 
their suitability for inclusion in the study.  
 
The sheep (n = 40) were screened for BVDV-1 infection status using quantitative real time PCR as 
described previously. [20] The sheep were also screened for the presence of BVDV IgG antibodies 
using an E2-specific ELISA (described below). Sera samples from the sheep were diluted from 
1:100 to 1:6400 for the ELISA assays. The ELISA results showed that 23 out of the 40 had an 
absorbance reading of less than 0.1 at 690 nm (data not shown) at 102 dilution of the sera samples.  
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This showed there was a no response to E2 and therefore these animals were designated BVDV 
negative. The other 17 animals had a range of absorbance readings from >0.1 to 0.4 at 102 dilution 
of the sera samples. For the immunisation trial 16 animals with no E2 ELISA response were 
randomly assigned into 4 groups (4 sheep per group). 
The sheep were closely monitored throughout the study and weighed routinely to monitor changes 
in health. All the animals remained in good health for the duration of the 7 month study with no 
visible deleterious health effects. The average weight range of the sheep at start of trial was 37 kg 
and at the end of the trial was 49 kg. 
 
5.2.7 Immunisation of sheep 
Four animals were allocated into each of the four treatment groups (Table 5.1). oE2 protein 
adsorption to HMSA was performed within 24 hr of animal immunisation.  
 
Injection doses of the E2 nanovaccine were prepared by isotherm adsorption reactions. 80 !g oE2 
binds per mg to The oE2/HMSA adsorption reactions were prepared aseptically using 500 !g oE2 
protein and 6.2 mg HMSA (10 mg/mL) in sterile 50 mM Tris, 0.2% Igepal CA630 buffer (pH 7.0) 
in a total volume of 5 mL at 25 °C, 200 rpm for 22 hr. Following adsorption the particles were 
centrifuged at 4500 g for 5 mins and the supernatant was removed.  
 
Freeze-dried oE2/HMSA nanoformulation included 5% trehalose and 1% glycine. Samples were 
frozen in liquid nitrogen then freeze-dried as described above. Freeze-dried samples were stored in 
a vacuum desiccator at ambient temperature (25oC) before use. 
 
Quil-A (2 mg/mL, Superfos Biosector, Vedback, Denmark) was resuspended in sterile injectable 
water (Pfizer). The doses were resuspended in 1 mL injectable saline (0.9%) and administered by 
subcutaneous injection at the base of the ear using a sterile 23 gauge needle. Three injections were 
administered at three week intervals. The injection doses (Table 5.1) administered were oE2 plus 
Quil-A (500 !g oE2 and 1 mg Quil-A), non-freeze-dried oE2-HMSA (500 !g/6.2 mg HMSA), 
freeze-dried oE2-HMSA (500 !g/6.2 mg HMSA) and HMSA (6.2 mg).  
 
Pre-immune (PI) blood samples were collected prior to immunisation and subsequent samples were 
collected at two-week intervals following each injection and then at monthly intervals for 5 months 
after the final injection. Blood samples were collected via jugular vein collection using 20 gauge 
needle into lithium-heparin vacutainer tubes (Becton Dickinson, New Jersey, USA). 
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Table 5.1. The immunisation groups in the sheep study. 
 
5.2.8 E2-specific ELISA 
ELISAs for the detection of oE2-specific antibodies were performed by coating microtitre plates 
(Nunc Maxisorb, Roskilde, Denmark) with 50 !L oE2 antigen solution (2 ng/!L) in PBS overnight 
at ambient temperature. The coating solution was removed and the plates were washed once with 
PBS-T (1x PBS, 0.1% Tween-20, Sigma Aldrich) and then blocked with 1% Bovine Serum 
Albumin (Sigma Aldrich) and 1% skim milk (Fonterra, Auckland, New Zealand) in 200 !L PBS for 
1 hr with gentle shaking at ambient temperature. Plates were washed three times with PBS-T. 
Sheep sera samples were diluted from 1:100 to 1:6400 in 50 !L PBS and added to the wells of the 
blocked plates followed by incubation for 2 hr at ambient temperature. To detect sheep antibodies 
100 !L HRP conjugated monoclonal anti-sheep IgG antibodies (Sigma Aldrich) diluted in PBS to 
1:40,000 were added to each well and incubated for 1 hr at ambient temperature with gentle 
shaking. The plates were washed three times in PBS-T and 100 !L TMB substrate (Life 
Technologies) was added and incubated for 15 min; 100 !L of 1 N HCl was added to the wells to 
stop the chromogenic reaction. The plates were read at 450 nm on a BioTek microplate reader 
(Winooski, US). 
 
5.2.9 Isolation of peripheral blood mononucleocytes and interferon-! (IFN-!) ELISPOT assay 
To 35 mL whole blood in a 50 mL tube (Falcon), 15 mL of D-PBS (Invitrogen) was added. The 
samples were mixed gently by inverting the tubes. The diluted blood was gently added on top of 15 
mL of Ficoll-Paque PLUS (GE Healthcare, Buckinghamshire, United Kingdom). Samples were 
centrifuged at 1000 g for 40 min at ambient temperature in a benchtop swing-out centrifuge (Sigma, 
settings were “No brake” and medium acceleration). Following centrifugation, the upper plasma 
layer was drawn off, leaving the lymphocyte layer undistributed at the interface. The lymphocyte 
layer was transferred and D-PBS up to 50 mL was added and centrifuged at 450 g for 10 min at 
ambient temperature (maximum brake and acceleration). The supernatant was removed leaving 1 
mL volume. Red blood cells were lysed by the addition of 9 mL of 0.17 M ammonium chloride pH  
 
Treatment 
Group 
Group 
Description 
Injected dose 
(1 ml) 
1 oE2 500 !g oE2 plus 1 mg Quil-A 
2 oE2/HMSA 500 !g oE2/6.2 mg HMSA 
 
 
HSHMSAHMSA 
3 Freeze-dried 
Opti-E2/HMSA 
Opti-E2/HMSA 
 
 
 
500 !g oE2/6.2 mg HMSA 
 4 HMSA only 6.2 mg HMSA 
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7.5 and the cell pellets were resuspended by gentle shaking. The samples were incubated at 4°C for 
10 min, then 30 mL of D-PBS was added, followed by centrifugation at 800 g (maximum brake and 
acceleration) for 10 min at ambient temperature. The cells were resuspended in RPMI-40 media and 
the viable cell number determined by trypan blue (0.2%) staining. Cells from each sheep were 
seeded at 1.0 - 1.5 x 105 cells/well in triplicate into Polyvinylidene fluoride (PVDF) ELISPOT 
plates coated with interferon- ! (IFN-!) (Mabtech, Sweden) capture antibody. Cells were incubated 
in complete DMEM medium at 37°C and 5% CO2 for 40 h in the presence or absence of 10 "g/mL 
oE2 antigen or the polyclonal activator concavalin A (Con A, 1 "g/mL, Sigma Aldrich) as a 
positive control. IFN-! ELISPOT assays were performed according to the manufacturer’s 
specifications. The ELISPOT plates were read on an ELISPOT reader (Autoimmun Diagnostika, 
Strassburg, Germany). 
 
5.2.10 Statistical analyses 
Statistical analysis of the ELISA data (Fig 5.6) was performed on the average OD values (at 450 
nm) of individual animals in each group (serum dilution of 1:200). The ELISA results were 
analysed by one-way analysis of variance and significant differences between groups were 
determined using Tukey’s HSD test (GraphPad Prism for Windows V5.04). 
Statistical analysis of the ELISPOT data (Fig 5.7) was performed on the number of SFU/million 
cells obtained for individual animals using an unpaired, two-tailed Student’s t-test (Microsoft 
Excel). 
 
5.3 Results and Discussion 
 
5.3.1 Characterisation of HMSA 
The HMSA were synthesised as described in our previous study with an E2 nanovaccine in 
mice.[17] The particles were of a uniform shape and size of 140 to 150 nm (Fig 5.1) as determined 
by size distribution analysis of transmission electron microscopy (TEM) images (Fig 5.2). These 
particles were larger than the HMSA used in the previous study (120 nm) although the thickness of 
the particle shell was the same at 20 nm. The pore structure of HMSA was characterised by nitrogen 
(N2) adsorption-desorption isotherms (Fig 5.3). The nanoparticle surface area which was calculated 
by the Barret-Emmett-Teller (BET) method was 71.04 m2 g-1 and the total pore volume was 0.39 m3 
g-1. The elemental analysis showed atomic percentages for nitrogen, carbon and hydrogen were 
0.93%, 24.12% and 4.91% respectively. 
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Fig 5.1. The morphology of HMSA observed by transmission electron microscopy.  
 
 
Fig 5.2. Particle size distribution of HMSA determined by TEM imaging 
 
 
 
 
S1 F ig. Particle size distribution of HMSA determined by TE  i aging (total particle 
number = 45). 
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Fig 5.3. N2 adsorption-desorption isotherms of HMSA. 
 
5.3.2 Freeze Drying of oE2 adsorbed HMSA  
The optimal combination of cryoprotectant and lyoprotectant that will preserve both the protein and 
the nanoparticles during the freeze-drying process needs to be empirically determined for each 
protein and nanoparticle combination. The oE2 protein was bound to HMSA using isotherm 
conditions which gives 80 µg oE2/mg HMSA.[17] Following adsorption the excipients were added 
to the oE2/HMSA and the nanoformulations were rapidly frozen in liquid nitrogen and 
subsequently freeze-dried.  
 
Previously we have shown successful freeze-drying of ovalbumin adsorbed mesoporous silica 
nanoparticles using 5% trehalose and 1% PEG8000.[21] Therefore the first combination that was 
trialed with oE2 bound HMSA was 5% trehalose with either 1%, 0.5% or 0.1% PEG8000. The 
integrity of the protein after freeze-drying was assessed by SDS-PAGE analysis of the reconstituted 
samples. The presence of PEG8000 in the samples distorted the electrophoretic migration of protein 
in SDS-PAGE gels, causing the protein to migrate at an apparently lower molecular weight. In the 
absence of PEG, the oE2 molecular weight was approximately 42 kDa (Fig 5.4A, Lane 1), while in 
the presence of PEG8000 the molecular weight was estimated to be 30 kDa (Fig 5.4A, Lane 2). 
After freeze-drying with the excipients, 5% trehalose and 1% or 0.5% PEG8000, the migration of 
oE2 was distorted and the protein appeared degraded as the intensity of the band was lower (Fig 
5.4A, Lanes 3 and 4) compared to the control oE2 protein (Fig 5.4A, Lane 1). The oE2/HMSA 
sample freeze-dried with 5% trehalose and 0.1% PEG8000 showed oE2 protein of 42 kDa (Fig 
5.4A, Lane 5). This lower concentration of PEG8000 did not affect the electrophoretic migration of 
oE2. However as with the higher concentrations of PEG8000 the protein was also degraded, as  
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suggested by the lower intensity of the band compared to the control oE2 protein band (Fig 5.4A). 
These results suggested that trehalose and PEG8000 were not able to stabilise the oE2 during either 
the freeze-drying or reconstitution processes and therefore a different lyoprotectant was required. 
 
Glycine was then tested as an alternative lyoprotectant since it has been used successfully for 
freeze-drying of other proteins such as lactate dehydrogenase and glucose 6-phosphate 
dehydrogenase in a sucrose-glycine based excipient system.[22] Glycine was used at 1%, 0.5% and 
0.1% in combination with 5% trehalose in the freeze-drying formulations. Reconstituted, freeze-
dried oE2/HMSA samples were analysed on SDS-PAGE gels and showed that the oE2 protein 
integrity was maintained at all three concentrations of glycine used (Fig 5.4B). Therefore 1% 
glycine was selected for freeze-drying of the nanovaccine formulation. The integrity of the 
nanoparticles following the freeze-drying process with 5% trehalose and 1% glycine was confirmed 
by TEM analyses. The resulting images showed that the HMSA remain intact and maintained their 
characteristic round shape and original size of 140-150 nm (Fig 5.5). The freeze-dried nanovaccine 
reconstituted easily and rapidly in less than 30 seconds. Furthermore, it was found that this 
excipient combination of 5% trehalose and 1% glycine for freeze-drying of oE2/HMSA maintained 
the protein integrity after long-term storage (14 months) at ambient temperature, whereas freeze-
drying with 5% trehalose and 1% PEG8000 resulted in completely degraded protein. 
 
Fig 5.4. (A) Evaluation by SDS-PAGE of oE2/HMSA formulations after freeze-drying with 
different combinations of trehalose and PEG8000. Lane 1: oE2 control; oE2/HMSA freeze-dried  
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with Lane 2: 1% PEG8000; lane 3: 5% trehalose and 0.5% PEG8000; lane 4: 5% trehalose and 
0.1% PEG8000.  
(B) Evaluation by SDS-PAGE of oE2/HMSA formulations after freeze-drying with different 
combinations of trehalose and glycine. Lane 1: oE2 control; oE2/HMSA freeze-dried with lane 2: 
5% trehalose and 1% glycine; lane 3: 5% trehalose and 0.5% glycine; lane 4: 5% trehalose and 
0.1% glycine. 
 
 
Fig 5.5. The morphology of oE2/HMSA particles visualised by transmission electron microscopy 
following freeze-drying with 5% trehalose and 1% glycine. 
 
5.3.3 Immunisation of sheep with oE2 nanovaccine formulations 
To determine if HMSA can act as a useful delivery vehicle for oE2 protein, in livestock animals, 
sheep were immunised three times at three week intervals. Freeze-drying is a relatively harsh 
process but can be used to generate nanoparticle preparations which have long-term stability at 
ambient temperatures. [23,24] To determine if freeze-drying affected the activity of the oE2 
nanoparticle formulation, it was tested in animals both before and after freeze-drying. The sheep 
trial comprised of 16 BVDV-1 negative animals divided into four groups. Group 1 (sheep 1 to 4) 
received 500 µg oE2 together with Quil-A, as a conventional adjuvant, Group 2 (sheep 5 to 8) 
received 500 µg oE2/6.2 mg HMSA which was not freeze-dried, Group 3 (sheep 9 to 12) sheep 
received 500 µg oE2 per 6.2 mg HMSA which had been freeze-dried with 5% trehalose and 1% 
glycine. Group 4 (sheep 13 to 16) received 6.2 mg HMSA particles only per dose (Table 5.1). Pre-
immune (PI) sera samples were collected prior to immunisation and subsequent sera samples were 
collected at two week intervals following each immunisation. All of the sheep remained healthy and 
within the normal weight range throughout the experimental period (data not shown). 
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Immune responses measured by an E2-specific Enzyme-linked Immunosorbent Assay (ELISA) 
showed E2-specific antibodies were detectable following two injections (data not shown). The total 
IgG responses were highest two weeks after the third injection (Fig 5.6). Group 1 animals 
immunised with oE2 (500 !g) plus Quil-A (1 mg) showed similar antibody responses (average OD 
value of 1.4) in all four sheep, therefore oE2 protein was immunogenic in a large animal model. 
Group 2 animals received three injections of the oE2/HMSA nanoformulation (500 !g oE2 
adsorbed to 6.2 mg HMSA). Sheep 6 and sheep 8 showed a similar level of oE2 specific antibody 
response (average OD value of 1.33, Fig 5.6) to Group 1 animals. Sheep 7, Group 2 showed a low 
antibody response as a result of not receiving the full booster dose during the second immunisation. 
All four animals in Group 3 immunised with the freeze-dried oE2/HMSA nanoformulation (500 !g 
oE2 adsorbed to 6.2 mg HMSA) showed strong antibody responses to oE2/HMSA (OD values from 
0.83 to 1.33). This result is important since it has demonstrated that freeze-drying of the oE2 
nanoformulation with the excipients 5% trehalose and 1% glycine maintained the immunological 
integrity of E2 protein. Group 4 sheep immunised with HMSA particles showed no specific 
antibody response to oE2 protein (Fig 5.6). These results confirmed that nanoformulations can 
deliver E2 antigen and act as a self-adjuvant in large animals without the need of a conventional 
adjuvant.  
 
The injections of oE2/HMSA in the sheep at the base of the ear did not result in localised skin 
redness indicating that subcutaneous route of immunisation of HMSA nanoparticles was well 
tolerated in sheep (data not shown). The route of immunisation together with adjuvant and the type 
of antigen itself are important considerations as they can influence the type of immunity generated 
in response to the vaccine antigen. The subcutaneous route of immunisation was selected based on 
our previous studies in mice with oE2 adsorbed to HMSA[17] in which this route of immunisation 
was well tolerated in mice. It has been demonstrated that immunisation of sheep with 50 nm 
polystyrene beads was most effective at inducing both cellular and humoral immunity when 
administered through intradermal and subcutaneous routes.[25] The effectiveness of the oE2 
nanovaccine formulation using this route of immunisation may result from slower antigen 
absorption from the subcutaneous injection site creating a depot effect and therefore prolonging the 
immune response. The BVDV-1 vaccine, Pestigard® used in Australia, is also administered 
subcutaneously in cattle, therefore subcutaneous delivery of nanovaccine formulations should be a 
viable immunisation strategy for industry use. 
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Fig 5.6. oE2-specific ELISA antibody responses in sheep after three subcutaneous immunisations. 
The individual response for each sheep is shown using a sera dilution of 1:200. Group 1 (sheep 1 to 
4) received 500 !g oE2 and 1 mg Quil-A; Group 2 (sheep 5 to 8) received the non-freeze-dried E2 
nanovaccine (500 !g oE2 adsorbed to 6.2 mg HMSA), Group 3 (sheep 9 to 12) received the freeze-
dried (FD) E2 nanovaccine (500 !g oE2 adsorbed to 6.2 mg HMSA), Group 4 (sheep 13 to 16) 
received HMSA particles (6.2 mg) only. Groups that do not share a common letter were 
significantly different (p<0.001, unpaired t-test analysis).  
 
5.3.4 Long-term cell-mediated immune responses to oE2/HMSA immunisation by ELISPOT 
assay  
 
The cell-mediated memory response to an antigen is a vital component of the immune system since 
it demonstrates uptake of the antigen by professional antigen presenting cells and presentation 
within the lymphoid organs, an essential process for developing immunity to invading pathogens. 
To determine if there were long-term cell-mediated immune responses in sheep after immunisation 
using HMSA, the peripheral blood mononucleocyte cell (PBMC) populations were isolated five 
months following the third immunisation. Stimulated PBMCs were then used in IFN-" Enzyme-
linked Immunosorbent Spot (ELISPOT) assay to determine if there was T-helper type 1 (Th1)  
 
 112 
cell-mediated immune response. Fig 5.7 shows the IFN-! response of individual sheep as indicated 
by the number of cells producing Spot Forming Units (SFU). The four animals in Group 1 which 
received oE2 plus Quil-A showed some variation in the responses. Sheep 1 and 3 showed lower 
level responses of 244 and 272 SFU/million cells and Sheep 2 and 4 showed high level responses of 
1869 and 2032 SFU/million cells in response to oE2 antigen (Fig 5.7, blue bars). One explanation 
for varied response could be the animal to animal variation of outbred animals. This has been 
observed in previously immunisation studies with the sheep model. [25-27]  
 
All the animals in Group 2 (sheep 5 to 8) injected with the oE2 nanoformulation showed similar 
low levels of cell-mediated immunity to oE2 antigen (from 213-500 SFU/million cells). Whereas, 
interestingly, it was found that Group 3 (sheep 9 to 12) immunised with freeze-dried oE2 
nanoformulation showed very high responses (> 2290 SFU/million cells). This result showed there 
was an excellent long-term Th1 memory response to immunisation with freeze-dried oE2 
nanovaccine formulation detectable five months after immunisation. It was also determined that 
sheep 11 and sheep 12 showed a higher “no antigen” response which we cannot account for. The 
freeze-dried formulation included the excipients 5% trehalose and 1% glycine which are not known 
to be immunogenic. We have previously used 5% trehalose and 1% PEG8000 [21] with ovalbumin 
protein to generate freeze-dried nanovaccine and did not see increased cell-mediated responses for 
the “no antigen” controls. Once the reconstituted vaccine is injected the excipients should be rapidly 
adsorbed, metabolised and cleared from the system and have no adjuvant effect on the immune 
system. 
 
One of the Group 4 sheep (number 3) which received HMSA particles showed 2296 SFU/million 
cells in the presence of oE2 this could indicate that this animal had become exposed to BVDV-1 as 
these animals were kept outside for a period of four months after the final immunisation. 
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Fig 5.7. The long-term immune memory response of sheep PBMC cells following stimulation to 
oE2 antigen. IFN-! secretion of PBMC cells obtained five months after immunisation was assessed 
by ELISPOT assay in response to oE2 (10 ng/"L, blue bars) and compared to unstimulated cells 
(red bars). The Mean Spot SFU /million cells is shown for each animal (assayed in triplicate) in the 
treatment groups. The polyclonal activator, Concavalin A, was used to confirm cell viability and 
functionality of the assay (data not shown). The asterisk (*) indicates significant responses with p < 
0.001 (unpaired t-test analysis). 
 
Importantly, this is the first study to the best of our knowledge to investigate the long-term immune 
responses in a large animal after immunisation with silica nanoparticles as all previous studies have 
been performed in mice. [16,17,21,28]  
 
The fact that the immune response in animals receiving the E2 nanoformualtion was balanced with 
both humoral and cellular immunity is an encouraging result. This has also been demonstrated in 
sheep immunised with ovalbumin covalently conjugated to polystyrene nanobeads of 50 nm in size. 
In that study both cellular and humoral immunity was induced most effectively when the nanobead 
formulation was administered through intradermal and subcutaneous routes compared to the 
intramuscular route. [25] 
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The freeze-drying process was not detrimental to the nanoformulation and in fact enhanced the 
levels of the cell-mediated immune responses in the animals receiving the freeze-dried formulation 
(Fig 5.7). Freeze-drying of cationically modified silica nanoparticles (28 nm in size) for gene 
delivery in Cos-1 showed that addition of either 5% trehalose or 10% glycerol conserved 
nanoparticle integrity and subsequent biological activity through DNA-binding and enhanced 
transfection efficiency. [29] 
 
Here we have demonstrated for the first time that HMSA have the capacity to act as both the 
antigen delivery vehicle and vaccine adjuvant in a large animal. This is a significant finding since 
sheep are a natural target species of BVDV-1. In addition, unlike previous studies using an inbred 
laboratory mice strain,[17] [21] sheep are an outbred animal and although the immune responses 
can be more variable, demonstration of the feasibility of silica nanovaccine technology in a large 
animal model is a critical research milestone.  
 
5.4 Conclusion 
 
Hollow mesoporous silica nanoparticles are an attractive new adjuvant which can be precisely 
tailored to accommodate different antigens. HMSA nanoparticles can have the following 
advantages; 1) providing stability for the protein antigen through adsorption/encapsulation and 
therefore improved protection from degradation in the cell environment; 2) are amenable to a 
freeze-drying process for increased stability at ambient temperatures during storage; 3) providing a 
mechanism of delivery through efficient uptake due to their size by circulating dendritic cells for 
subsequent antigen presentation in the lymphoid organs and 4) stimulating a balanced immune 
response with both humoral and cell-mediated immunity.  
 
The results presented here for a target species of BVDV-1 are a promising step towards establishing 
the use of silica nanoparticles for an oE2 subunit vaccine for the livestock industry. The effective 
freeze-drying of the E2 nanoformulation is a significant step towards the development of such a 
vaccine. The next step in the development of this vaccine delivery system will be to demonstrate the 
capacity of silica nanoparticle formulations to protect animals from infection in challenge studies. 
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6. 
Silica Vesicles as Nanocarriers and Adjuvants for 
generating both Antibody and T-cell mediated Immune 
Responses to Bovine Viral Diarrhoea Virus E2 protein 
 
 
 
 
 
 
 
 
 
The Chapter 6 describes a detailed study on Bovine Viral Diarrhoea Virus-1 (BVDV-1) protein E2 
loaded silica vesicles (SV) for the development of efficient vaccine delivery systems. A two-step 
self-assembly approach have been used to synthesise SV with a uniform 50 nm particle size with 
precisely controlled entrance size by Zhang et al. [1] These SV displayed desirable characteristics 
like large entrance size and thin shell wall of 6 nm. Our collaborator Prof. Chengzhong (Michael) 
Yu at Australian Institute for Bioengineering and Nanotechnology (AIBN) provided the four 
different types of SV (SV-140, SV-140-A, SV-100 and SV-100-A) investigated in this study.  
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The four SV with different physico-chemical characteristics were evaluated for adsorption of 
BVDV-1 protein E2 and its sustained release in different types of buffer. After optimising the 
adsorption and release kinetics, the cellular uptake and in vitro cytotoxicity of the four SV was 
tested. The unfunctionalised SV-140 was selected as antigen carrier for in vivo investigation based 
on the results from in vitro studies and exhibition of the desirable characteristics such as efficient 
antigen loading, cellular uptake proficiency and non-toxicity. Most importantly, to the best of our 
knowledge this study was the first to demonstrate induction of excellent immune responses to 
BVDV-1 E2 protein adsorbed on to the SV-140 vesicles. Chapter 6 is published in Biomaterials 
2014, 35, 9972-9983. 
 
6.1 Introduction 
 
Bovine Viral Diarrhoea (BVD) is a prevalent cattle infection of great importance in several 
countries due to its economical importance to the cattle industries. BVDV causes serious mucosal 
lesions and clinical disorders such as reproductive loss, congenital defects and persistent infections. 
[2, 3] An economic analysis in 2009 has shown that yearly losses due to BVDV could reach 
approximately US$88 per animal. [4] BVDV vaccines are broadly divided in two categories; 
Modified Live Virus (MLV) and Killed Virus (KV) vaccines. Both of these types of vaccines can 
have certain drawbacks: MLV vaccines may be deactivated beyond certain temperatures or by some 
chemicals and revert to virulence while KV vaccines require more antigen per dose compared to the 
MLV and are more expensive. [5] BVDV commonly known as bovine pestivirus, is a single-
stranded RNA virus which infects cattle and sheep. [6] The BVDV genome is a 12.3 kb single 
stranded RNA molecule, containing a single open reading frame that is translated into a single 
polyprotein, which is processed into individual viral proteins by viral and cellular proteases. [7] The 
structural envelope glycoprotein, E2, is the major immunogenic determinant of BVDV virion 
making it an ideal candidate as a subunit vaccine component. [2, 8-11] 
 
Subunit vaccines comprise of highly purified recombinant antigens such as proteins and peptides 
and offer advantages such as increased stability and better safety profiles compared to conventional 
vaccines. [12] However, a limiting factor in the development of subunit vaccines is the need to elicit 
both the arms of defence, antibody and T- cell mediated immunity. Proteases can degrade the 
protein or peptide in the biological system, which might limit their bioavailability and subsequent  
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presentation to the immune system. Hence, adjuvants are often added to in subunit vaccine 
formulations as helping agents to induce strong antigen specific immune responses. [13]  
 
Quil-A, an extract from the bark of Quillaja saponaria is one of the most common adjuvant used in 
mice trials. The saponin-based adjuvants stimulate Th1 immune responses and production of CD8+ 
cytotoxic T-lymphocytes against antigens. [14-16] However, disadvantages including pain at the 
site of injection, severe local reactions and toxicity profile are associated with saponin-based 
adjuvants. [17, 18] Freund’s complete adjuvant (FCA) is one of the most effective adjuvants, 
nevertheless, FCA is known to induce high toxicity and severe reactions. [19] The drawbacks 
associated with alum-type adjuvants are that they are not effective for all antigens and often induce 
local reactions at the site of injection and generally fail to induce CD8+ T-cell immunity. [20] As 
reviewed recently most conventional vaccines produce either a Th1 or Th2 mediated response, 
hence there is a need for a robust, non-toxic and effective adjuvant that can induce balanced 
immune responses (both cellular and humoral) with minimal or no side effects. [21, 22, 29]  
 
In the past few years, silica nanoparticles have been explored as nanocarriers for vaccine delivery. 
[23-26] In particular, Mesoporous Silica Nanoparticles (MSNs) have desirable properties including 
ease of synthesis and surface functionalisation, large surface area, and excellent in vivo 
biocompatibility. [27] The controllable pore structures make MSNs excellent candidates to tune the 
adsorption and release of biomolecules. [28] A few studies on the potential of MSNs as vaccine 
adjuvants and antigen carriers have been explored, [26, 29, 30] the adjuvant property of MSNs on 
human-monocyte-derived dendritic cells, showing the capability to tune autologous naïve T cells 
into different effector cells has been demonstrated. [31] Most of these studies used model proteins 
such as bovine serum albumin (BSA) [32, 33], cytochrome c [34, 35] and ovalbumin (OVA). [26] 
Recently, Guo et al.[36] used hollow structured MSNs (HMSNs) as delivery vehicles for Porcine 
CircoVirus type-2 (PCV2) ORF2 protein. However, the antibody response was significantly lower 
for the group immunised with the protein loaded nanoparticles HMSNs/GST-ORF2-E in 
comparison to the group treated with GST-ORF2-E protein alone.  
 
Previously, we have described the use of OVA loaded amino functionalised MSNs and BVDV-1 E2 
loaded on hollow mesoporous silica nanoparticles (HMSA) to develop vaccine delivery systems. 
[23-25] Though, we were able to get low levels of detectable antibody and cell mediated responses, 
the major limitations were very low protein loading efficiency (60-80 µg/mg of particles), small  
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entrance size (2-3.5nm) and possibly only surface presentation of proteins on these silica 
nanocarriers. Despite of several studies describing the use of silica nanoparticles as vaccine 
adjuvants, no previous studies have evaluated structural modification of the particles to increase the 
antigen adsorption, facilitate sustained release by surface as well as internal cavity loading and 
improve their adjuvanticity so that no additional adjuvant is required.   
 
We have developed a silica vesicle (SV) nano-carrier delivery system that demonstrates strong self-
adjuvant effect, elicits higher antibody and T-cell mediated response and has the potential for 
reducing dose number, parameters of high significance for an improved vaccine formulation. In this 
study, for the first time, we have demonstrated the induction of excellent immune responses to a 
recombinant BVDV-1 E2 protein expressed from a codon-optimised E2 gene (oE2) adsorbed to SV, 
also termed as ‘nanovaccine’ treatment group. The carefully tailored SV are sized for effective 
endocytosis (50 nm), have a total pore volume in the range of (0.49-1.24 cm3/g) to accommodate 
high antigen loadings and a thin, porous shell (wall thickness ~ 6 nm) with controllable entrance 
size (5.7 nm to16 nm) facilitating both surface and internal cavity loading for sustained release of 
the antigen. Our work may pave the way in the development of state-of-the-art nanotechnology for 
improved veterinary vaccination. 
 
6.2 Materials & Methods 
 
6.2.1 Chemicals 
EO39BO47EO39 [commercial name B50-6600, EO is poly(ethylene oxide) and BO is poly(butylene 
oxide)] was received from Dow Company. Tetraethyl orthosilicate (TEOS), (3-
aminopropyl)triethoxysilane (APTES), fluorescein-5-isothiocyanate (FITC), were purchased from 
Sigma-Aldrich (St. Louis, USA). Analytical reagent grade sodium acetate (NaAc) and acetic acid 
(HAc) are received from ChemSupply (Port Adelaide, Australia) and Ajax Finechem Pty Ltd 
(Sydney, Australia), respectively. 
 
6.2.2 Synthesis of hollow silica vesicles 
For the synthesis of the silica vesicles (SV), a procedure from the literature was used with some 
modification [37, 38], 0.5 g of EO39BO47EO39 and 0.852 g of Na2SO4 were dissolved in 30 g of pH 
= 4.7 NaAc-HAc buffer solution ([NaAc] = [HAc] = 0.40 M) to form a homogenous solution under 
stirring at 10 °C, 3.57 mL (3.33 g) of TEOS was added with continuously stirring for 24 h. The 
reaction mixture was then moved to an autoclave and hydrothermally treated at 100 or 140 °C for  
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another 24 h, denoted by SV-100 or SV-140, respectively. The as-synthesised samples were 
collected by filtration and thoroughly washed with deionized water to remove the added salts. The 
samples were then dried in air. The final products were obtained by calcination at 550 °C for 5 h in 
air. 
 
6.2.3 Characterisation 
Field emission scanning electron microscope (FE-SEM) images were obtained using JEOL JSM 
7800 operated at 0.6 kV. Transmission electron microscopy (TEM) images were obtained with 
JEOL 2100 operated at 200 kV. For TEM measurements, the samples were prepared by dispersing 
and drying the powder samples-ethanol dispersion on carbon film on a Cu grid. Nitrogen 
adsorption-desorption isotherms were measured at 77 K by using a Micromeritics Tristar II system, 
before which the samples were degassed at 453 K overnight on a vacuum line. The total pore 
volume was calculated from the amount adsorbed at a maximum relative pressure (P/P0) of 0.99. 
The Barrett–Joyner–Halanda (BJH) method was utilized to calculate the entrance size from the 
desorption branches of the isotherms, and the Brunauer–Emmett–Teller (BET) method was utilized 
to calculate the specific surface areas. Zeta potential measurements were conducted on a Zetasizer 
Nano ZS analyzer (Malvern Instruments, Worcestershire,UK). 
 
6.2.4 Amino and FITC modification of hollow silica vesicles 
In a typical amino-modification process, 1.5 g of calcined SV-100 or SV-140 and 60 mL toluene 
were added to a flask, and the mixture was stirred for 6 h before adding 1.0 mL APTES. After 
stirring at 110 °C for 12 h, the mixture was cooled to room temperature (RT), centrifuged, 
extensively washed with toluene and ethanol, participate was then dried in a fume-hood at RT. The 
amino- modified sample was denoted by SV-100-A or SV-140-A, respectively. 
 
In FITC modification, 20 mg powdered SV-100-A or SV-140-A was dispersed in 3 mL deionized 
water, mixed with 5 mL FITC ethanol solution (0.3 mg/mL), and stirred in the dark at RT for 6 h. 
The products were centrifuged and washed with ethanol extensively until the supernatant was 
colourless. 
 
6.2.5 oE2 adsorption to SV 
Adsorption reactions used 2 mg of SV-140, SV-100, SV-140-A, SV-100-A with 500 µg of oE2 in 
sterile 50mM Tris buffer (pH7.0) containing 0.2% Igepal CA630, in a 2 mL final volume. This 
particle-protein slurry was placed on a shaker at RT, 200 rpm. After 24 h a sample of  
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particle-protein slurry (50 !L) was removed and centrifuged at 16.2 g for 1 minute. The amount of 
unbound oE2 protein was assessed by electrophoresis of the supernatants and the particles on SDS-
PAGE gels. Protein assay was conducted on the adsorbed supernatant, using the BioRad DC kit 
(Hercules, USA), to quantify the amount of the unbound protein; this was done in order to calculate 
the amount of protein bound to the nanoparticles.  
 
6.2.6 Desorption studies 
The oE2 loaded SV-140, SV-100, SV-140-A and SV-100-A vesicle pellets were resuspended in 2 
mL of PBS or 2 mL of PBS plus 0.1% sodium lauryl sulfate (SLS). The resuspended samples were 
left on the shaker at 37 °C for 24 h at 16.2 g. 50 !L aliquots were taken at 5 min, 15 min, 30 min, 3 
h and 24 h. The oE2 protein released from the SV was assessed by electrophoresis of the 
supernatants and the particles on SDS-PAGE gels. 
 
6.2.7 Polyacryalamide gel electrophoresis (PAGE)  
The pellet samples were resuspended in 15 !L of PBS and 5 !L SRB (SDS Reducing Buffer 
consisting of 62.5 mM Tris-HCl (pH 6.8), 117 mM DTT, 10% Glycerol, 2% SDS, 0.02% 
Bromophenol blue), incubated at 85 °C for 2 min then subjected to electrophoresis on 10% Tris-
Glycine gels (Life Technologies, Carlsbad, USA). The gels were visualised by staining in 50% 
methanol, 10% acetic acid, 0.25% Coomassie Blue R250 for 30 min, followed by destaining in 
30% methanol, 10% acetic acid for three 30 min washes.  
 
6.2.8 Cell uptake studies using flow cytometry 
The cellular uptake was investigated using fluorescence activated cell sorting (FACS) for which the 
MDBK cells were seeded at 1.0 x 106 cells/mL in Earle’s Minimum Essential Media (Life 
Technologies) containing 5% FBS. The MDBK cells were incubated in 5 mL petri dishes and 
allowed to adhere overnight in a 37 °C, 5% CO2 incubator. Next day, the cells were treated with 
SV-140-A-FITC and SV-100-A-FITC at two different concentrations of 0.02 mg/mL and 0.004 
mg/mL for 2 h. Media was carefully removed and the dishes were gently washed three times with 
PBS to remove the nanoparticles. Three millilitres of PBS was added and the cells were collected in 
a 15 mL falcon tube. The cells were centrifuged at 1000 g for 6 min at 5 °C. The supernatant was 
discarded and the pellet was resuspended in 2% PFA and subsequently transferred into FACS tubes 
(Becton Dickinson, Franklin Lakes, NJ). BD LSRII analyser was used to determine the cell uptake.  
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6.2.9 Trypan blue staining for in vitro cytotoxicity assay 
MDBK cells (ATCC) were seeded at 80-90% confluency onto glass coverslips in a 24 well plate 
and allowed to adhere overnight in a 37 °C, 5% CO2 incubator. To investigate the effect of 
nanoparticle concentration on the cells a dilution range (0.5 mg/mL, 0.1 mg/mL and 0.01 mg/mL) 
of SV in Earle’s Minimum Essential Media [containing 5% foetal bovine serum (FBS) (Life 
Technologies)] were prepared and gently added drop wise to the adherent cells. The cells were 
incubated in the presence of SV-140, SV-100, SV-140-A, SV-100-A vesicles and MCM-41 as 
synthesised nanoparticles at 37 °C, 5% CO2 for 20 h. Media was carefully removed and the wells 
were gently washed three times with PBS to remove the nanoparticles. To determine cell viability 
0.2% trypan blue stain (Life Technologies) was added for 2 min. Trypan blue stain was carefully 
removed and the wells were washed once with PBS. Cells were fixed in 4% paraformaldehyde 
(PFA) pH 7.4 for 15 min, and then washed three times with PBS. Coverslips were mounted with 5 
!L of MOWIOL (Sigma-Aldrich). Cell viability was determined by imaging on a Zeiss HAL100 
microscope under bright field.  
 
6.2.10 Cell Viability Assay  
The cytotoxicity of the oE2 protein in PBS, oE2/SV-140 and oE2/SV-140 plus traditional adjuvant 
Quil-A was quantified using the colorimetric assay (MTT based) (Roche cell proliferation Kit I). In 
a 96 well flat bottom cell culture plate, the MDBK cells were seeded at 5 x 104 cells/well in 100 !L 
of Earle’s Minimum Essential Media containing 5% FBS, and incubated overnight in at 37 °C, 5% 
CO2. On the following day, different treatments were added to the cells at concentrations of 0.1 
mg/mL, 0.02 mg/mL and 0.01 mg/mL, Triton X-100 at a concentration of 0.1 mg/mL was used a 
positive control for cell death, and the plate was incubated overnight at 37 °C, 5% CO2. Post 
overnight incubation, 10 !L of MTT (0.5 mg/mL final concentration) was added to each well and 
the plate was further incubated for 4 h at 37 °C, 5% CO2. After 4 h, 100 !L of the solubilising 
agent was added to all the wells and the plate was incubated overnight at 37 °C, 5% CO2. Next 
day, the plate was read at 570 nm using BioTek microplate reader (Winooski, US). 
 
6.2.11 Immunization studies conducted in mice 
C57BL/6J mice were purchased from and housed in the Biological Resource Facility, The 
University of Queensland, Brisbane, Australia under specific pathogen-free conditions. Eight week 
old female mice were housed in HEPA-filtered cages with 4 animals per group in an 
environmentally controlled area with a cycle of 12 h of light and 12 h of darkness. Food and water 
were given ad libitum. All procedures were approved by The University of Queensland, Ethics 
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Committee. Animals were closely monitored throughout the study. All the animals remained in 
good health for the duration of the study with no visible deleterious health effects. 
 
Pre-immunisation blood samples were collected by retro-orbital bleeds using heparin coated 
hematocrit tubes (Hirschmann Laborgeräte, Heilbronn, Germany). Pre-immunisation blood 
samples collected prior to the first immunisation were referred to as the pre-immune (PI) samples. 
Table 6.1 shows the different treatment groups in the study. Adsorption reactions were prepared 
aseptically as described above and the adsorbed oE2/SV pellet was washed in 1 mL of saline 
before preparing the final injectable doses. Quil-A (Superfos Biosector, Vedback, Denmark) was 
resuspended at 2 mg/mL in sterile injectable water (Pfizer, Brooklyn, USA). The injectable doses 
were administered to investigate the difference between the immune responses produced by the 
oE2/SV-140 and oE2/SV-140 plus Quil-A. The positive control group of mice received 50 µg oE2 
protein and 10 µg Quil-A. The negative control groups received injections of SV-140 (250 µg) plus 
Quil-A (10 µg). Dose volumes of 100 !L (in 0.9% saline, Pfizer) were administered by 
subcutaneous injection at the tail base using a sterile 27 gauge needle (Terumo, Tokyo, Japan). 
Three injections were administered at 2 week intervals to all the treatment groups except for the 
unimmunised group and mice were sacrificed 14 days after the final immunisation. The animals 
were weighed and monitored for their health once a week. In addition, they were also observed for 
clinical signs, any signs of illness were converted to a numerical score as follows: 0 = normal, 1-4 
= Moderate changes, animals need to monitored daily, 5-10 = Significant changes: monitor twice 
daily and the consultant the chief veterinary officer at the animal facility and >10 = Euthanize.  
 
Table 6.1. Immunisation groups in mice trial. All doses were administered at the tail base. 
 
6.2.12 Enzyme-Linked ImmunoSorbent Assay (ELISA) protocol 
Detection of oE2-specific antibody responses: ELISA for the detection of oE2-specific antibodies 
were performed by coating microtitre plates (96 well, Nunc, Maxisorb, Roskilde, Denmark) with 
oE2 antigen solution (2 ng/!L, 50 !L) in PBS overnight at 4°C. The coating solution was removed  
Group Prototype Vaccine / Injection Dose 
1 oE2 (50 µg) + QuilA (10 µg) 
2 oE2 (50 µg) / SV-140 (250 µg) 
3 oE2 (50 µg) / SV-140 (250 µg) 
+ Quil-A (10 µg) 
4 SV-140 (250 µg) + Quil-A (10 µg) 
5 Unimmunised 
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and the plates were washed once with PBS-T (1x PBS, 0.1% Tween-20, Sigma-Aldrich) and 
blocked with Bovine Serum Albumin (5%, Sigma-Aldrich) and skim milk (5%, Fonterra, 
Auckland, New Zealand) in 200 !L PBS for 1 h with gentle shaking at RT. Plates were washed 
three times with PBS-T.  
 
Mouse sera samples were diluted from 1:1000 to 1:2048000 in 50 !L PBS and each dilution was 
added to the wells of the blocked plates followed by incubation for 2 h at RT. To detect mouse 
antibodies HRP conjugated polyclonal sheep anti-mouse IgG antibodies (Chemicon Australia, 
Melbourne, VIC, Australia) diluted in PBS to 1:10000 were added to each well and incubated for 1 
h at RT with gentle shaking. Plates were washed three times in PBS-T. TMB substrate (100 !L, 
Life Technologies) was added to each well and incubated for 15 min at RT; 100 !L of 1N HCl was 
added to the wells to stop the chromogenic reaction. The plates were read at 450 nm on the BioTek 
microplate reader (Winooski, US). 
 
6.2.13 Isolation of murine splenocytes and enzyme-linked immunosorbent spot (ELISPOT) 
Assay 
Spleens were aseptically removed following euthanasia and placed into 5 mL ice cold DMEM 
media (Life Technologies) supplemented with 10% foetal bovine serum (FBS, Life Technologies), 
20 mM Hepes (pH 7.3), 1 M sodium pyruvate, 1 M Glutamax, 100 units/mL penicillin G, 100 
!g/mL streptomycin, 0.25 !g/mL Fungizone. Spleens were gently disrupted and passed through a 
100 !m nylon mesh (Becton Dickinson) using a syringe plunger. Cells were washed with 5 mL 
DMEM and centrifuged at 800 g for 5 min at 4°C and then resuspended in 1 mL lysis buffer (0.15 
M NH4Cl, 10 mM KHCO3, 0.1 mM Na2-EDTA) for 5 min at RT. Repeat wash steps twice with 
DMEM (9 mL and 5 mL) each time. Cell pellets were resuspended in 2 mL DMEM and cell 
numbers determined by staining with 0.2 % trypan blue. Cells from each mouse spleen were seeded 
at 1.0 - 1.5 x 105 cells/well in triplicate into Polyvinylidene fluoride (PVDF) ELISPOT plates 
precoated with monoclonal interferon- " (IFN-") (Mabtech, Sweden) capture antibody. Cells were 
incubated in complete DMEM medium at 37°C and 5% CO2 for 40 h in the presence or absence of 
1 !g/mL oE2 antigen or the polyclonal activator concavalin A (Con A, 1 !g/mL, Sigma Aldrich) as 
a positive control. IFN-" ELISPOT assays were performed according to the manufacturer’s 
specifications. The ELISPOT plates were read on an ELISPOT reader (Autoimmun Diagnostika, 
Strassburg, Germany). 
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6.3 Results 
 
We initially characterised  SV-100  and SV-140 with and without amino modification as 
potential nano-carriers for BVDV-1 oE2 vaccine formulation. The SEM images (Fig 6.1, a and 
c) of SV show that both SV-100 and SV-140 have spherical morphology with a uniform 
particle size of 50 nm, while some openings can be observed on the surface of SV-140. Both 
SV show a hollow nature with wall thickness of ~ 6 nm and cavity size of ~ 40 nm (Fig 6.1, b 
and d). Small openings (also called entrance) on the siliceous walls can be directly observed in 
TEM images (indicated by white arrows) and the entrance size can be measured to be about 6 
and >10 nm for SV-100 and SV-140, respectively. The pore structure of SV is further 
investigated by N2 sorption analysis. Both SV-100 and SV-140 show type IV isotherms and 
type H3 hysteresis loop (Fig 6.2a) with the adsorption branch showing major capillary 
condensation at relative pressure (P/P0) of ! 0.9. The desorption branch of SV-140 shifts to 
higher relative pressure compared to that of SV-100, indicating a larger entrance size. The 
entrance size of SV was calculated by the BJH method from the desorption branch (Fig 6.2b).  
 
The entrance sizes of SV-100 and SV-140 were found to be 5.9 and 16 nm, respectively. The 
other structrual information of SV are listed in Table 6.2. The total pore volume and BET 
surface area of SV-100 were 1.24 cm3/g and 450 m2/g, respectively. SV-140 has a smaller total 
pore volume and BET surface area (0.78 cm3/g and 273 m2/g) because the spherical integrity of 
SV-140 decreased with larger entrance on the wall. After surface functionalization with amino-
groups, the zeta potential of SV becomes positive (33.9 and 23.8 mV for SV-100-A and SV-
140-A, respectively). The SV-A (where A denotes amino modification) showed similar N2 
sorption isotherms as unmodified SV (Fig 6.2a). As a result, SV-100-A and SV-140-A maitain 
the same entrance sizes (5.7 and 16 nm, respectively) from BJH pore size distribution 
calculated from the desorption branches (Fig 6.2b). However, the total pore volume and BET 
surface area of SV-A decreased after amino-modification (0.67 cm3/g and 219 m2/g for SV-
100-A, 0.49 cm3/g and 153 m2/g for SV-140-A) as mentioned in Table 6.2.  
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Table 6.2. Structural information from N2 sorption results of SV. 
 
Note: Vp: total pore colume; SBET: BET surface area 
 
 
Fig 6.1. Field-emission scanning electron microscope (FE-SEM) image (a) transmission 
electron microscopy (TEM) image (b) SV-100 after calcination; (c) FE-SEM and TEM image 
of (d) SV-140 after calcination.   
 
 
 
 
 
 
 
Sample 
Name 
Entrance Size 
(nm) 
Vp(cm
3/g) SBET (m
2/g) Zeta 
Potential 
(mV) 
SV-100 5.9 1.24 450 -16.7±1.0 
SV-100-A 5.7 0.67 219 33.9±2.0 
SV-140 16 0.78 273 -15.9±0.4 
SV-140-A 16 0.49 153 23.8±0.8 
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Fig 6.2. Nitrogen sorption isotherm plot (a) Barrett-Joyner-Halanda pore size distribution 
curve calculated from desorption branches (b) of SV.  
 
6.3.1 Adsorption  
Adsorption tests were conducted to determine the ability of SV-140, SV-100, SV-140-A and SV-
100-A to bind to the oE2 protein by incubating 500 µg of oE2 with 2 mg of each SV for 24 h. The 
molecular weight of the expressed oE2 is 42 kDa. The samples of the protein and particle slurry 
were collected and separated into supernatant and particle samples and analysed by SDS-PAGE to 
determine the protein loading on the vesicles. The gel analysis indicates that after 24 h of binding 
with all the four SV, no protein could be was detected in the supernatants (Fig 6.3).  
 
Fig 6.3. Adsorption of the oE2 protein on SV on SDS-PAGE. Lane 1:  Marker; lane 2: oE2 
protein; lane 3: oE2/SV-140 supernatant; lane 4: oE2/SV-140 pellet; lane 5: oE2/SV-140-A 
supernatant; lane 6: oE2/SV-140-A pellet; lane 7: oE2/SV-100 supernatant; lane 8: oE2/SV-
100 pellet; lane 9: oE2/SV-100-A supernatant; lane 10: oE2/SV-100-A pellet. 
 
The amount of protein loaded onto the nanoparticles was quantified by performing protein assays 
on the supernatants. The oE2 protein adsorbed was found to be 216, 249, 248 and 236 !g to per mg 
of SV-100, SV-100-A, SV-140 and SV-140-A respectively (Fig 6.4).  
 
 
 
 
 132 
 
Fig 6.4. Adsorption amount of oE2 protein on the different SV. The amonut of protein bound 
to the nanoparticles was calculated using protein assay. (The average of two repeat adsorptions 
was used to calculate the oE2 protein loading).  
 
6.3.2 Desorption studies 
Desorption studies were conducted on protein loaded SV to investigate the release of protein. To 
determine the desorption profiles, sample slurry of the protein and particles were collected at five 
different time points ranging from 5 min to 24 h, separated into desorbed supernatant and particles 
samples and analysed by SDS-PAGE. The gel analysis following desorption in PBS showed that the 
protein remained strongly bound to the vesicles, indicating no oE2 protein desorbed from the SV-
140, SV-140-A, SV-100 or SV-100-A vesicles, after 24 h incubation (Fig 6.5). 
 
 
Fig 6.5. SDS-PAGE analysis – Desorption of the oE2 protein on SV in PBS after 24 h. Lane 1: 
oE2/SV-140 supernatant; lane 2: oE2/SV-140 pellet; lane 2: oE2/SV-140-A supernatant; lane 4: 
oE2/SV-140-A pellet; lane 5: oE2/SV-100 supernatant; lane 6: oE2/SV-100 pellet; lane 7: oE2/SV-
100-A supernatant; lane 8: oE2/SV-100-A pellet. 
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A second release study conducted using PBS plus 0.1% SLS buffer, showed rapid (after 5 min) 
release of the oE2 protein into the supernatants from the particle pellets (Fig 6.6, lane 1) and no 
protein band was observed in the pellet after 24 h (Fig 6.6, lane 10). All the four vesicles exhibited 
similar desorption profiles, hence the gel analysis of the protein desorption for only one vesicle, SV-
140, has been shown in Fig 6.6. The exact amount of protein released in the supernatant could not be 
quantified due to the presence of SLS, which inhibited the protein assay. However, the SDS-PAGE 
results indicate that about >95% of the oE2 protein was released in the supernant after 24 h.  
 
 
Fig 6.6. SDS-PAGE analysis – Desorption studies of oE2/SV-140 in PBS plus 0.1% SLS at 
different time points. Lane 1: Supernatant 5 min; lane 2: Pellet 5 min; lane 3: Supernatant 15 
min; lane 4: Pellet 15 min; lane 5: Supernatant 30 min; lane 6: Pellet 30 min; lane 7: 
Supernatant 3 h; lane 8: Pellet 3 h; lane 9: Supernatant 24 h; lane 10: Pellet 24 h. 
 
6.3.3 Cell uptake studies using FITC labelled silica vesicles  
Cellular uptake is usually a prerequisite when developing a vaccine using nanoparticles. Cellular 
uptake of FITC labeled SV was studied in MDBK cells at two different concentrations of 0.02 
mg/mL and 0.004 mg/mL and was compared to the untreated cells. At 0.02 mg/mL the SV-140-A-
FITC were taken up by 86.4% of the total cell population and the SV-100-A-FITC by 97.3%. 
Furthermore, the Mean Fluorescence Intensity (MFI) values, which is proportional to the amount of 
FITC labelled vesicles taken up by the cells, followed the order SV-100-A-FITC 0.02 mg/mL > SV-
140-A-FITC 0.02 mg/mL > SV-100-A-FITC 0.004 mg/mL > SV-140-FITC 0.004 mg/mL > MDBK 
cells alone (non-treated cells). The amino functionalised SV-100-A-FITC at the 0.02 mg/mL 
concentration showed the highest cellular uptake, which might be due the specific characteristics of 
SV-100-A, a large surface area and the high charge interaction with cell membranes. The cellular 
uptake was found to be dose dependant, however, the difference between the SV-140-A-FITC and 
SV-100-A-FITC at both 0.02 mg/mL and 0.004 mg/mL was found to be less than ~10% (Fig 6.7). 
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Fig 6.7. Flow cytometry histogram. Uptake of SV-140-A-FITC and SV-100-A-FITC 
nanoparticles were analysed by flow cytometry. The FITC labelled and SV-140-A and SV-100-
A vesicles were added to the MDBK cells at different concentrations of 0.02 mg/mL and 0.04 
mg/mL and incubated for 2 h. The cells were harvested and analysed by flow cytometry. Cell 
counts versus the FITC fluorescence are shown; (A) MDBK cells only (control), (B) SV-140-
A-FITC 0.02 mg/mL, (C) SV-100-A-FITC 0.02 mg/mL, (D) SV-140-A-FITC 0.004 mg/mL, 
(E) SV-100-A-FITC 0.004 mg/mL. The number of cells taking up FITC is represented in 
percentage of total counting cells. Mean fluorescence intensity (MFI) is indicated in the panel. 
 
 6.3.4 In vitro cytotoxicity studies 
The in vitro cytotoxicity of all the four SV was determined by trypan blue dye exclusion 
staining of MDBK cells. The cells were treated with three different concentrations (0.5 mg/mL, 
0.1 mg/mL and 0.01 mg/mL) of SV for 20 h. As synthesised MCM-41 nanoparticles were used 
as a positive control for cell death and untreated cells as negative control. The cell membrane 
of the viable cells remains intact, hence they do not take up the trypan blue stain, whereas, the 
dead cells exhibit a blue colour due to the uptake of the dye via permeabilised cell membranes. 
The cells incubated with lower concentrations (0.1 mg/mL and 0.01 mg/mL) of all four SV  
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appeared comparable to the non-treated cells (Fig 6.8, b, c, e, f, h, I, k and l). However, the 
amino functionalised SV-140-A and SV-100-A at 0.5 mg/mL were found to have a toxic effect 
on the MDBK cells (Fig 6.8, g and j) in comparison to their unfunctionalised counter parts SV-
140 and SV-100 (Fig 6.8, a and d). 
 
Fig 6.8. Semi-quantitative assay to determine the cytotoxicity of nanoparticles using trypan blue 
Staining (0.2%) of MDBK cells;  (a) 0.5 mg/mL SV-140; (b) 0.1 mg/mL SV-140; (c) 0.01 
mg/mL SV-140; (d) 0.5 mg/mL SV-100; (e) 0.1 mg/mL SV-100; (f) 0.01 mg/mL SV-100; (g) 
0.5 mg/mL SV-140-A; (h) 0.1 mg/mL SV-140-A; (i) 0.01 mg/mL SV-140-A; (j) 0.5 mg/mL SV-
100-A; (k) 0.1 mg/mL SV-100-A; (l) 0.01 mg/mL SV-100-A; (m) cells alone without 
nanoparticles; (n) 0.5mg/mL MCM-41 as synthesised particles. All images were taken at ! 20 
magnification. 
 
The four vesicles SV-100, SV-100-A, SV-140 and SV-140-A demonstrated similar adsorption 
and desorption characteristics. However, SV-100-A, SV-140 and SV-140-A were found to have 
a marginally better adsorption capacity of the oE2 protein in comparison to SV-100 (Fig 6.4). 
The cellular uptake difference between the SV-140-A-FITC and SV-100-A-FITC vesicles was 
found to be less than 10%. Nevertheless, both amino functionalised SV-100-A and SV-140-A  
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were found to be toxic on the MDBK cells at a higher concentration.  
 
Hence, based on the results from in vitro studies described above and exhibition of the desirable 
characteristics such as efficient antigen loading, cellular uptake proficiency, non-toxicity on MDBK 
cells at all the three concentrations, the unfunctionalised SV-140 was selected as antigen carrier for 
in vivo investigation. 
 
6.3.5 Cell Viability  
Before commencing with the animal trial with selected SV-140 as vesicle of choice, the cytotoxicity 
of the vaccine formulations oE2, oE2/SV-140 and oE2/SV-140 plus Quil-A, was quantified using 
MTT assay. Quantitative cytotoxicity analyses were conducted at three different concentrations of 
0.1 mg/mL, 0.2 mg/mL and 0.01 mg/mL in MDBK cell lines. The treatment formulations were 
prepared similar to the injectable samples as described in the methods section. The MDBK cells 
were incubated with the treatment formulations for 24 h. At the higher concentration of 0.1 mg/mL 
the oE2, oE2/SV-140 and oE2/SV-140 plus Quil-A, the cells exhibited cell viability of >70%. 
However, at lower concentrations of 0.02 and 0.01 mg/mL the oE2 protein, oE2/SV-140 and 
oE2/SV-140 plus Quil-A the MBDK cells exhibited cell viability of >85% cell (Fig 6.9). Addition of 
two adjuvants Quil-A plus SV did not have a detrimental affect on the cell viability of the MDBK 
cells, suggesting that the nanovaccine formulations were suitable for use in animal studies. 
 
Fig 6.9. Cytotoxicity of the oE2 in PBS, SV-140, oE2 loaded SV-140 and oE2 loaded SV-140 
plus Quil-A was evaluated using the MTT assay. Different concentrations of both the 
nanoparticles and oE2 protein were tested. 
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6.3.6 ELISA data 
The mice were immunised with vaccine formulations comprising of unfunctionalised SV-140 
vesicle as described above. The total IgG responses of the immunised mice were analysed by anti-
oE2-specific ELISA, following three subcutaneous vaccine injections. The vaccine formulations 
were freshly prepared on the day of the injection. PI sera samples from mice were collected at the 
start of the trial, and subsequent sera samples were collected at two-week intervals following each 
injection over a 6 week period. All the mice remained healthy and in the normal weight range 
throughout the experiment (Fig 6.10).  
 
 
Fig 6.10. Mice weight chart, individual lines represent average of four animals per group.  
 
The nanovaccine treatment group immunised with oE2/SV-140, without any traditional adjuvant 
elicited strong antibody responses end-point titres of 2.56 x 105 (1:256000) (Fig 6.11 B). The 
antibody response generated by the group injected with oE2/SV-140 was found to be stronger than 
the response obtained from the positive control oE2 plus Quil-A, which showed detectable oE2 
specific antibody responses at an end-point titre of 3.2 x 104 (1:32000). Interestingly, the co-
administration of two adjuvants, SV along with traditional adjuvant Quil-A, did not result in a 
more robust immune response, as the antibody responses generated by this group was of 6.4 x 104 
(1:64000) (Fig 6.11 C). The IgG response elicited by oE2/SV-140 plus Quil-A appeared to be 
almost similar to the positive control group oE2 plus Quil-A, (Fig 6.11 A & C) however, they were 
both lower than that of oE2/SV-140 (Fig 6.11 B). The ELISA result from the terminal bleeds, 
suggest that the negative control groups receiving SV-140 vesicles plus Quil-A (Fig 6.11 D) and 
the unimmunised group (Fig 6.11), showed no oE2-specific antibody responses.  
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Fig 6.11. End point titer data of terminal sera bleeds (average of all 4 individual mice in 
each group). All the mice were administered 100 !L dose at 2 week intervals to the tail 
base. A) oE2 (50 µg) + Quil-A (10 µg); B) oE2 (50 µg) loaded SV-140 (250 µg); C) oE2 
(50 µg) loaded SV-140 (250 µg) plus Quil-A (10 µg); D) SV-140 plus Quil-A; E) 
Unimmunised group. Sera of individual animals were diluted from 1:1000 to 1:2048000. 
 
6.3.7 ELISPOT Assay 
ELISPOT assays were used to determine the T-helper type 1 (Th1) cell mediated interferon- " 
(IFN-") responses to oE2 antigen. Two weeks post the final immunisation; spleens from sacrificed 
mice were collected and harvested to obtain splenocyte cell populations. The mice receiving 
nanovaccine formulations oE2/SV-140 showed an excellent cell-mediated immune response to oE2  
 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
10
00
 
20
00
 
40
00
 
80
00
 
16
00
0 
32
00
0 
64
00
0 
12
80
00
 
25
60
00
 
51
20
00
 
10
24
00
0 
20
48
00
0 
O
D
 @
 4
50
 n
m
 
Dilution 
A) 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
10
00
 
20
00
 
40
00
 
80
00
 
16
00
0 
32
00
0 
64
00
0 
12
80
00
 
25
60
00
 
51
20
00
 
10
24
00
0 
20
48
00
0 
O
D
 @
 4
50
 n
m
 
Dilution 
B) 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
10
00
 
20
00
 
40
00
 
80
00
 
16
00
0 
32
00
0 
64
00
0 
12
80
00
 
25
60
00
 
51
20
00
 
10
24
00
0 
20
48
00
0 
O
D
 @
 4
50
 n
m
 
Dilution 
D) 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
10
00
 
20
00
 
40
00
 
80
00
 
16
00
0 
32
00
0 
64
00
0 
12
80
00
 
25
60
00
 
51
20
00
 
10
24
00
0 
20
48
00
0 
O
D
 @
 4
50
 n
m
 
Dilution 
C) 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
10
00
 
20
00
 
40
00
 
80
00
 
16
00
0 
32
00
0 
64
00
0 
12
80
00
 
25
60
00
 
51
20
00
 
10
24
00
0 
20
48
00
0 
O
D
 @
 4
50
 n
m
 
Dilution 
E) 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1. 0 
1.40 
1.60 
1.80 
10
00
 
20
00
 
40
00
 
80
00
 
16
00
 
32
00
0 
64
00
0 
12
80
00
 
25
60
00
 
51
20
00
 
10
24
00
0 
20
48
00
0 
MOUSE 1 MOUSE 2 MOUSE 3 MOUSE 4 AVERAGE 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
1.60 
1.80 
10
00
 
20
00
 
40
00
 
80
00
 
16
00
0 
32
00
0 
64
00
0 
12
80
00
 
25
60
00
 
51
20
00
 
10
24
00
0 
20
48
00
0 
MOUSE 1 MOUSE 2 MOUSE 3 MOUSE 4 AVERAGE 
 139 
antigen as indicated by the number of cells producing Spot Forming Units (SFU). The bars in the 
Fig 6.12 indicate the responses to oE2 antigen. All the animals in the oE2 plus traditional adjuvant 
Quil-A showed a low cell-mediated immune response ranging from 499-755 SFU/million cells, in 
comparison to animals in oE2/SV-140 group, which produced strong responses in the range of 
1954-2628 SFU/million cells. The three out of four mice vaccinated with the oE2/SV-140 plus 
Quil-A nanovaccine formulation, showed a low cell mediated response (512-1369 SFU/million 
cells) and only one animal induced a high oE2-specific response >3000 SFU/million cells. The 
oE2-specific response elicited by all the individual animals in the oE2/SV-140 was much stronger 
in comparison to the positive control group oE2 plus Quil-A as well as the oE2/SV-140 plus Quil-A 
group. The excellent IFN-! response generated by oE2/SV-140 highlights the potential of SV as 
exceptional adjuvants and their ability to induce memory responses. The animals in the negative 
control groups, SV-140 plus Quil-A and the unimmunised group did not produce IFN-! response 
specific to the oE2 antigen, expect for only one animal in the unimmunised group, which produced 
some background Th1 response (Fig 6.12).  
 
Fig 6.12. Detection of antigen specific IFN-! secretion by ELISPOT assay of murine splenocytes 
from immunised mice. M1 to M4 are the individual mice in each group. The bars in the figure 
indicate the number of cells producing IFN-! in response to the oE2 antigen. 
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6.4 Discussion 
 
The current research was aimed at addressing the issues in delivery of subunit vaccines in terms of 
eliciting sustained humoral and cell-mediated response as well as overcoming the limitations of 
available adjuvants by improving the particle design. The rationale behind the design of SV was to 
minimise the use of silica to be administered as a positive step towards regulatory framework. In 
this paper, we report the use of SV synthesised using the two-step self-assembly approach with a 
uniform 50 nm particle size and precisely controlled large entrance size as well as internal cavity 
and thin porous shell as optimal carriers for vaccine delivery.  The SV were able to maintain the 
integrity of vesicular structure even in the presence of entrance pores as big as 15 nm and shell wall 
thickness of only 6 nm. These characteristics of the SV improved the protein loading and extended 
release of the antigen, allowing a sustained immune response.  
 
To demonstrate that this new generation of SV can efficiently deliver a real virus antigen, we chose 
the BVDV-1 oE2 protein due to the economic significance associated with the disease throughout 
the world. Pestigard® (Zoetis) is the only BVDV vaccine approved for use in Australia. This 
vaccine is an inactivated viral vaccine with a shelf-life of one month after opening and needs to be 
refrigerated. It also has to be administered as two initial doses, 4-6 weeks apart and then an annual 
booster dose thereafter. BVDV vaccine Bovilis BVD by Merck is available in the UK; this 
inactivated vaccine contains BVDV strain C86, which also requires an annual booster dose. The 
shelf-life of this vaccine is 18 months when stored at +2 to +8 °C; however, the shelf-life is reduced 
to 10 h once the vaccine bottle is opened. [39] The neutralising antibodies produced by E2 protein 
after natural infection or vaccination is considered as the most important protective mediator against 
subsequent BVDV infection. [40-42] In our laboratory, generation of soluble and endotoxin-free 
oE2 using an E. coli expression system has been well established. [43, 44]  
 
The adsorption capacity of proteins to the nanoparticles is greatly dependant on the 
physicochemical characteristics of the proteins as well as the nanoparticles. Proteins with the 
hydrodynamic diameter that is smaller than the pore diameter can easily enter the mesopores and 
show higher loading capacity, while the ones with larger diameter adsorb on the outer surface of the 
nanoparticles. [45] Previously, we reported the use of HMSA surface functionalised with amino 
groups for the development of BVDV-1 E2 nanovaccine. [24] However, the amount of protein that 
could be loaded on the HMSA, which was only 80 !g of the oE2 protein per mg of HMSA (particle 
size 120 nm). Additionally, most of the protein was possibly presented on the outer surface on  
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HMSA due to small entrance size of 2 nm to 3 nm. The four SV (particle size 50 nm) used in the 
current study, with different entrance sizes (5.7/5.9 and 16 nm) enhanced the oE2 protein loading 
efficiency by three times. The oE2 protein loading on SV-140, SV-140-A, SV-100 and SV-100-A 
vesicles was approximately in the range of 216 to 249 !g protein/mg of vesicles after overnight 
adsorption (Fig 6.4). As determined by DLS the hydrodynamic size of oE2 is 7.1 nm. [44] Utilising 
the iTasser protein structure prediction software [46, 47] and the recent publication on E2 crystal 
structure, 2YQ2[48] as a structural template, oE2 is hypothesised to be an elongated protein with an 
estimated physical size length of 12-13 nm and a width of 3-4 nm. [24] Since the entrance size of 
the SV is in the range of 5.7 nm to 16 nm (Table 6.2), which is larger than the estimated width size 
of the oE2, which supports our hypothesis that the protein gets adsorbed on the internal as well as 
external wall of the vesicles leading to higher loading capacity.  
 
The in vitro release studies on the oE2 loaded SV at 37 °C in PBS buffer indicated that protein 
once bound to the vesicles does not dissociate easily. SLS is the most commonly used surfactant in 
dissolution media for poorly water-soluble drugs to facilitate the significant release of drugs. [49] 
The release profile of the drugs/vaccines can be adjusted by changing the concentration of the 
surfactant in the medium. We observed release of the oE2 protein in the presence of surfactant 
0.1% (w/v) SLS in the PBS buffer (Fig 6.6) after only 5 minutes. oE2 protein was not observed in 
the pellet of the four SV after 24 h of desorption 0.1% (w/v) SLS buffer therefore indicating that 
>95% of the oE2 protein got released from the vesicles. This confirms the usefulness of SV as both 
an adjuvant and delivery vehicles, with the ability of sustained release of the bound protein. 
Different researchers observed similar findings as they found that the in vitro dissolution rate of 
curcumin formulations improved in the presence of 0.5% w/v SLS as a surfactant. [50, 51] 
 
Cytotoxicity of nanoparticles is an important parameter to consider while developing vaccines. 
Since, the thiocyanate group of FITC is highly aminoreactive, the amino functionalised SV were 
labelled with the fluorescence dye FITC. The cellular uptake by the MDBK cells was noticeably 
higher with SV-100-A-FITC compared to SV-140-A-FITC (Fig 6.7). The higher MFI values of the 
FITC SV-100-A can be attributed partly due to the difference in the surface characteristics 
confirming that the surface, particle characteristics along with the net charge of the carrier play a 
significant role in cellular uptake. In previous reports, MSNs functionalised by aminofluorescein 
[52] and FITC tagged HMSNs [53] were efficiently taken up into the cell cytoplasm after 
intracellular uptake in HeLa cell lines. A study, demonstrated that the cellular uptake was found to 
be two times higher for 50 nm sized MSNs compared to 30 nm MSNs, while for larger sized  
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MSNs (110 nm, 280 nm and 170 nm) the cellular uptake was found to be proportionally lower. 
[54] The 50 nm SV used in the current study were of optimal size for cellular uptake. The pore 
structure of MSNs is also known to have a great influence on biocompatibility and biological 
response. [55] The in vitro cytotoxic effects of MSNs in various cell lines have been established 
[56-59]; at lower concentrations MSNs have been found to be non-toxic, but at higher 
concentrations, they can have a toxic effect on the cells. [60-62] We tested the cytotoxicity of all 
the four SV and observed similar results, as the amino functionalised SV-140-A and SV-100-A at 
the higher concentration of 0.5 mg/mL were found to have a toxic effect on the cells compared to 
its unfunctionalised counter parts SV-140 and SV-100 (Fig 6.8). Even though, the cellular uptake 
was higher with the SV-100-A-FITC, the cytotoxicity results indicate that both the amino 
functionalised vesicles SV-140-A and SV-100-A were found to be more toxic on the MDBK cells. 
Hence, to demonstrate that the SV can efficiently deliver the real viral antigen and act as excellent 
adjuvants and based on the results from the adsorption, release, cellular uptake and cytotoxicity 
studies, the unfunctionalised SV-140 vesicle was selected for mice immunisations. However, 
before proceeding with the animal trial, quantitative toxicity analyses were conducted on the 
nanovaccine formulations to be used in the animal trial. At lower concentrations of 0.02 mg/mL 
and 0.01 mg/mL the nanovaccine treatment groups were found to have the least toxic effect on the 
MDBK cells viability (Fig 6.9). This also reiterates the importance of high loading, which reduces 
the dose of SV keeping it well within its toxicity limits. 
 
The process of generating an immune response to a vaccine greatly depends on the efficient uptake 
of the antigen by dendritic cells and subsequent presentation of the antigen within the major 
lymphoid organs. Silica nanoparticles can protect the antigen and also slowly release the antigen in 
vivo. [63] To date there are very few studies that have reported the use of silica nanoparticles for in 
vivo delivery of proteins. In a study, BSA adsorbed/encapsulated in SBA-15 (a silica cylinder 
mesostructure of 2 µm in length) particles were administered via intramuscular and oral routes in 
high and low antibody responder mice lines; the SBA-15 particles proved to efficient adjuvants as 
well as delivery vehicles as the protein loaded nanoparticles both humoral and cell-mediated 
immunity in mice. [33]  
 
In the past, we have reported the induction of humoral and cell mediated immune responses by 
amino functionalised MSNs as well as HMSAs [24, 26], however due to the low loading of 
proteins obtained on the nanoparticles, a direct comparison between the positive control group 
comprising of conventional adjuvant and the nanovaccine treatment could not be performed. In the  
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current research study, the improvement in the particle design enabled us to directly compare the 
immune responses generated by the conventional adjuvant used in the positive control group (oE2 
plus Quil-A) and the nanovaccine treatment group. Moreover, variation in one parameter such as 
the antigen or silica nanoparticles may change the generation of the overall immune response. [29]  
 
Hence, to clearly understand the efficacy of SV as adjuvants on the induction of immune responses 
as well as the significance of using two adjuvants in one vaccine formulation, three treatment 
groups oE2 plus Quil-A, oE2/SV-140 and oE2/SV-140 plus Quil-A were tested (Table 6.1). All the 
animals remained healthy throughout the duration of the trial and none of the nanovaccine 
formulations caused localised skin redness or reaction at the site of the injection, indicating that the 
SV were very well tolerated in mice. The treatment groups injected with oE2/SV-140 (50 µg/250 
µg) induced excellent antibody response at 105 titre, which was higher than the positive control 
group oE2 (50 µg) plus Quil-A (10 µg) (104 titre) as well as the responses generated by the mice 
treated with oE2/HMSA (103 titre) [24] . In addition to elicitation of the humoral response, the 
oE2/SV-140 induced a stronger and higher memory response (1954-2628 SFU/million cells) 
compared to the group treated with Quil-A (512-1369 SFU/million cells). For the first time, we 
have shown that the BVDV oE2 loaded SV induced stronger Th1 as well as Th2 responses 
compared to the traditional adjuvant. This is a significant finding, as it shows that SV synthesised 
with a large entrance size can act as efficient delivery vehicles plus strong adjuvants, with a 
potential to remove the use of conventional adjuvants in a vaccine formulation. 
 
Adjuvants act as immunostimulators or antigen delivery vehicles, Quil-A is known to initiate T-
cell mediated immune response and from our previous experiments we know that silica 
nanoparticles have the ability to induce both antibody and T-cell mediated responses. [24-26] 
Immunisation of rats with the combination of tetanus toxoid antigen with biodegradable 
nanoparticles and alum induced a rapid induction of antibody response. However, administration of 
single injection of tetanus toxoid antigen with nanoparticles alone or tetanus toxoid antigen with 
Alum did not induce a stronger systemic IgG response. [64]  
 
Few reports have highlighted the synergistic effect of vaccine adjuvants when they are used in 
combinations. Adjuvants like liposomes and microspheres when mixed with mineral oil have 
shown to have a synergistic effect. [65] Therefore, we hypothesised that co-administration of Quil-
A and SV would induce robust immune responses. The mechanism of action of saponins is to 
interact with APCs to induce production of cytokines such as interleukins and interferons to  
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facilitate immunostimulant effects. [66, 67] Secondly, the small sized (50 nm) SV would create a 
‘slow release’ effect at the site of injection and provide sufficient time for the antigen to interact 
with the macrophages and APCs. However, this was not the case, as the total antibody responses as 
well as the cell-mediated responses generated by the co-administration of Quil-A and SV were 
lower than oE2/SV-140. This suggests that Quil-A and SV may have failed to show a synergistic 
effect on the induction of strong immune responses. The presence of two strong adjuvants such as 
Quil-A and SV in one formulation may have resulted in too high responses and the immune system 
didn’t cope well. Further studies are required to elucidate this finding. 
 
6.5 Conclusion 
  
In conclusion, the rationally designed SV with thin shell wall, large cavity and entrance size, 
improved the protein adsorption and release. The oE2/SV-140 formulation induced higher anti-oE2 
IgG as well as IFN-! responses compared to the positive control group oE2 plus Quil-A, 
demonstrating the potential of SV as both efficient vaccine delivery vehicles and potent adjuvants. 
The large internal cavity acts as a high capacity reservoir for biologics such as proteins, which are 
easily loaded through the large entrance in the vesicle walls. The slow release of vaccine means 
that larger than normal amounts can be delivered in a single dose as not all vaccine is bioavailable 
on administration. The size of the vesicle pores can be tailored for a specific release rate and 
specific molecules. The work identifies the use of SV towards the development of a new platform 
technology for safer and more effective subunit vaccines. 
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7. 
Silica Vesicle Nanovaccine Formulations Stimulate  
Long-term Immune Responses to  
the Bovine Viral Diarrhoea Virus E2 Protein 
 
 
 
 
 
 
 
 
 
The SV-140 vesicles (particle size 50 nm, wall thickness 6 nm, perforated by pores of entrance size 
16 nm and total pore volume of 0.934 cm3g-1) proved to be ideal candidates to load BVDV-1 
Escherichia coli-expressed optimised E2 (oE2) antigen and generate immune responses. In this 
chapter the ability of freeze-dried (FD) as well as non-FD oE2/SV140 nanovaccine formulation to 
induce long-term balanced antibody and cell mediated memory responses with a shortened dosing 
regimen of two doses in small animal model was determined. This study was the first to show that  
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both non-FD and FD oE2/SV-140 induced oE2 specific antibody and cell-mediated immune 
responses in mice for at least six months post the final immunisation. The manuscript is submitted 
to PLoS ONE.  
 
7.1 Introduction 
 
Development of veterinary vaccines comes with a spectrum of challenges, as the storage, shipping 
and administration of the vaccine should be easy and also the cost of veterinary vaccine production 
needs to be kept low. [1] Subunit vaccines often need to be refrigerated, require addition of 
adjuvants and also need to be administered multiple times in order to induce long-term immunity. 
Therefore, to reduce the need for booster immunisations, a system needs to be developed that 
delivers the antigen and is also efficient as an adjuvant. Adjuvants are biomolecules that are added 
to vaccines to stimulate immune responses, however, only a few adjuvants have been approved for 
human as well as veterinary use. [2] Another issue that needs to be taken into account is transport 
and storage of subunit vaccines requiring cold chain storage, which can be challenging and 
expensive, especially in remote areas. The storage stability of the subunit vaccines can be improved 
by freeze-drying the vaccine formulations. Excipients such as sugars, surfactants, amino acids and 
polymers are typically added to the vaccine formulations to prevent degradation in the freeze-drying 
process and aide in the reconstitution of vaccines prior to use. [3,4] 
 
Bovine viral diarrhoea virus 1 (BVDV-1) is a single-stranded RNA virus that is a major contributor 
to the bovine respiratory disease complex and other disease of cattle. BVDV-1 infection of cattle 
has been highly investigated in several countries as it causes tremendous economic losses to the 
cattle industry. [5] The major source of new BVDV-1 infection in herds is transmission from 
susceptible animals coming contact with secretions or body fluids of persistent infected or acutely 
infected animals. [6] Immunosuppression caused by BVDV-1 infection can lead to a secondary 
infection, which is a major cause of death in BVDV-1 infected cattle. [7] The current BVDV-1 
vaccine approved for use in Australia needs to be refrigerated at 2°C to 8°C. 
 
The structural protein, E2, from BVDV is a major immunogenic determinant and is an ideal 
candidate as a subunit vaccine as it can elicit neutralising antibodies. [8] In a recent study, a plant 
expressed truncated version of BVDV E2 fused to molecule that targets antigen presenting cells 
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(APCH-tE2) induced neutralising antibodies in bovines. [1] Further, BVDV E2 formulated with a 
combination adjuvant poly[di(sodium carboxylatoethylphenoxy)]-phosphazene, a toll-like receptor 
agonist and an innate defence regulator peptide (designated as TriAdj) induced antibody and cell-
mediated immune responses and provided protection in animals from BVDV-2 infection. [9] 
 
The role of mesoporous silica nanoparticles (MSNs), as antigen carriers and self-adjuvant vaccines 
has been investigated to develop successful vaccine delivery systems targeting BVDV-1. 
[10,11,12,13] In addition, we have also been focusing on developing freeze-dried (FD) silica 
nanoparticle based vaccine delivery systems and have demonstrated that the model protein 
ovalbumin (OVA) adsorbed mesoporous silica nanoparticles can be freeze-dried using 5% (w/v) 
trehalose and 1% PEG8000 (w/v) as excipients. [10] The FD 10 µg OVA/150 µg AM-41 
formulation was tested in mice and has shown to stimulate both antibody and cell-mediated immune 
responses.  [10,13]  
 
Amino functionalised hollow mesoporous silica nanoparticles (HMSAs) with small pore entrance 
size 2 to 3.5 nm [12] were trialled for BVDV codon optimised E2 expressed in E. coli (oE2) 
adsorption (80 µg oE2 bound to per 1 mg of HMSA). Although this formulation elicited antibody as 
well as cell mediated responses after three injections, the constraint here was also the low antigen 
binding capacity of the HMSA particles. [12] To address this issue and in order to move towards 
our goal of generating enhanced immune response in comparison to conventional adjuvant Quil-A, 
we designed novel silica vesicles (SV) of 50 nm with a thin shell wall of 6 nm and controlled 
entrance size varying between 5.7 nm to 16 nm. These SV exhibited higher loading to Ribonuclease 
A with sustained release behaviour. [14] The SV-140 with an entrance size of 16 nm significantly 
improved the oE2 adsorption as ~250 µg oE2 bound to per mg SV. The oE2 (50 µg)/SV-140 (250 
µg) induced anti-oE2 IgG (105) and interferon-! (IFN-!) responses stronger than the conventional 
adjuvant Quil-A (anti-oE2 IgG response of 104) after three subcutaneous injections. [11] 
 
To further develop SVs as vaccine nanocarriers, which are self-adjuvanting, the first goal of the 
current study was to determine if the oE2/SV140 formulation previously shown to be effective in 
generating antibody and cell mediated responses could also stimulate long-term immune responses 
with reduced number of injections. The second goal was to develop FD oE2/SV140 formulation and  
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compare it with oE2/SV140 for addressing the issue of storability. In this work for the first time we 
have demonstrated that vaccination with oE2 (100 µg)/SV-140 (500 µg) elicited balanced T-helper 
type 2 (Th2) antibody and T-helper type 1 (Th1) cell-mediated responses not only after three weeks 
of two subcutaneous injections but also showed strong cell-mediated responses for at least six 
months after the second immunisation. In addition, we have also shown that FD oE2/SV-140 nano-
formulation also induced both antibody and cell-mediated immune responses. This work for the 
first time clearly demonstrates the potential of silica vesicles for developing a nanovaccine with 
reduced number of injections, induction of long-term immune responses and improved storage. 
 
7.2 Materials and Methods 
 
7.2.1 Preparation of SV-140 and Adsorption of oE2 on SV-140 
The SV-140 were prepared and adsorption reactions were set up as previously described and the 
amount of unbound oE2 protein was assessed by electrophoresis of the supernatants and the 
particles on SDS-PAGE gels. [11]  
 
7.2.2 Freeze-drying process 
The oE2 adsorbed SV-140 samples were centrifuged at 16.2 g for 5 min and the supernatants were 
removed. Prior to freeze-drying, oE2/SV-140 pellets were resuspended in different combinations 
and concentrations of excipients (Table 7.1). Samples were frozen in liquid nitrogen then placed in 
a freeze-dryer (Martin Christ Model LPC-32, Osterode AM Harz, Germany) at 24°C, 0.11 mbar for 
22 h for drying. Freeze-dried samples were stored in a vacuum desiccator at ambient temperature 
(25°C). The optimal excipients trehalose (5% final concentration) and glycine (0.1% final 
concentration) were added to the oE2 bound vesicles and the final volume adjusted to 1 ml. The 
oE2 (500 !g) plus Quil-A (2mg/mL) sample was prepared in sterile injectable water without any 
excipients and the SV-140 alone with excipients 5% trehalose and 0.1% glycine. All the samples 
were freeze-dried as described in this section. 
  
Table 7.1. Different concentrations of Trehalose and Glycine tested to freeze-dry oE2/SV-140. 
 
 
Excipients added 0.1% Glycine 0.5% Glycine 1% Glycine 
5% Trehalose * * * 
10% Trehalose * * * 
20% Trehalose * * * 
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7.2.3 Western hybridisation  
Following SDS-PAGE electrophoresis the oE2 protein in the nanovaccine formulations was 
detected using Western blot hybridisation as previously described. [12] 
 
7.2.4 Reconstitution and transmission electron microscope (TEM) and scanning electron 
microscope (SEM) of lyophilised samples  
Samples were reconstituted in 1 mL water. The physical characteristics of the freeze-dried vesicles 
in solution were observed using transmission electron microscopy (TEM) and scanning electron 
microscopy (SEM) before and after reconstitution the freeze-drying preparations. 
 
7.2.5 Ethics Statement 
All procedures were approved by The University of Queensland, Ethics Committee, (Approval No: 
2012001137) as required by the Animal Care and Protection Act (2001) and The Australian 
Code for the Care and Use of Animals for Scientific Purposes (8th Edition). [21] 
 
7.2.6 Immunisation studies conducted in mice 
C57BL/6J mice were purchased from and housed in the Biological Resource Facility, The 
University of Queensland, Brisbane, Australia under specific pathogen-free conditions. Eight week 
old female mice were housed in HEPA-filtered cages with eight animals per group in an 
environmentally controlled area with a cycle of 12 h of light and 12 h of darkness. Food and water 
were given ad libitum.  
 
Pre-immunisation (PI) blood samples were collected and processed; immunisations were prepared 
and administrated as detailed in [11]. The conventional adjuvant Quil-A (Superfos Biosector, 
Vedback, Denmark) was resuspended at 2 mg/mL in sterile injectable water (Pfizer, Brooklyn, 
USA). The injectable doses were administered to investigate the induction of immune responses 
and the treatment groups received injections as mentioned in Table 7.2. Two injections were 
administered at 3 week intervals to all the treatment groups except for the unimmunised group. 
Four mice from each group were sacrificed 21 days after the final immunisation. Blood samples 
from the remaining four mice were collected every four weeks via tail bleeds for up to six months 
and at the end of the trial period animals were sacrificed. The animals were weighed and monitored 
for general health once a week. All the animals were assessed weekly and they remained in good 
health throughout the duration of the study. 
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Table 7.2. Immunisation groups in mice trial. All doses were administered subcutaneously at the 
tail base. 
 
 
7.2.7 Enzyme-Linked ImmunoSorbent Assay (ELISA) protocol 
The detection of oE2-specific antibodies were performed by coating microtitre plates (96 well, 
Nunc, Maxisorb, Roskilde, Denmark) with oE2 antigen solution (2 ng/!L, 50 !L) in PBS overnight 
at 4°C. The coating solution was removed and the plates were washed once with PBS-T (1x PBS, 
0.1% Tween-20, Sigma-Aldrich) and blocked with Bovine Serum Albumin (5%, Sigma-Aldrich) 
and skim milk (5%, Fonterra, Auckland, New Zealand) in 200 !L PBS for 1 h with gentle shaking 
at RT. Plates were washed three times with PBS-T.  
 
Mouse sera samples were diluted from 1:100 to 1:6400 in 50 !L PBS and each dilution was added 
to the wells of the blocked plates followed by incubation for 2 h at RT. To detect mouse antibodies 
HRP conjugated polyclonal sheep anti-mouse IgG antibodies (Chemicon Australia, Melbourne, 
VIC, Australia) diluted in PBS to 1:50,000 were added to each well and incubated for 1 h at RT 
with gentle shaking. Plates were washed three times in PBS-T. TMB substrate (100 !L, Life 
Technologies) was added to each well and incubated for 15 min at RT; 100 !L of 1N HCl was 
added to the wells to stop the chromogenic reaction. The plates were read at 450 nm on the BioTek 
microplate reader (Winooski, US). 
 
 
 
 
 
 
Group Prototype vaccine/Injection Dose 
1 oE2 (100 µg) + Quil-A (10 µg) 
2 FD oE2 (100 µg) + Quil-A (10 µg) 
3 oE2 (100 µg) / SV-140 (500 µg) 
4 FD oE2 (100 µg) / SV-140 (500 µg) 
5 FD SV-140 (500 µg) 
6 Unimmunised 
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7.2.8 Isolation of murine splenocytes and enzyme-linked immunosorbent spot (ELISPOT) 
Assay 
Spleens were aseptically removed following euthanasia from the four animals sacrificed at three 
weeks and the other four at six months after the final immunisation; the collected spleens were 
processed as previously described. [11] 
 
7.2.9 Immunohistochemistry (IHC) 
Spleen sections were collected from the sacrificed mice at both the time points three weeks and six 
months. A part of the spleen was dissected and frozen in OCT embedding medium and 5 µm 
sections were cut using Hyrax C60 cryostat. The slides with cryosections were fixed in cold ethanol 
on ice for 8 min and then dried at RT for 20 min. The slides were then washed 3 x 5 min in PBS, 
left to dry at RT for 20 min and using a Dako pen circles were marked around the sections. The 
sections were then incubated overnight with the blocking buffer (PBS containing 1% BSA and 5% 
FBS) at 4°C. Next day, to remove the block the slides were washed for 5 min in PBS three times. 
The sections were then incubated with Alexa Fluor 488 Goat Anti-Mouse IgG at 1:500 for 1 h at 
RT in dark, the slides were then washed as previously described in PBS. To stain the nuclei of cells 
the sections were then incubated with DAPI for 5 min and quickly washed in PBS. The sections 
were mounted with ProLong® Gold Antifade mounting medium and examined under the 
microscope.  
 
7.2.10 Histopathology 
Heart, kidney, liver and injection sites from the sacrificed mice were collected and fixed in 10% 
formalin for 48 h. The organs were further processed and embedded in paraffin and 8 µm sections 
were cut using the Leica RM 2245 Rotary Microtome. The sections were then stained using the 
following haematoxylin and eosin staining procedure. Sections were first Dewaxed in xylene (3 
changes of 2 min each), and then rehydrated in absolute alcohol (2 changes of 2 min each), in 90% 
for 2 min, in 70% for 2 min. Then washed in running tap water for 2 min and stained in 
haematoxylin for 3 min and again washed in running tap water for 2 min. Sections were then 
washed in 70% alcohol for 2 min and stained in eosin for 3 min. Sections were then washed in 95% 
alcohol for 2 min, then in absolute alcohol (3 changes of 2 min each). Finally, the sections were 
rapidly dehydrated and fixed in xylene (3 changes of 2 min each) and mounted in DePeX. The 
sections were then observed under the Zeiss LSM 510 META confocal microscope. 
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7.3 Results  
 
7.3.1 Physicochemical properties of FD oE2 SV-140  
The SV-140 particles investigated in this study have been characterised previously [11,14] and have 
been shown to load ~250 !g of oE2 protein adsorbed to per mg of the SV-140 vesicles. [11] 
Different concentrations of 5%, 10% and 20% (w/v) trehalose in combination with 0.1%, 0.5% or 
1% (w/v) glycine as excipients were tested to develop FD oE2/SV-140 nanovaccine following 
adsorption. The samples freeze-dried with different concentrations of trehalose and glycine looked 
voluminous and snow-like (Fig 7.1a), as opposed to samples freeze-dried without excipients, which 
failed to form a freeze-dried cake (Fig 7.1b) The FD oE2/SV-140 developed with combination of 
5% trehalose and 0.1% glycine as excipients reconstituted within 10 seconds on addition of 1 mL of 
water. However, the samples containing 10% and 20% trehalose required additional measure like 
shaking to obtain complete resuspension.  
 
The SDS-PAGE analyses on the reconstituted sample freeze-dried with 5% trehalose and 0.1% 
glycine showed that the integrity of oE2 protein was preserved post freeze-drying (Fig 7.1c, lane 4). 
Furthermore, Western blot recognised the oE2 protein in the non-FD and the FD vaccine 
formulations (Fig 7.1d, lane 3 and 4).  
 
 
Fig 7.1: Photograph of FD oE2/SV-140 a) with 5% trehalose and 0.1% glycine; b) without 
excipients; c) SDS PAGE - adsorption of oE2 on SV-140, lane 1 – marker, lane 2 – oE2/SV-140 
pellet, lane 3 – FD oE2/SV-140 pellet; d) Western hybridisation analysis of oE2 in the vaccine 
formulations, lane 1 – oE2 protein, lane 2 – oE2 plus Quil-A, lane 3 – oE2/SV-140, lane 4 – FD 
oE2/SV-140. 
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The integrity of the vesicles following freeze-drying with 5% trehalose and 0.1% glycine was 
further confirmed by TEM and SEM analyses. The TEM results show that the silica vesicles 
remained intact and maintained their characteristic round shape and size of 50 nm post freeze-
drying. Furthermore, the SEM also data indicated that the FD SV-140 and FD oE2/SV-140 samples 
did not suffer structural collapse (Fig 7.2 c and d). The in vivo efficacy of the oE2/SV140 freeze-
dried with 5% trehalose and 0.1% glycine and the oE2/SV-140 was investigated in a mice trial.  
 
 
Fig 7.2: The morphology of FD SV-140 vesicles visualized by transmission electron microscope 
(TEM), (a) SV-140 and (b) oE2/SV-140 after lyophilisation in the presence of 5% trehalose and 
0.1% glycine. The appearance of FD SV-140 by scanning electron microscope (SEM), (c) SV-140 
(d) oE2/SV-140 after lyophilisation in the presence of 5% trehalose and 0.1% glycine. 
 
7.3.2 Generation of antibody and cell-mediated immune responses three weeks post 
immunisation 
To evaluate the efficacy of the oE2/SV-140 and FD oE2/SV-140 nanovaccine formulations, animals 
were immunised with two subcutaneous vaccinations at a three-week interval. The mice trial 
comprised of 48 animals divided into six groups and were immunised as described in Table 7.1. PI 
sera samples were collected prior to immunisation. Three weeks after the second vaccination sera 
samples were collected from all eight mice in each group and four randomly selected mice from  
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each group were sacrificed for the analyses of Th1 response. The total IgG responses of the 
immunised mice were analysed by anti-oE2-specific ELISA assays. The animals in all the treatment 
groups remained healthy and in the normal weight range throughout the trial period. The non-FD 
and FD oE2 plus Quil-A and the FD oE2/SV-140 showed a similar trend of reduction in the level of 
the antibody responses and were not found to be significantly different at 1:1600 dilution (Fig 7.3). 
The FD oE2/SV-140 induced strong responses (average OD value of 1.42). Less animal-to-animal 
variation was observed in the mice treated with the oE2/SV-140 nanovaccine (average OD value of 
1.18) (Fig 7.3).  The average OD values for oE2 plus Quil-A and FD oE2 plus Quil-A were 2.07 
and 1.34 respectively. The mice receiving the FD SV-140 only and the unimmunised group showed 
no oE2 specific antibody responses.  
 
 
Fig 7.3: oE2-specific ELISA antibody responses in 8 mice after two subcutaneous immunisations. 
The individual response for each mouse is shown using a sera dilution of 1:1600. Group 1 (mouse 1 
to 8) received 100 !g oE2 plus 10 !g Quil-A; Group 2 (mouse 1 to 8) received the 100 !g FD oE2 
plus 10 !g Quil-A, Group 3 (mouse 1 to 8) received the oE2/SV-140 nanovaccine (100 !g oE2 
adsorbed to 500 !g SV-140), Group 4 (mouse 1 to 8) received the FD oE2/SV-140 nanovaccine 
(100 !g oE2 adsorbed to 500 !g SV-140), Group 5 (mouse 1 to 8) received the 500 !g FD SV-140 
only, Group 6 (mouse 1 to 8) was the unimmunised group and did not receive any vaccination. The  
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black symbols in each group represent the 4 mice that were monitored for six months. The letter ‘a’ 
denotes that the groups were not significantly different. Groups that do not share a common letter 
were significantly different (* low and **** high) (p<0.001, unpaired t-test analysis). 
 
ELISPOT assays were used to determine the Th1 cell-mediated IFN-! responses. Three weeks post 
the final immunisation spleens were collected from the four mice of the eight mice (mice shown as 
grey in Fig 7.3). The remaining four mice were retained for investigating the long-term immune 
responses. The number of cells producing Spot Forming Units (SFU) indicates cell-mediated 
immune responses to oE2 epitope. The four individual mice in oE2 plus Quil-A (551-1500 
SFU/million cells) and the FD oE2 plus Quil-A (766-1500 SFU/million cells) induced strong cell-
mediated responses. The oE2 specific memory responses generated by oE2/SV-140 (599-1500 
SFU/million cells; average of four mice 1095 SFU/million cells) were similar to oE2 plus Quil-A 
(average of four mice 1094 SFU/million cells). The FD oE2/SV-140 elicited responses in the range 
of 222-1500 SFU/million cells; the difference in the Th1 response might be attributed to the mice-
to-mice variation with 1-2 mice in each group showing a low response (Fig 7.4). As expected, the 
negative controls SV-140 freeze-dried with 5% trehalose and 0.1% glycine and unimmunised 
treatment groups did not generate oE2 specific responses (Fig 7.4). 
 
Fig 7.4: Detection of antigen specific IFN-! secretion by ELISPOT assay of murine splenocytes 
from immunised mice. The black bars represent the number of cells producing IFN-! in response to  
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the oE2 antigen 3 weeks after the final immunisation. The grey bars show the average for each 
group and M1 to M4 represent the four individual mice in each group. 
 
7.3.3 Generation of long-term antibody and cell-mediated immune responses six months post 
immunisation 
To monitor the long-term responses sera samples were collected once every four weeks for up to six 
months after the final second immunisation. oE2-specific humoral immune responses were 
measured by ELISA at the different time points. A gradual trend of reduction in the antibody 
responses generated by the oE2 injected with conventional adjuvant Quil-A as well as SV-140 was 
observed at 7 weeks, 11 weeks, 15 weeks and 19 weeks (Fig 7.5). Antibody responses to the oE2 
epitope generated by the oE2 plus Quil-A, FD oE2 plus Quil-A, oE2/SV-140 as well as FD 
oE2/SV-140 reduced significantly by the end of six months, however, detectable level of antibody 
responses were still generated at 1:1600 dilution by both oE2/SV-140 (average OD value of 0.19) 
and FD oE2/SV-140 (average OD value of 0.13, Fig 7.6) at the six month time point. The oE2 plus 
Quil-A induced strong antibody responses (average OD value of 0.68), which could be due to the 
two mice in this group showing higher response. The FD oE2 plus Quil-A also showed high 
antibody responses (average OD values of 0.43). The FD SV-140 alone and the unimmunised 
treatments did not generate oE2 specific antibody responses. This is an important finding as for the 
first time we have demonstrated that the oE2 adsorbed SV-140 induced long-term antibody 
responses in mice and also that freeze-drying the oE2/SV-140 nanovaccine with 5% trehalose and 
0.1% glycine maintained the immunological integrity of oE2 protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 164 
 
 
Fig 7.5: oE2-specific ELISA antibody responses in mice after two subcutaneous immunisations. 
The individual response for each mouse is shown using a sera dilution of 1:1600. Group 1 (mouse 5 
to 8) received 100 !g oE2 plus 10 !g Quil-A; Group 2 (mouse 5 to 8) received the FD 100 !g oE2 
plus 10 !g Quil-A, Group 3 (mouse 5 to 8) received the oE2 nanovaccine (100 !g oE2 adsorbed to 
500 !g SV-140), Group 4 (mouse 5 to 8) received the FD oE2 nanovaccine (100 !g oE2 adsorbed 
to 500 !g SV-140), Group 5 (mouse 5 to 8) received the FD 500 !g SV-140, Group 6 (mouse 5 to 
8) was the unimmunised group and did not receive any vaccination.  
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Fig 7.6: oE2-specific ELISA antibody responses in mice after two subcutaneous immunisations. 
The individual response for each mouse is shown using a sera dilution of 1:1600. Group 1 (mouse 5 
to 8) received 100 !g oE2 plus 10 !g Quil-A; Group 2 (mouse 5 to 8) received the FD 100 !g oE2 
plus 10 !g Quil-A, Group 3 (mouse 5 to 8) received the oE2 nanovaccine (100 !g oE2 adsorbed to 
500 !g SV-140), Group 4 (mouse 5 to 8) received the FD oE2 nanovaccine (100 !g oE2 adsorbed 
to 500 !g SV-140), Group 5 (mouse 5 to 8) received the FD 500 !g SV-140, Group 6 (mouse 5 to 
8) was the unimmunised group and did not receive any vaccination. The letter ‘a’ denotes that the 
groups were not significantly different. Groups that do not share a common letter were significantly 
different (p<0.001, unpaired t-test analysis). 
 
Generation of long-term cell-mediated immune response is crucial as it shows uptake of the antigen 
by the antigen presenting cells, which is an essential process for developing immunity to invading 
pathogens. To determine the long-term cell-mediated immune responses spleens were collected 
from the four sacrificed mice at the end of the trial at six months following the second 
immunisation. The negative controls FD SV-140 alone and unimmunised did not generate oE2 
specific cell-mediated responses (Fig 7.7). The oE2/SV-140 generated very strong long-term Th1 
responses, the average value was found to be significantly higher (1500 SFU/million cells) than all 
the treatment groups. The FD oE2/SV-140 treatment group showed some variation in Th1 cell- 
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mediated immune responses to oE2 antigen as two mice generated low level responses of 340-1049 
SFU/million cells while the other two mice generated high level responses of 1500 SFU/million 
cells. Similarly, two mice in the oE2 plus Quil-A group induced low level of responses (473-690 
SFU/million cells) whereas the other two mice generated high level of responses (1406-1500 
SFU/million cells), this varied response can be attributed to mouse-to-mouse variation. All the four 
mice in the FD oE2 plus Quil-A group induced low level responses of 206-583 SFU/million cells.   
 
 
Fig 7.7: Detection of antigen specific IFN-! secretion by ELISPOT assay of murine splenocytes 
from immunised mice. The bars represent the number of cells producing IFN-! in response to the 
oE2 antigen six months after the final immunisation. The grey bars show the average for each group 
and M5 to M8 represent the four individual mice in each group. 
 
ELISA and ELISpot assay results showed good oE2-specific antibody and cell-mediated immune 
responses at three week and six month time points and this further confirmed the effectiveness of 
the non-FD and the FD SV-140 as self-adjuvants and efficient nanocarriers. This is a significant 
finding as for the first time we have shown that the SV can induce long-term balanced immune 
responses. 
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7.3.4 IHC analyses  
Immunohistochemistry analyses of mice spleen sections were conducted to determine semi 
quantitative IgG responses and the representative results are shown in Fig 7.8. The fluorescent 
FITC staining in the spleen section represents the presence of total IgG response; spleen section 
from one mouse in each group was investigated. The IgG responses appeared stronger at both the 
time points (three weeks and six months) with oE2/SV-140 (Fig 7.8 e and f) compared to the 
positive control oE2 plus Quil-A (Fig 7.8 a and b). Similarly, even the FD oE2/SV-140 showed 
good antibody responses after three weeks (Fig 7.8 g) and six months (Fig 7.8 h) compared to the 
FD oE2 plus Quil-A (Fig 7.8 c and d). The absence of the green color in the sections of the FD SV-
140 and the unimmunised treatment group confirms that the mice in the negative control group did 
not generate specific antibody responses [Fig 7.8 (i and j) and (k and l)].   
 
 
Fig 7.8: Representative immunohistochemistry analyses to determine the induction of total IgG 
in the spleen sections of the vaccinated animals after three weeks and six months post the final 
immunisation, oE2 plus Quil-A (a) and (b); FD oE2 plus Quil-A (c) and (d); oE2/SV-140 (e) 
and (f); FD oE2/SV-140 (g) and (h); FD SV-140 (i) and (j); unimmnised (k) and (l). 
 
7.3.5 Histopathology data  
To determine if there were deleterious side effects associated with the administration of 500 µg SV-
140 vesicles, tissue from the injection sites and different organs were harvested from two mice in 
each group. The sections were then stained with hematoxylin and eosin stain to examine the effect 
of nano-vaccination. No morphological changes could were observed in the tissue at the site of 
injection and in the organs of the mice vaccinated with 500 µg of 50 nm SV-140. The 
histopathology results demonstrate that administration of the oE2/SV-140, FD oE2/SV-140 and FD 
SV-140 alone did not have a detrimental effect on the mouse organs at three weeks as well as six 
months as the sections of mice injected with the nanoformulations looked similar to the 
unimmunised treatment group (Fig 7.9 A & B).  
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Fig 7.9: Histopathology studies of tissue organs from a mouse injected with nanovaccine 
immunisations; A) Three weeks post the final immunisation, organs fixed in formalin were 
harvested from two mice for each treatment group and embedded in paraffin, sections were 
stained with hematoxylin and eosin stain. i) Heart, ii) Injection sites, iii) Kidney, iv) Liver. 
B) Six months post the final immunisation, organs fixed in formalin were harvested from two 
mice for each treatment group and embedded in paraffin, sections were stained with hematoxylin 
and eosin stain. i) Heart, ii) Injection sites, iii) Kidney, iv) Liver. 
 
7.4 Discussion 
 
For subunit vaccines to be commercial success it is important that they induce balanced antibody 
and cell-mediated responses as well as sustain long-term immunogenicity. This research work aims 
on developing a freeze-dried and non freeze-dried veterinary subunit vaccine delivery system, using  
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SV-140 as adjuvants and delivery vehicles for BVDV-1 oE2 antigen, with the potential to initiate 
long-term immunity. Here, for the first time we have shown that the oE2/SV-140 formulation 
induced humoral and cell-mediated immune responses for up to six months in mice after two 
subcutaneous immunisations. In addition, FD of the oE2/SV-140 formulation also generated 
balanced long-term antibody and cell-mediated immune responses for up to six months.  
 
In a recent study, we reported the capacity of SV-140 as nanocarriers for efficient adsorption of 
oE2; SV-140 materials displayed excellent cellular uptake proficiency and were found to be non-
toxic on MDBK cells. The oE2/SV-140 formulation was then tested in mice and the animals were 
vaccinated with three vaccinations at two week intervals subcutaneously with 50 µg oE2/250 µg 
SV-140 and 50 µg oE2 plus 10 µg Quil-A as positive control. The oE2/SV-140 induced higher anti-
oE2 IgG as well as IFN-! responses compared to traditional adjuvant Quil-A, demonstrating the 
potential of SV-140 as both efficient vaccine delivery vehicles and potent adjuvants. [11] These 
results encouraged us to test the long-term efficacy of the oE2/SV-140 nanovaccine, as generation 
of long-term immunity is a requisite for the development of a successful subunit vaccine. We also 
developed and tested the ability of the FD oE2/SV-140 nanovaccine to generate immunity in mice 
to address the issue of cold chain storage often associated to subunit vaccines.  
 
Freeze-drying is considered an excellent technique to improve the long-term stability of the 
nanoformulations but it is a very complex process. Post freeze-drying the integrity of the 
nanoparticles and protein needs to be investigated. Various studies have reported the use of 
trehalose in combination to preserve the immunogenicity of proteins such as lactose dehydrogenase, 
hepatitis B surface antigen (HBsAg) and human serum albumin. [15,16,17] Likewise, glycine also 
has been used successfully for freeze-drying of model proteins lactate dehydrogenase and glucose 
6-phosphate dehydrogenase in a sucrose-glycine based excipient system. [18] In the past, we have 
observed that 5% trehalose along with either 1% PEG8000 helped preserve silica nanoparticles and 
immunogenicity of OVA protein. [10]  
 
For freeze-drying, oE2 adsorbed SV-140 the combination of 5% trehalose and 0.1% glycine was 
found to be suitable as it preserved the structural integrity of the vesicles as well as the integrity of 
the oE2 protein. As determined by western analyses the antigenicity of the FD BVDV oE2 adsorbed 
on SV-140 was preserved (Fig 7.1d lane 4). Sameti et al. demonstrated that the activity of cationic 
silica nanoparticles was preserved when freeze-dried with either trehalose or glycerol. [19] The  
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freeze-drying process did not have an adverse affect on the ability of the dried formulations the 
oE2/SV-140 and SV-140 to spontaneously go into the solution upon hydration. Furthermore, as 
observed by TEM and SEM the structural integrity of the SV-140 adsorbed with oE2 and SV-140 
before and after freeze-drying was well preserved. In addition, previous work from our laboratory 
has demonstrated that the FD silica nanovaccine formulations (OVA/AM-41 and oE2/HMSA) 
induced both antibody and cell-mediated immune responses in mice [10] and sheep (personal 
communication).  
 
In the current study, mice were administered with two vaccinations of the non-FD and the FD 100 
µg oE2/500 µg SV-140 formulations at three week intervals. The animals were maintained for up 
to six months post the final immunisation and mice in all the groups remaining healthy throughout 
the trial period. Quantitative toxicity analyses on SV-140 nanovaccine formulations conducted at 
0.02 mg/mL and 0.01 mg/mL showed that >85% of the MDBK cells remained viable. [11] Both 
oE2/SV-140 and the FD oE2/SV-140 induced oE2 specific antibody responses (1:1600) at three 
weeks (average OD range of 1.18 vs. 1.42) and six months (average OD range of 0.19 vs. 0.13) 
after the final second immunisation (Fig 7.3 and 7.6). As expected, with time the oE2/SV-140, oE2 
plus Quil-A, the FD oE2/SV-140 and FD oE2 plus Quil-A showed a gradual trend of reduction in 
the antibody response. Hollow mesoporous silica nanoparticles used to deliver Porcine Circovirus 
Type 2 ORF2 protein in mice showed significant reduction in the antibody titres at the six week 
time point post immunisation. [20]  
 
The cell-mediated response, which is very important part of the anti-viral response, was found to 
be strong with oE2/SV-140 and FD oE2/SV-140 at the three week as well as six month time points 
(222-1500 SFU/million cells) (Fig 7.4 & 7.7). The uniformly strong high cell-mediated response 
induced by the four mice (1500 SFU/million cells) in the oE2/SV-140 could be due to the 
sustained release of the antigen from the vesicles. Even though, the oE2 specific cell-mediated 
immune responses with the oE2/SV-140 were higher than the FD oE2/SV-140 at 3 weeks as well 
as six months, this study confirms the ability of FD oE2/SV-140 to induce long-term Th1 and Th2 
immune responses. Tonnis et al. [15] demonstrated similar finding as they found that the freeze-
dried aluminum hydroxide adjuvanted HBsAg formulation did not induce high immune responses 
but was able to induce both Th1 and Th2 responses. [15]  
 
 
 
 171 
 
The elicitation of total IgG response was further confirmed by fluorescent FITC staining of the 
spleen sections, which showed that both oE2/SV-140 as well as FD oE2/SV-140 generated strong 
antibody responses at three week and six month time points. Previously, we have demonstrated 
that administration of 150 µg AM-41 silica nanoparticles did not cause any morphological changes 
in the mice organs. [13] Similarly, the histopathology studies on different organs of mice 
immunised with the oE2/SV-140, FD oE2/SV-140 and FD SV-140 nanovaccine treatments groups 
confirmed that the 50 nm SV are biocompatible materials and that administration of 500 µg SV-
140 vesicles did not have deleterious side effects (Fig 7.9).  
 
In conclusion, the elicitation of balanced Th1 and Th2 responses by the non-FD and FD oE2 
adsorbed to SV-140 for up to six months after the final second vaccination, further proves the 
potential of silica vesicles as a promising new generation adjuvant and delivery vehicle for the 
development of BVDV subunit vaccine. The efficacy of this adjuvant platform suggests that it can 
be applied to produce cost effective veterinary subunit vaccines with improved shelf-life.  
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8. 
Conclusions and Recommendations 
 
 
 
 
 
 
 
 
 
 
The research that was carried out within the scope of this project has advanced the application of 
silica nanoparticles as a highly effective vaccine delivery system. A thorough review of the 
literature identified two fundamental issues which have been a bottleneck in the field of subunit 
vaccine development. These are the lack of efficient adjuvants that can induce both humoral and 
cell-mediated immune responses and the cold storage restrictions of current vaccines.  
  
Previous work established that OVA protein bound to the AM-41 nanoparticles at a capacity of 72 
µg OVA/mg AM-41. The adsorption was due to the strong electrostatic interactions between the  
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positive amino groups on the particles and the negative carboxyl groups present on the protein. The 
first major finding of this study was that the freeze-dried silica nanoparticles could elicit immune 
responses. As demonstrated in Chapter 4, the OVA adsorbed AM-41 freeze-dried with 5% trehalose 
and 1% PEG8000 induced total anti-OVA-specific IgG responses and the anti-OVA-specific IFN-! 
responses after four immunisations in mice. This study established that the immunogenicity of the 
protein adsorbed silica nanoparticles was preserved post freeze-drying.  
 
The second advancement that was made as a result of this study was the investigation of using 
amino functionalised hollow mesoporous silica nanoparticles (HMSA) with shell thickness of 20 
nm and entrance size of 2 to 3.5 nm for the delivery of BVDV-1 codon optimised E2 (oE2) protein. 
As described in Chapter 5, this study was the first to demonstrate that humoral and cell-mediated 
immune responses were generated by freeze-dried silica mesoporous nanovaccine formulation in a 
production in sheep. However, the major constraint of AM-41 and HMSA nanoparticles was the 
low protein loading efficiency as discussed in Chapter 6. In both the cases, due to the pore size of 
the nanoparticles being limited to 1 to 2 nm, the presentation of antigen may have been only on the 
surface of the particles. 
 
The results obtained with OVA and BVDV oE2 delivery using AM-41 and HMSA resulted in 
further work to improve the nanoparticle design to accommodate more protein and possible 
sustained release to reduce the number of injections. The novel 50 nm silica vesicles (SV) with a 
thin shell wall of 6 nm, entrance size ranging from 5.7 nm to 16 nm were found to greatly improve 
the oE2 adsorption (~250 "g to per mg of SV). The SV improved the BVDV-1 adsorption by ~3 
fold compared to the HMSAs. Since the entrance size of the SV is in the range of 5.7 nm to 16 nm, 
which is larger than the estimated width size of the oE2 (3 to 4 nm), it is highly probable that the 
protein was adsorbed in the internal cavity as well as external surface of the vesicles leading to 
higher loading of the BVDV-1 E2 protein. The oE2/ SV-140 induced oE2 specific antibody and 
cell-mediated responses higher than the oE2 plus Quil-A after three subcutaneous injections as 
described in Chapter 6.  
 
The next step was to investigate whether the number of subcutaneous injections could be reduced to 
two in addition to generating long term (up to 6 months) immune responses upon the delivery of 
oE2 protein bound to SVs. The ability of non-FD and FD oE2/SV-140 to induce long-term 
immunogenicity was further evaluated as discussed in Chapter 7. This was the first study that  
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demonstrated that silica nanoformulations induced long-term balanced Th1 and Th2 immune 
responses for at least six month post the final second immunisation in mice. The long-term immune 
responses by silica nanovaccines might have been due to the sustained release of the antigen from 
the vesicles resulting in its efficient uptake by antigen presenting cells, efficient processing and 
continuous presentation to T-helper cells. Furthermore, the FD oE2/SV-140 nanoformulation was 
developed by using 5% trehalose and 0.1% glycine as excipients. The FD oE2/SV-140 
nanoformulation injected in mice also yielded humoral and cell-mediated immune responses for six 
months, which showed the potential to eliminate cold chain storage for vaccine delivery. 
Quantitative cytotoxicity assays on the oE2 adsorbed SV-140 and SV-140 alone, showed that the 
Madin-Darby bovine kidney cells exhibited cell viability of  >90% at lower concentrations. The 
histopathology analyses on the organs of the mouse treated with 500 µg SV-140 showed that the 
silica vesicles did not have a toxic effect. The SV-140 were found to be biocompatible material as it 
elicited immune responses in animals without producing any adverse effects.  
 
8.1 Contribution to knowledge 
 
The findings presented here offer a significant contribution to research in development of novel 
vaccine delivery systems using silica nanoparticles by: 1) investigating a variety of novel MSNs to 
accommodate high antigen loadings and sustained release of the antigen, 2) developing stable 
protein adsorbed nanovaccine formulations using the freeze-drying process for increased stability at 
ambient temperatures during storage, and 3) validating the efficacy of the developed nanovaccines 
in animal trials.  
 
This thesis has successfully delivered a platform using silica nanoparticles for the development of 
vaccine delivery systems. The developed nanovaccines generated balanced immune responses in 
animal trials. The silica materials were designed for effective endocytosis and displayed a strong 
adjuvant effect, with a potential to remove the requirement for dedicated adjuvants in the vaccine 
formulation. Development of this novel delivery platform aims to reduce the administration costs of 
vaccines, which will offer significant advantages for immunisation regimes especially in remote 
areas. In addition, freeze-drying the vaccine formulation can reduce the volume for storage as the 
end product is in a powder form and this would enable easy handling and transport of the vaccine. 
The highly stable nanoformulations will allow stockpiling of vaccines to be distributed in case of  
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epidemics, a major breakthrough for Queensland with its tropical/subtropical environment and 
biosecurity issues. 
 
8.2 Recommendations for future work 
 
This thesis has provided a pathway towards developing efficient silica nanoparticle based vaccine 
delivery systems by providing a proof-of-concept that the novel silica nanoparticles can be the new 
generation ‘self-adjuvants’ and ‘nanocarriers’. 
 
A.) Determining the location of protein adsorption on the nanoparticles 
Whether the protein adsorbs on the outside or inside of the nanoparticles has been debated for years. 
This is a critical issue in the challenging field of developing delivery systems using nanoparticles. 
In Prof. Yu’s laboratory, attempts were made to determine how much protein is adsorbed on the 
surface of particles by using solid silica spheres without any entrance pores and extrapolate the 
difference with protein bound to the SV. However, the exact location of the protein on SV could not 
be determined using UV measurements due to the buffer in which the adsorption reaction was 
performed. Future work will need to focus on the development of an experimental methodology that 
will allow the quantification of surface vs internal protein adsorbed to nanoparticles. The capacity 
to measure this ratio may influence the type and duration of the immune response elicited. For 
example, if the majority of the protein is absorbed on the surface of the nanoparticles the duration 
of exposure to the immune system might be shorter, however if the protein is adsorbed on the inside 
of the nanoparticles the protein might get released overtime thus prolonging immune stimulation. 
Thus, the ratio of internal to external adsorption could be an important immunological determinant, 
which requires further investigation. 
 
B.) Biocompatibility and Bio-distribution of the nanoparticles 
Understanding the in vivo fate of nanoparticles and breakdown products is an essential in preclinical 
investigations. In spite of the ability of the silica nanoparticles to induce immunogenicity, the 
knowledge of their in vivo biocompatibility and bio-distribution remains limited. Urine and faeces 
samples were collected from the animals administered with 500 µg of SV-140, to investigate the 
amount of silica excreted in the samples using inductively coupled plasma mass spectrometry. 
However, the collected data could not be analysed, as the amount of silica injected was below 
detection limits following excretion. Further investigations would therefore need to either tag the  
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nanoparticles or deliver a higher dose of the nanovaccine to examine the fate of the silica 
nanoparticles. A variety of fluorescent probes have been developed for in vitro/in vivo sensing and 
imaging applications. Fluorescence imaging techniques could be used to better understand the fate 
of the particles in vivo. For example, the bio-distribution of the nanoparticles could be understood 
by administering animals with fluorescence tagged nanoparticles and screening the site of injection 
and organs from these animals for the presence of fluorescence signals. Once the fate of the 
nanoparticles is determined research maybe required to determine the fate of any breakdown 
products from the nanoparticles, particularly if used in food producing animals where chemical 
residues are tightly regulated. Attempts were made to address this issue in the current study; 
however, no products could be detected which suggests if breakdown was occurring it was below 
the level of detection. Future studies should continue similar monitoring as a failure to detect any 
products will provide some of the critical information required to satisfy the authorities who would 
regulate nanoparticle vaccine usage. 
 
C.) Testing the applicability of the developed platform technology 
The final area of the future research required on the silica nanoparticle platform is translating the 
capacity of the developed nanovaccines to induce strong immunological responses in small animal 
to production and companion animals. The SV platform also opens up the possibility of translation 
to human vaccine applications. This concept is strongly supported by the animal trials conducted, as 
the initial histopathology studies indicate no adverse effect on all organs tested even with a dose of 
500 µg of SV in mice. For an average mouse weighing 20 g, this dose equates to 0.0025% of body 
weight; direct translation of this dose to a bovine weighing 500 kg would result a 12.5 g SV dose, 
which may not be feasible. However, similar arguments were made when DNA vaccines were first 
introduced and it has since been demonstrated that linear determination of dose is always applicable 
when moving to larger animals. It is anticipated a similar scenario will eventuate with the SV 
platform, as described here when a dose of 6.2 mg HMSA nanoparticles was effective in sheep 
(weighing 49 kg) equating to 0.000012% of body weight. The enhanced loading capacity of SV 
particles and dose titration experiments may allow further reductions in the amount of nanoparticles 
administered. 
 
Further development of the SV platform will also require the loading capacity of antigens from 
pathogens to be determined. It is possible that the systems for adsorption can be optimised by 
varying the binding conditions to match the properties of the antigen in question. The final stage in  
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the development of the SV nanovaccine platform would be the testing of the immunological 
responses in a pathogen challenge model whereby the effectiveness of the stimulated 
immunological responses can be interpreted in the context of protection from infection and/or 
disease. 
 
These areas of future research were beyond the scope of the studies presented here. However, these 
studies provide an excellent framework for the future development and application of SV 
nanovaccine formulations that will lead to improve disease management by addressing the 
limitations of many existing vaccine technologies. 
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